var title_f28_39_29296="Teratoma PA and CT";
var content_f28_39_29296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Teratoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The PA radiograph (left panel) demonstrates a mass to the right of the trachea (arrow). Both the hilum and spine are well seen suggesting that the mass may be anterior. A CT scan obtained just above the level of the right pulmonary artery (right panel) demonstrates an anterior mediastinal mass with multiple distinct densities. The rounded area of low attenuation in the middle of the mass indicates the presence of fat and is highly suggestive of a teratoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29296=[""].join("\n");
var outline_f28_39_29296=null;
var title_f28_39_29297="Cobb angle measurement";
var content_f28_39_29297=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Cobb angle measurement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Cobb angle (arrow in radiograph) is formed by the intersection of a line parallel to the superior end plate of the most cephalad vertebra in a particular curve, with the line parallel to the inferior end plate of the most caudad vertebra of the curve. The intersection of these lines may occur outside the border of the actual film. Therefore, by convention, perpendiculars to the parallels are drawn, and the angle between their intersection is measured. The Cobb angle in the above radiograph is 63&deg;. The most cephalad vertebra is the vertebra that has the greatest tilt from horizontal of its superior end plate (red line). The most caudal vertebra is the vertebra that has the greatest tilt from horizontal of its inferior end plate (blue line). Drawing lines along several vertebrae near each end of a curve (dashed lines) is helpful in determining that with the greatest tilt.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Radiograph courtesy of Dr. Susan Scherl.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29297=[""].join("\n");
var outline_f28_39_29297=null;
var title_f28_39_29298="Breast MRI of silicone implant";
var content_f28_39_29298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Breast MRI of silicone implant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breast MRI is useful for the assessment of silicone implant integrity.",
"    <br>",
"     (A) Axial image of a intact subglandular silicone implant with radial folds (normal infolding of the implant envelope).",
"     <br>",
"      (B) Axial image of subglandular silicone implant shows curvilinear low signal within the silicone corresponding to a collapsed envelope (linguine sign) consistent with an intracapsular rupture.",
"      <br>",
"       (C) Axial image shows rupture of the envelope and capsule with extrusion of silicone into surrounding breast tissue consistent with an extracapsular rupture.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29298=[""].join("\n");
var outline_f28_39_29298=null;
var title_f28_39_29299="HP bronchiolitis Light";
var content_f28_39_29299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cellular bronchiolitis in hypersensitivity pneumonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 189px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAC9ASADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2iPPHU81lahpz2NteXmkpcNespYL5jMkeAT8qZGAT1C4yTXN+D7zWbjxPLb3cM/kRoZbiQ36TrH5g3RxlQBtbDZCjIAxya2PGN7FZ6lpov7Np9LOZLidXK/Z9hyGODnbyQcfjkV8tGlKFTkvfr/Wp6MYtOyOVR/s95cfYdSnVL/PnKkCxTySboUMyoUzsEgky54AbuMEdxp18r3U3h3VY2PlhvKuHACTIu3lT0JGRxnI6EdCcM6RoNtay2+lS3JS6lRmeXzHREZNiqjngr0JGSc8k+l26gvdREd7a3dmsrRvbwgW6ny5NxG4ksc7QMMvOWXt0roqctTfT109NjbcvXtrKtqtm0VtvjYF0aIkOFyVkHPsMjqMcYqTwvcaL4S8M2Vrc6lFE0jPIzXM4M08rvlmI6lizDp6iq9lHNZwxW8c7Xc1vOd8s5KfI7HftBzwN3yr06DIHNZNhaQ39+7x3b3yQM7lHQPFDMGCuxLZ+dSgKgYChmIznNZKKlFqT08i3DmVmdppvinTr7Vv7LJnt78oZVhnTG9M4yCCQe/HXg+la2o3kdhYXN44kZIImkZY1LMQATgAck8YxXEeG/DD3uprq17qt9M8EqgxtF5IeRMgsEOSoI2DOTnaCCBXeXtxBZ2ctxeTJBbxqTJI5wFHvXLVhCM0oa/10MakYprlOKY65quv2l7ZWM+mOIlW5lmCndFsZhEOo3CRgGAIzsHIApdL0W001nuxpjXmtzyySyGXbvTcADliTywAwpYkBsZAquLuQ2boNUv7Gza8b7N8qRSMFYsApAJZGC7ueSrYNOtIIbWRPtd1I8koIaeRS88r5QZKKBgY25OAMAcV1Sulbb7/xOmNOTWmx0GieJop9sN7ZPp5SNncn5oYdoJZGkHyqyjkjpjoTXD67Hr/i/XbwW19eWWgiR4Htp49sVxCu0B42C7ZVlBfqxABBIPy46u71e0msppmu4msrSTM0+AyKI2O4Y/hzyD6Dj3rmdOv/ALJdi3jlZdV1FgkE1zAwt38pFy/DAYb5cAHClhxgGtKEeW84xs/vM40knzELaF9ktdTi0N7mFtqRR27eZaJFtOWHnIFfDE5KBscg4IPOVo9jqGnaddatqNsuo3bxQQPZrIDHFHG7lvNZxgsgl34TC5XgAVu2un/btYtUaBbNLOR3dtPlAgjDRrvgf++5YbiQAQMc4NRXujajqugXtrqV1faZE7lptQnkimLxhsJGwwpKNnOQAQT94gCupVLK03ppf+vl6mjjZ7amV4d12KTX9b1U2IhhujHFOllNHdOZEfaC5jZgMq+TnAAjxWpqmpNbeILS9s9LKX1vi7iFxF5clxEwZZPlPzrIAj5O0YVV5PaPWgroFhk1C9sJZGjtU+0qFlLggBJNmd0ew4+b+I5J5FYHiDQNT0/Si+kW2ryweYZrlre53h4Y44UAkDqwbLNKfLJ4ALADpVRhCo1La+m/T7wkpU/iWh7foeu6drcLNp1zHJLGqNNBuHmwbhlRImcqTg9euDiptVsF1C2ZVkaC4VT5M6gMYmyCGAPB5VetfPw0q4g0i5u9H1XUojd5g0r7LM6SySb2CwJ5jb0wVj3l9wUMy4B6eg/CvxLqF5ql7pmq6uuqDfJ5E+xBuKbSxDKeUfzCUyB8sZx0OOOtgvZp1KUtEcUocj91ljxJo2szXUNmNWgv2lkWaRG2pNapvYeZHHtbeMMRgkD5Mc5NU9Ps9fj0Kxs7LSpdIF1dRXF7F5az+akjbZQTnEZVRvOACTgAZ3Z2tGvItT+Jeu3X2QyLp1oljHcjkght7qo9SW5/3B61r20HiV0nuJL2xhlcO0NnJB5iRnHyhnVgT07DuaTqyglF26PX/Jf5GkpyStKxwnxH8KTxalfanDeBdGv4dmoreOZkOzaUUKBvOTk8NgbegGazbHUofDFt/ZWn6IUbTp2eNNRnaKWdyfl8ojgK2NwA3ABG4JArq1i8UaEksZsV1lmaSQXdzcNJhiCSqRKpIB5HLBVGADjgprnjiwYSaHLdPoOqNp8c0l9KE8nT5JB8sbMT8smCcZAB9c8VrCU2lG3Ml2f+WvkV7TlSi9Ud3DcW1zErwyxTQyEqrBgwYjOQPU8H8qnHtXIaVqo0HwhA3iG5luJbeUW0tzBp0kSu2fvgYwV77x8rduTiumsL231G1W4sphJCxIDgEDI+orzp0nG7S0vuc8o29CwSOh5+tefeOdMh1PWrWOe08qWCOV4Z3DGGYMAGRipHlEkr85yOoPbPoB9aoaxpFprEIgv7eGaLa65ZTvXcMEo4IKHHcc/SijNQldl0ajpyUkeN6df6r4ev/wCz7rQ5LVLhmjRSVy6DGZEK53AcE55zjmrmrhLW+sbo6Y2oW0koBuoAyi3lkdQQ5PUbXHB7pjGcEdfqCWPhZPsF/f3I0a4tpSd0u1rVVKKvlbcP/wAtMfLk9CffldU0DU767sraP7dqHhsPJL/aNjenc+35Qk0SAOZFYFSVPG0nAYkD1aLg3zNafn/wfK/3nfPFc+uzfXv/AME1AETxFYLHdT2Merl1Z4pGDeahJBQHI8tixXaemVwemaWl6ppUOrro9xbWz6XNe3DXL3RECQOWCxNEHIGGkjcgR5wWB6nJTV4r0eLvCdvNLDDd2jh7e2uBn7QGKhyjFsgIF+6QSMg5PbU8U6Ilr4himvo3l8OTytcSKDuxPsYjIxkBSodTnGSQRnaaVoaKXVP8Nvn280c71069C9e6BpOo2lxpVylve3auZbfzlXbI5j5K/wAJYhTkc4IJxUKxWmveH7a9tBaXMsgRGLwAK8q5zxgdwQRxzxxUUFnJ4ZksJY4S9ikpnl1BAAjK6YcyR5yuOxB6465NXPFsDNp413Q5EuUHlARwMdkqNIFeTK8ZUHOcHhT9RjyJSS6dH5/pf5EqTutTM1PRbLVoIjZpp0kkMvzQXSMqA4BYOFwSRuHB9fpWPqnh24h1tJPtWnJpO0hXNtGDbsQFOFK4O49znvnnqeMMPrsepy3D21myRhZ9wy7hseW644Y5Ug559Bjm7rc4SY2rB5VgcvLHGfMDrsO0EDqGOOD6A1pGhs0dsK04K173T38zP8L6bBY6ZA09laPLFJgyGBF87aFG7b1AyCBnnjPSrvxT8PWUulx6xZ21pDcWyllzAgX7rHn04OCTnj35oktX/sSOyt5PsUrxCMMmA8YwfugcBh7VreM7zTIPCanUbwohi8lZEP3ZGXCknPynPIOetVP+Kpx3v2/rc5ZtqaZy/hea48MaZfXmu2lyup3GJJfmaRWAbaCMDgDgbUB/rW7cDVP7DN3qtjuntbw3DiORd726c71QE9s/uycnHOCcVZ1ZrPVHks51ia1tjm7eUFNvAYKDxkEEZ6g9PWq0kF7rs1wYJJvsdwWSV4brYFRdyiMFckHcctjByBzxiuVzUnzyVnu/+B8v0M1d6k2lfbZdSljMMMll5gDSHC4jMRI47yFgAOBxuPXG60sLQ6osc6AWsESNHOzJ80mOcqB+OfUmqF/e6lp+pxRTxWljpkYMhcb3MrEbRz2IyM4znd+Imsr03EMs1tDciRiqrHPHtXooJQHnacdDyT9aUou3M9rGsLt3Rpvf6dKUMF4jzwy5IiOc5BUg+x3dPUA9q5nRbWC6Md3aoHsFz5dzdB5bqRvmG8tJhkAJYbeeD/CKvaXbxi2mitjHCZS8u638t3QFsb/ujHzEgBs/jzT9Ak+1aUl3czw3El2xRniuS2MADbGrAqB8h5GOrY5OapLki+X+v61NF7uqLVlqqQTSw215bJrCArJEFkFu0nVV3beeOTwSM56YpuvapPd291bN9nuLxEDrazB4rYA7QxaQDkDJOevsM1QvDdWF4+oXWkwR20MpkEsbiR1TYAxKumeg/gIJ9x121jhD3V9bpJNuTJj83cFKn5WCsdq4zyVGTkelHLGLUrfluJxW5kaFot6mk2tvdAAWibQ/mSToQQdwJYKXXnGOM8V0EkOn+HbGFtQnjjuJlZIUc5kbapOI0yQSBzgZxnrWLearqNykay2zPGInLxJcYw3BHOVyeCAcgc8+q1IbK3tpUuIQJpJWWJdkvmMxY8KuW4XPU5xx3NDpubvP8DS0uVRlKyNU6xGtrcX72t08QgVGgJ3sApY7wM4DfOc+wHpWZpIsNL06W50uzMombAF9dNGsoBwDuKnjGdvrnOeaju4Lq/lvLG6026MEhhyvmRi3eJMsyFsggSZKnbuIwuRyKuu+oQXcMSW/nhtsYtBAoRF+6MNzhR7AnHTAFbKCSsnv59AXLd2WnqSiGzNp5+maYdN1VVzEgc/Z1PIZhgFRkO3OzJOCecEYmkQtpWqxw3Fzd3ReQybYv3SB3J+V1A2+X97gDJPLZyNulfpaLDDay21vEVkDj/SVgkUr0LEsDjP8TZBJHXIBbcxIzRLaXEx3xyLI0U8bKC2cgkgsxAJwBgDtg4qo6RcXs/63KjGOqj+Y/Ur2bUbiS8s7uOyMLwxuuobYYvmKmQnYWJkCAIAwADZwT2c9vqccFvBYWq3WphJGF9GzyRwK5KsVkcgq+1uBhydq5GBuq8ljDqVrbmYmO9jVVzE4EbEeis2VB64yRnsaoXFjPaRzx3rzjjDSRwAPtyfl7krg9h9D2Ci47Lp0M/Z8y5b28jhIry50G6xqFzqNzq9r9mtLk221pppjHN5XmEKcxlGDElnJdFBAxk73hqS4tfFlnCyxI8mrPEy3EyTSIoiB8uNkRREiBGXZ0ZgOTk5uLcPZx6rf6VeJa3QgRUF5OZEMqtlWZW3ZJHyhkPOc/NgYW9ttRm1rSbi5hhllt44re4u0VV88iRJDLtyPutHlehG7+LJA6pSUr3S1X6djP2ck3Fo9D8OeH10W51ScXUlw99P5vzj7igYC5ySep5PXNbmPeue8H+Io9bs/Ju5LePWYBi7tI2IaM9jtPIBBB74zjJroq8Ssp879puefPm5nzbiEDPSvH/jj4WtRp41mOxSaR5vKupk5uBE42kIADuI4Cg5wTkV7DVXUbeS4tWjiMWSQGWVNysuRuGMjkjIB7E96vC1XRqKSKpT5ZJnz/wDDr4iX3jKM+CNbtbX7RNYslleKBjz4l3qHHI4AU5ABBXGCTx2Xw+tPE3hvxFDo+o2xbTpYgu+NS8ZMaEGbzC2QWxGCCO4AA28+P2fhu1vvHUY0e7lsZrZjc2+noUZlmiLs0bSkgI37v5WcNxnPI594/wCFn6NLorXaC6jkCorlYvNWGR+FX5T85B6quT6gZr2cXTcbxoxupbrs+j/rsaxjPWKV1/Wp0XivxFp/hjSP7Q1MybGkWGKNFy8kjfdQZwAeD19Kmt9VF94eh1TTLaa4E8SyRQsNj/NjhgfukZ59MGuLfWLlbzT9A8X2Elzp2rmWHzrpUBjkI/dxsU+6SFcg8H5l7qa4y0m8Xa7q0dtq9z/ZnhhOPstv+5GFjIeIkHzCS5HLHoGyAcCvPhg01Z9Nb9Gu3qVGjdfP+vyPW9VuNRg0CPU5rC2F9aKZp4BmXaADuEbYBJ4B4H64rmNKu7u4j1jUdDN7PZ3Ks1zZTylJrKXYCEhTB2k7tx9+2SccPaTWd7pb3NlPqIsIJFWC1iLRM8ZY8iUAOzBQXO1zgoVJFdF4b8Xabff6RHqN3FeuGgsndldryCJSwdiQd+wtJySpIPzEnk7rDOEZWV/l+BtKlyRS36/1/mVbbUJRpdl5ml21jLcyR6dBf4Lz7y6hd6qd3mcFhkrjHYV6ImuR3GtxaOdI1V45YWeS6ntCtumACEYt1JHpkduucc/8PhbabrF1YTXQF5JbwskLzM+5sOz7SxIJBPRT09sV6B1z1/PisMXOPPy8vp8zGvO8rWOOewu7bxRqt9pUFrPBBaCNLBGSMvO53segA3AglmJJPpjJ43UfDfifSL6+1y1gWSwvJ3N7oy3TSIYJMCQlSdp43NheVJOCQSK2vEJ1K18U6lf6Bc2MgvIoIT8+/Y8bHeJFUgjjAByMZOQeBWbp3jnxJJeX66tpMMdpBa/6to2LTyCRopAiqGZlJG7P8K9cj5q6aUaiSnGz0W+/oFpNLazNKGwe10eBop57vS50aMzahMFuASThH3YEiEEgHBbp1GSOZi0620TxBcI2pXQN3A0kMEwkk8twvJCY2nCgHqDhSMYBNXIrvXbnTfDniTxDDYXkRYNa2FzOtuyvIuzGXwrEj5l3EkE471Pd3beHtektdCvBprXf7mGzvLOW4aGd3zjcm792doKjOBzyAABaUotq927/ANPfbvbU1jNxVkXrXRNVvLC4vtPs/sgMZFnbXshSNk3uFLDBaNtuw9D1AwMVzet6QtjILvxhcizONyQ21w8ivKPkRlYqAD0bA2njJDGrPiPRPD0vhjULqV9buLuZiPtssLtskUkKzdAEQkk5bOM5OeAvwq0m6uIL8aveWeo6b5ds8Nut156pIqKWkZWG5SSmRnGcnrkmqjJxjKopWS8tfk/8/wAOkubj8Wq+40NQuDJok8Fir/bywluFuEMW/HJ4bkr7Lkn0wc10cutw2Gl6fKbaRjNHG5VQE8pWXO5l+93PygEk9h1rmYr6S517WNZOn7bXTV+y7Z4kSWaWNmISKTPRmZRggckDJxxjzQNN4in1Wxazj1aY/LJchp2hZcCToQMKG24UgkeuMVwxoqekun59vkLl5kbcV3cyzyX2qC9eS4TzYolQhUhz8mFxlDz90/MxDHHAqGOV9e0wxkvpml7cXE0kyQGWQyYWNZGzgYHI25+bHHGalhDdtYPcaXPIl6wQxzqQ2BI8mCTJknYXBOcDK4CrjFVrrUTYeH7Sw07VI9MjsrkSTyTbVW8IRHOyMgkKTlOTxtbg10xpXlaO9/u/rp/wDS7skjctbq8lNtZulyTdIyOscaQ2hjU7SikZkckEhcuMjkDqBU1e+1Cya3msoY9Gt0eO2a9vYuYoySSkcXO05Cje424Y46ZpvhDVNdvLGV4LsW1hbxslvbR6YPOfBfAD4VV+6uMp90g8HpiJc694f1uyt/FGrQ3s3kgeajl470bmJV8um/5GdQhBGdp56VUKL5nF2uun9afmSr7WOtOu2zwTpqSL9vnhWO5ESmVXDbkGZAACFIZDnBXODgkAyaVbl1RJ2vvmXO24VVbaMAZG0HnJ4bnINZGuXK6dFBGb67fSvPji0+4SR1ljfyfMbzAigEjCBYsKCBgls4GdomsXVvJosdnqJuI7yRYzazOZtpkVnQB8fu1VVAZt0pHzYXAJM+wvC8TSE7RukdxJb2sSRT3ELyLC3mRhY2k5AJHyqDk/UYzj2qk2rSQXCTXUd6zXCeXaRzSBN7E5HmhgFjfdnaAefmGCQMctq+panHI9hLZXd9L5iu0lpfPbxySEOWEHmgeYqkBcIRksv3ciqWj2lvJBH5kuvQXF1IVuDBBIkkirGkazNvkKhAGxkFw524PYXDC2V5v+vvBzUmdZqGtRWv2n7RqbQXVuIliEhWKRpnEshVmdGRY9oA3gNwrdwAafh/WJb02mnWuq3scdvczRXEN6rSTyDJZJIndRuX5CeVOAcDJwp57WLzRtStbKRI9a1BY2e2a5UG2aykSMTbYh03PsC/MTgng8kGx8PbzS5NRW/tdEa01WOeaK1la1a2htV2nzFmYM4dtsYAwoJOOFzxq8PFU2+XX5ehE5K+mpvWt74kviiu9iCU80DUPKiu4yz7QpiVlUAKrEuQCxIAXiq15c3UmpJLNdeH1jDw2/2i0vN8qMZSduwb8j7vy45PORxjJ0lR4h1pvC6+Zb2gRpZNsrM43LER87hmPK53KVBK7gBmofGulWfh3xToNpo959nvIrhXYykmNUHLOc55yUHTv6ZrSNKCnybO17JdDVKW1zov7bn861XULjSdjqUdvtqGSV8bRiFgh+8CW2gknAVc9NiCQ6db/a7iO5sljiZ3gkmViiAZZmQF1Xr3GeQDjpXIvq1pYyPfw6A5tb8tL55dZZEkVYt4ldyVG1gT5hJ5T3UmDwwviCaxF5pWorY6VA8sUaMplnEIckneSwLEHhgSCCpFS8OnG+y/rtccZSf+R0d34gfTgbhLi0hs5EIildGlLkgAqqq4LMpyxwo444wTU2j6q7W+HRDaHEcTRrs8tgMEFcnCnGV7gEK2CprH0+2nv9I083eqJcvNbLK7SWsbidCmCrggMwLNGxUsQSg6cVmT6ba+HbywkvruKWzeJ7a1uo7Z5HtX3GTc6bic+Y0zE85DbQeoZexpv3Ov8AXluW3KLvY2rnRLLWvFmnXlrcyy6jpt3EyTiRQkJZVypPmBnZlRcfKwxkMO9dt4g1K8m8SWVtouv21qbco11b3EO9JkckKA4HykkHg8kjjvXnFjqehW3i7Rr868NQZ7ea6jAsZI7mRX3RuVbeAHLl3wEDFVAHbPf6D4VF14ol1zVL+a9kth5WnMmI0WBuc5Q/vO4yeQB361zYhKDTlslpp17anJNxbc5EWt3Pi6we81C81LS9P06xXEIk2+Xd8L80zEbkywIwg796v6B8RtD1i7W3DyWzyO6RNMMLKVBJx3+6CeQPrmun1bTbLWNOnsNVtYbuynXbJDMoZWGcjg+hAIPYgEV574g+GNle2NzY6TaaMlu00LqGieKSIom075ImDSAr0U7epyTXNSnQqrlqqz7o51KM1aS27HR+KPDugzTza5qAEEn2Z7eadG2rJG4UfvMfeA2r36D0rjdA8Ky+C9Pht7/xXDbW89y80CwBVeXGcAF8gqIySQBgHnOOK6r4f6BqGj6KbDU9rWiqUFu8pnGQ2AVY9E2hcKSTnJODnORrl94X13wsL/xFAumXNiJLaONhJ51sZPkAVUAch12/dHIPHrW1Oc4t01Jyjfyfpoy4Np8q1X6HI6P4h1Gx0TVtNv5xrVrdm6ixPMss0QyUAyrrujVdpYAKFyTkDO3HgB0ae5XSdU0FW+zJDdhHe2ygjDRObhi+4H5gpJ5RiMnGa6f4cQ2d5YaVdy6hpeqXNjO0luIZTCfu7JHaPYH3feA8zOfl5FSXp0q7+KdxbhJALrT/APTLmV1lhePH7tTg/KFIDBl6EDJyRjv54xqSio92/l5f1qaqz2RyGoXtldR/Y49QSzhtLQ3C2zwu72cTRuj7ZFGJHQMTtAXG1tzZ5G14J0oXCeIdU0+2ji0hLW2lt3hRhdSmNGZjlc7ZD8wKAfxLkZznJ1u3kF/pvhyO8Eujs48w2yM4FqZGZRcSvgrgh3GSV5GQerep63B4l8O22k2/hKLSptOgG27+1BYSMEYOQQAWBIyAeQDjk0sRU5IqMXrLv63103/q4nOS33OO1Lw7e63odlq2ri1OmWFq6zW85kgVzIqmSYYAKbDuwCCeuCCcjX0zxRdeLPD0mjo6PcXLiwe6snG7y3iO+XZIwcbTknPUcrnNLrfiPVopzq0kd2biz2PBpmnXAkSRdwWZJZApRm6EA4I+XG0k5mfTLjT/AB94cvLSOc2Bt1RY2BZlyjKVZxknG/flsjg8jisLqUbVLX1a7d7efrtv2QS7tehxenG08NFm0nTb59XsbZbVJZHlUSQ+aygSFAQmWLHkEqF5IHzVR1aOytvDulXZ0wnU7HyrRIIJJEuoMBlRVB+f3OfTvxXc+JPh3fX/AIgbVNKn0wvHdLMIvntiSGLkPKhYn5mJK7QDnqM8ZPii38R6ZbnxLqGiWQ1PTZdkN5bzTM8m+YqoEKYDKA3JbkqxxjpW0K0J8rjK7e+v4fj0KVVdNTvtS0nSrnwzp9j4inSNLGCOeQzXAynlqAXZm5OO7HvzXJeGVtPF3jrWdTuoQlxZMDZXATDrgyRrIobKsVAJHBHzqfQ1zWn6019KviPVbprW51lpNPHlWJQRiJAVMqsWJCuQMDvkc8Uzw9rcmoa6t/bWepxzySPIupCIhWOFVo2BDZQrGmCcAjnhqzhhpxjLXW2/RPqJQaja561cfY/D/h68S5mFzHFFNcSC7kTdKWJYg7sLgk7RnjoM15hba7a6f4TRtR8PWNrc68iqZLTbFFcQSMS4ByOVEhAwTktx6V0Op+DYr29k8VWWo28dzfwxNOb8F4SmBtVfmGwHPTnrjvWfr7ah4t1HX5AsjaBpCFLWCGzBnllCkMYSeGHykehBGByDWFCMF8Tv33VrdPm2RBLqQ6l/bD6vexwXhSGZ0uYLbYFjwZUIZyCGJJWQkg4xngkcs1PT8QW1/FeW2kPpqSSmVogRHuVgcqAOAxzu3DOO+as3UN/Jpp1eaKa1lhtY4pYUYbQy/Msq7sDbyVOemz65xLyzlvr3WBDc3epWkri1FrbwECGT9yQXd8IykEE5JyHLDJXIdJX6pW8vRPy+80uuWyII7dtIsbrRL8HTzqMsqC9MihGG4qqxjGWyW3EEl/m5IzSePjb29tpt0sAi0288t/tQaUReYuf4o2wJSfmDN6HnqKk0u6mvLl7TWdYlsNREqRRi/wDKe3ZozHKzbS20s7fdYDKZI7Lm3r3hmS20HUdIjtvNtJ1V0uY0DNFcFi2ZI84dW3ls4wpB6ZrqjK1Rc2j/ADv1/q+w4roeoeDpLIWYjhu7W5mO6UtC+8lWbK5zznBAOcV5X+0HoKJa2+pQwh0iuAxAiLFR1Y4PBGcnt3Jpvwb8V6L4c0+PSr6b/iZr8kjMiwkxltysEOCR82cjJOfTFev+MLjSoPDk9xr80UGmqBvlk5C7htBHfv0HJ9689c+Dxd7Np/iZ83LK72Z434Y1zwdYwyWl5DPqS3cQkFuiRtDclsDdtHWTzA/znBG8jOE4zrTWF1LXrSO30Sa6OPtNxaXLSfabe62YR7mV/lKFWIU8D5myAcZ67QfDngrw3NFdW9ybkzj9zN9nOFQszcMRjOW7H0zUlvrHhzR/FdxB9jvDdyXEUF0XMcRT5SU3qcHGMkZPbivQ9rFuThFvTr/SNuVXcl/X3nM6nbXekTXl7ey+fZtNLe3NmdrxWu8qWCFeQdu7cVIUrnOScVp6Y8d3Z6ffeGtTXQj5AMVjcXcvlOcKUkAznaHdMjc6FT7muxTXvDWurfaQIRaXckgRRKiukzHhG3glSCTjk8k4Gc14n4+0C98G3k1nE8xtJ4/NMcqtIkKKDlP9sMwHHbI59NKEvb+5UXLL81+RUXdNJW/r8jqNb8O/bdPtpkmtdMMNp9nuYJLdWW4b5QQgABk4RRtBAGAflOTUWlpcWt0tveaVLpEg1OSe0E4HMpbEZwrFm2o7OXJ5EIUnDFTi6TrG8WFjGllZJA7GynubYT+SGUqGXYAFBYAksc/7x4F3UvFGp3+nSWtjHaeI7mQrFLffZe+5im1WUcocgMMg4z7V0uFRe49v6/ruNw1O4+Cpl1HV9QvtQZru6jlljF3IGLylNq55AwMEYA9egrg/FGsasvxTu5razmu5baF4o9rsFVmcljxxnoOg6c5xz6j8FtA1/SLed9egW3Ds7LEFAYbghJPryCT0OTVjxX4k8L+DI7u+ntPNk3738tFYLIXJxnPByOfp+Fef9YSxM+Rc2llbYlT99212OR0D4VTX62s2uvNcyRxgRiR2jEOANqkeijcmBwfoK7Px7M2geAp4AkwubgMryxyeXtXjPzj7qhQBx0AFYtr8WiuiyavdWTLpoldPtEf75VAC4yyZQHc+OW7e4rYbUtJ+I3hySON0kIDKuGxv4IbGcEHGDjHynBNRUeIdSNTEL3U+hHM3Jc1rHMaBdH/hGNPntLuWe9URwS3KRKGn25wuOjKSeAp6MDnjBvLa3EsN81zPNAZlw76fL50kCFzJh1HC8BQWXBfcTjvWHpUN1pEbaVeweXf2zRtHM5kMEzbmG9OGIYBgGDfL0PBAyzxFe3VjJfxz3yaWGmadbiH93I4WNmMQZchmTCtyp3bAAATkdUqV5e511OnmVi9d6HNHol9dWrWPiVrOMRxSJKIri1bbuDlMALmVQ2NwwBkk4rO8P6neeDL+4urTWbaXQbyaS8+x5G2GMsy75H2hlIk+RwFZgUyc4Iq9Z3OoeXZ6nbH7XiNd80MbSR3JVkK/cAKE8kAAghmxVXxe2haWIkeCK6SwgMcNpqF2tu5idsTFFIDOrBmBLspH3trYySzleE9b/wBf1t95jUilruj2Sy8SWM0Ooy3TfYorFsyTXJEcbxkZWVXPBjI/i9QR2rn/AAjZk+Jr97vVNVmuY5JJPss9v5URzhFkDAYchVIA3cA52jiqvhy31S88IWmk31t5sUbyRzvK4keJFIeOMqw+cgFVPQHb6cU6TVNP0TTf+Eh8RJqEF2G+wXNyzkKVilliWQ42oN25nwBxuGOgry1SUHKMeunR/wBX1/A5lFxvFdTlJ5E1/wASXdiZdTtLnTb944WS7lS3e2XCFQA4G9g+STljg54IWtjwr4eisZ73/hIIJoNN06Qf2bN54jxCIyoDJG3BX5ir4D9OeMVg+Afh1NqGjNdjUby2e5YkXbusrNE2wuiLtGA+GBYknhcZAyeu1J18BaHc3XiHUdT14Tl1VNqxpHEqMxBVcDoMFjknIA9K6qtRJ+ypPXa3X79vvNajiv3a3/H7xNE8O2lh8RJ0sdStpYkgd5dPlLSyrFKF+Yu5Jb94rHrwHPrzpRaz4X0jUZdC0O1t571owZbKwRMBN2MMSQo+8x25zjdgEkA8PoNzqfjBNQ1jS7ZraC+j+zq9harDK8AJAUTTAE9MZGz72QOK9A8P+CbLTtMNvePJdSyrtlZXaJB14RVI2gdByWAA571jiLQf76d3a1l+v9fMylyrWTMrw9oem2viR5dC0/8AstEQNM9uxlSeNQy+Q6kYTBbcoQn7vYYzyi3WiXn9swWHhe51DT3u0gliu5PLieUssW4ykthgMAL15VQNwIHs1rbQ20CwwptRVxySSR7k8k+5rz6HTofD93dRXdtBaxTXPn+fbWbYnAYlASoPzID95sEnJA4qaFdScm7t6W1ff7wpyUm7HLQ6h/Ymq6lfeGJjYW9vFJfXdpeQqUuImTajJODjG5C48wqxDY4AwKF/rPiu5tbiEw6jqM0aKW0608xVQvEBh5Lc8d22McnK4OMmuoi0211rxfHGbSWUyRFZJppZZbW4tc5YKQMKwLHCk7fmY9ciu41/UrHwnod7qYspHjV0Z4bGFTJK7MsYOOAT90ZJ6D2roqV4wlGKjeT77/f+u43Pk0tdnmGseF30Pw4mrSatB4W1692Ge5iaZ/mwWdSittLHLEkqw3Hr0NNWOTV/CMz6vYXniO2DxywCa6lgJSSQkhy5Ktj5CqgFsbfY10V18RbJtRutP1HTtPiaE74Re3qqrEBiCTsKodoJHJ+vXHHa14tutc1Jm1WzmTRJbaNZNKhnXz9zZZJoyMNkY2kjI7dudKcK8178fO91t2XX8SoqV/eF1zxLIV0vSYNB0y1top3tRpjAPLGw2ltoLKjukg3ZVmJ3BuoNX/Bmj2er67YPbSahYNak3UykFZLnBUmN2C7fKy5+VWK8tjJLGuCv72PTvEN/ptzC1/p0DB3W9ZJZEuCxOYnG0oxbcpO3B2DjjI9Z+Cdt5nh+XVJIRbyXEjQRQg8QwxnaqY7HIJPA57cCtMQvYUOaOn/B/q/6lzUVBpnZ66+nWmkySarcC002FkaRidi43DCnHYnAx3zivOPD95eJdarrLadBDaSW1w8kaOd3lbmMeSDgMFCA4J74612vj/w4nifRYrWYl0huUuPK2KwlwGBVg3BGGP0OD2ry9Irue91TwnoN9arHp1ozXmnmMyzTrhT5OeMBWbblDgg464rz8JGMqcve169ku5lTaUdev+Z6PF/pcUTaZdx332Vvs13EzB/NUZVgTnhwQSM9SCPccjqVva6TNHrOj3G+xEi2k/mRPlQ5RAGckY2lUwcHIXbyRz0Z0W5sf7Qvraae7v3leW3YKoEKNg+VgDJAxxwfwzXMz3xtIJ9d1Hw5LpN5HE4dgMQ3UbNnMsWOGYZODyCcE+mWGWvuu626a/136DhvoJdlfEOkW/kadb39tYXxzErxkssYJBXd8qsX6hiOOg541tetoda+02U6SrHINhUkKj7cMBg5BU4APXvWVqsVjaeC01F1L6VI0cQ+0XLo0DYKoY3AJUcpgjnPXoWrfuZXt/DMWoMRcy2cpZ3h+djCWCluB94Z3kDIHIHHTduzTj3svX/hzeMlc8z1h7yCS3urDVbKwuWjjupZmRoEZy5jkVmCHIVlEYwDvGc5HNenadZ3Gu+DH0q6FreICVcQlcll5AztAHI252g/TrWL4g03S30m+F08GnWpK/vhAFVnKFdhAJycgEHA+YBhk5qt+z8o0nw/P5t+stu5zEpyGX5jkHPfp+ftW1eSnR9rDeLXQiUbJ23OtGh6R4VsrCSVrqdrNMpAshECkY3SMvRVXruY8fWsC4+KZn3v4c0SW51GUhGTyW3Mu4KrMwHPJIAGeciuR8ZavpfiTUQ91dXUunzLmK2toS7uVJDMhzxtJKfNgAnPIHL9Suxpz3Om2mkTTXskMYmt55N0ca73zH+7P7tf9VypXIGcH5s608HFpOsuaX3WK9mrXlqy1qfxTvo7HUH1zRrW601jJGXYK6ywklNqY24GVPBJOc8gAAemeENKsdX8MWl00uoTW1wBLbxXVz5rWoxt2pJ94jj+It9a8v8ADfgfxB4omU61HFZaX+5Z7a2XbC7oNucknK4wQF46dK9l0HUNHtI4dIsrxS0WY0DnJY5JOD0J61zY504R5aG61duhlVSivc3Rymt/CbTr2CYWly8E7OJEuNgEyYJIVZBjauTnpmtLwloHh34e6bJGbgRyoE865uByS2cAHHOSD0yc9a7kV45+0w9zH4Tge3I2hwGG3JyXUDHvnFYYerVxc40Kk3ZmcKkqr5ZPQZrnxcSPWoxbO0dhDNslnELNEmVOBKw6Z46DjOeRWP8AF210zXdJTUbe8ElvIySrAj7klZyM5287ht3ZPHqDXN6Day/ZbhtOyb/UiH8q5gjjgjY7lHLgxkCRDtBQsBt+7ya3dStDYX1rZarpnhmZwkskUlpMTcvOFkldiN/QFcFgpMfG3OQB7Sw9KhOPs9LfiutzqvGm9rLYh03w5Zadb289kDausjQyrJaM3mlzGCGZCC6mPcxxtDZUhc8VDBpk/h6O01DZZ+HfKvMRpZwyTrfYB3M+N7KDk/ebO0tjGMGXVJ7aa4tr1nil04RNHCrTbbkJHG25GCjl13M67mblOiscDH1LV47i5dC8iPJcxCxjRIoBKRIYzHyjgAFQdm8hh83yGt4wnLV7f1/Wo201dnZzXUOqanYyanfSQvDdvbiGK5aPc4+U7xtDfMcZIIxlQdpytVr/AEXSLq8iF/a/ZoPOlRLuOcMVkG1oC7lSBlQ6hS2CCvBzkZulzrptldJYXVzcKYSj3lhaD7VFL5ic+Y2xZI1O4qRt4OcYBNRandRT6/fR31w1zc75GmNhDBE3lbQgcMwf5WcbmVmxnG0sODmqbvaLsl/X9XHrsjsroXNql9DPbXNsFTIuo5SGCHau4FWGOCwAyoyM8EgjBuLsala6dca9bW0VlAJfNmvL4+YHWMOp5YkowJyqNntzgGn+ENPuI5ptQvYLFZ5jujRFQSWalTtKNCVQjGTnb156nFM8Q3dlp0tvcz301ncFmUyR28Y8u2CnfsATcHVInZW+92JwwU4xilPkjq++pVRStzNFjSdX1FLSztdSW+07T55GurvUdNv/ALVLMwCGIeYAeHLbSBnogB5JpkurR+JIJZX8CT6n5ybJWa9Mbuu5TlVZc7SB1yAdvXBBrGu7yxs/IuGvLe31CENEgWCG3tN5fCtM8RZcqEYAsmAyjdju25GjwSqLubVJtWWCKK8t4MziWFlYAbo0KPIQ67jIoY8sOcCtFRV+a2vlf9Gn269jluludz4e8b6i6x6douh6PZWqOUgSW+bcVLnHyKh+cgF9pbLA8Z5Iv3E/jHU59R0ya3ltpJJ0SO9tSI4o4Cp3MA4JY8LleuZODxkcJdX1tbwJeaRDcpKsxt7RYo5Lu0uwqKhKB1wzYlk27R82MgHJrobX4gtoN1c31xa3o0SZsSJqF0FlhkBJ2wKR8+UZW2kr0wCTmuWrhrXlSgn69/vBR0vBJs77QY9R0Waz0XybrUbWOPL6ldTlpD1yXO3DHOAADkDrjjPTVneHdcsPEOkwalpcpltpRkZUqyn0YHkH2NaXavDquTm+ZWfX1OOT11QnOTSMoZSrDcpGCDzmuH1v4jWFprF9pOmQLe6hZ7lmWS4SBEYRmTBLHOMDlsY68naceen4sTeIdTtLKG5s7GZJonhktjLPHLKrDdExUfMrDnOF4OPeumll9eor2st/kaQoylboe16Vo2m6PCYdLs4rWIsW2RDaMnrxV8DBrzuw1PxpPpt7q8n9n2lsIRJFb36iMJlvmLPwVVUGfmBJz2rOufFXjqxsEvZ7HQ7uB5hEv2ZmeMqxIU+aG+8eOAhA6ll6UfU6lR/Em/XqU6Ur2buw8QQzaR8PdXk1aD7Pef2hJa2s1x5dwYop5RGrA4GFKvkjkjJHbA56x1W3j+HMV3IdOmh0a7jhaa3gXzJ5VZUiIByBGd43NkNgMBg1o6j498WW2pT6TrHhmyukMHmNxJCjjbuYK37wNt4wRknsBg4z/BXjnwtpaXMsmnajaySRATx3VwkkaruCHYZCi4yQCcdSuMivRp06sabbjd3T0a/rub2lyu+55VcjTVnvb23Kyxz+Y5mvhGrTsQsj4jjfCDEmSBhsDpkEH6Q+Ekds3w90eS3ZpkmiLs0iBSWyVwQPTaF+grxDxnrGj+I40l0ee4ttOR0EWkyxRxM0hBA3FGdnYuqY34AXJBwpFekfs+Xcv9iarpskUSwWtz5tu8Nx50bRyFsBD1CjbwMDg5xzW2YqU8Le1rNf5enXoTVXuqx6D4l1a28P6YbyVYdzSxwxo0gj8x3YDAJ9ufwrxm615dH8UzeLX8I3SyXcs0Uc0F0JPPj3BCxUYPzMEVTjqR7V7F4o0Ua5DbRCXyDE5kE6oGaM8fdycAkZ5wcdsHmsrxf4Rg1HwpJpdjBHuEbRrvcoSGYMx3YPzZ+Yf7WOleXhatKmlzK7ej32IjyWs9zS0K9h1PTILq0lZ45lBV3j2tz6oeVPsQK4qK0vNa1aR76a+nji+YWRmDQLGTgtJjG/cyELweAeOprofCfmW6zGaWHyJyHiIJJZmY98kY7D/wCtV/xJb6gdMuBocsC37NG8cVwVSNtp+ZcgZ5HOTnkdq46cvZTcV16spNQbRkfEGdLXStOhe1Q6Q8qvcZQFB86kAneuByzdD0HTvmS6v/ZcV3/assVk8pESSNC3kq8vAJAJBAYheDnIyQOQNHSfDWo3960evQyS6NIjmW1v7lLli+75QuF+RcHdw3G0AAckYNjZ3untdWam+t0srmSd/NDXUkhk+YDg4KiMJtAy2444wd3ZS9nycl72/r/gPR9DSm7+6mb7wRXFqLeDU/tEsTG5RY22SCNwCiuvbOG64yPxrJtPD9i0rTsutWE0QVvNWaKOC4KoFDGPOVG7B299oyTnFT+HooY9PuJSs1w1z88s8kxeKRiAAUDPv2EY52qCMfSpdc1eGztreS8a4mN1PHCzw25CxksA7ONrADk4z6dc4NVFzjJwg/6+Rbva7MnUtIfT/DrzQpLLBFLMr26SqNxK7E81yo+Ukl2OAoOOuMm34OtNE0Pw7HrGuTeVHJFHdTPK6upcqoBJRQGPsAASc4yasxTW2oT3GpabPd28AEkEkk1tGWuAdw2KHDsQCFO3bgnk9a57xLpuk29hctKZ7f7VkK4aER3r7iz7FfGFRUJB4Bye+CemL9ovZzbV38/QWr6mj4v8V32r6bd/2TbfZtGgieSW9lGTJGPlMkUeR5m3O7B4yMEE8V53OIdHurKx8MFp7/VRFOLq4ikN0UEzbWi5G0ttHO0EDaCFrctNN1rXtantfB86W9uJla7nzmMAMx2I+0g89W57DLYFekzDw/8ADfRmubqSC41Zl5uJtomuHOep68k9fzPFbOccMlSpq7fTr8xtxhaMdfI7yzaR7WFrhQszIpdR0DY5/WuE+KmhS+JPBUq3sosJAFY7Dv2HepAJ+oXkV5jrfxF+IVne3GorBZwaREUmmjCCQwRv0WTn5WODj34zkYr3jRtRtPEOiqweGXzIgtxErAmNivKkc4/GvNeHq4KUartv06HLyujLnex866BeTXeib/tJg02xCzTxSTCMNOjZwC4YhTsfhSvHGArZrcewutA1lbmxMS2bB7uKeSRNryHbu2KFkYZ3becffYqPlGGeIPBfiLwfrU19ozwT6fJI1w6PEMswHHzZ44AHPTcSOadHrN211pF3othHdWBctcxwSL5m4BvOUHbhg6FWycbyg/iJr33NVFz07OLv/XqdztJXWpTt2+3avaJYXAttAurZHS5nnSZ57eLzFlUueWlwCCFO7aTgqFYtcsb/AF6ax0tlsdU1GaUkRWEhXO1mk/fzZBYKmRhWUgER/M5By+C10281GySyt7nyYWLowm82aRAXCSJMHT5lBUGNw/ACjLA1Dp8ktjbLqFpDp/mTCG3iltMlpENxt/eI5yuAzBvl3F1yWOcUpO6slr5/PzIjBsiksYdK1QWl/fz2mo2VrHbpeovlQI5IZULuoWT5RKpZwqjAG3JAHQaUl3qthBeOjHVtKdUd4bN4fmZQHjYMSMNwB5YAwQeM4qKW8jvdBWzdIf7LLL5Ef9pQwrJlMhSzp8uAVJzlhngHAFZP2VNIkiGoaZJBb6Y21H+0x3LIhjb7sgiBbDKSGJY5TbhTUWlNWfxfL+te2w72na5vXdiyW0l1balfS3ssrTLZpZxySO27cy/M2WAY5x2zyMcVyt/r+h6t4ku/7Xtkj/s9RGL9Z9xUFd0gWJwY24zuQsGxnCsVNdDr2qCeG20/TtQMMsiM8cutRzXEkyfL5kSqoyz5ZRwW3KcKTji1Z6bptu0v2LWXv7hDDLdWlvp8DQhcsURFZfkddzNgnJONwAPE05KCvUTv0/pL8xVKnNojK0PSrRruKDToF1LUbBX2QXFuqFPkZDsQ3BUEszOwZWzkcDbWHLb68ss1vpvhO8vZURzP5wntbaWXO5mVIyE34TiRWVWJOE6GtDVdEdXeSeSy+z20w8q6aJ4JrVTnCOFkUPuztADArkdTxXa+BPB2lW0Vjq/itFi1K3kkc3F7cruuj8uHdc42rtBHJOcnPJzupX1Tv/XqtPx9Tnq+4rnFXvgDxI1pZ6lc6Tb3YuoImNsBIkySBhhXjTarEKS2WIJYZJHIOJrNm+najqljp7LLbtcvFqRjWcy2/JAYfL8hLbOM5k37c7DmvonXvGvhuyZ7G71ZEuJMRYhDuVZshcsgO08HqR69K8R1LVNXm1SCUaRrkBgkk+e2kmurdxtdU/dRgebGSruWb7wYD7pFW5yb12MqUnKLvoUbGLTbTSbq/wBJt9WtpozEo1hblrdXl8xl3MCwXdvLBoyrZ4A2jLV3mmfFaS3u7e319NJuC9ytmG02+VpI5mViodGwNrbeHBxk4wDxXl13pGv2st3p+u/Zgbq5t2e3t1klXzXf/WOXbMacqp5UZwAQMZfb6q+p3OnXOj6foDXV401ps3b1U7gdpZ8KiYSPblWUqCASSynOrhaddXnr8/LuaSScdd/68zuA7HULlNSsbC5XVTcS2tqSq3V0jt5kquxYLGo8twpyWG0HjaQejT4jaJ4XtodFn0y+stRto0hNpIYiY8RhgXkDY2hSpLd84GSCBxOl+GLm10+3uJtLa/vWXfc2FvqsW+BnPlDZFsZArb5GAyQDtG4BSawtUg0ubxBqT2ZfUFjiM8EGqzSpMHeNPNiYrlAqbgWRlyCMAgc1j9Wo1nZu6Xb/AIf/AIfdaEuXPZC+IPG2o+J5prm91GH7FARsFnefZ7Y/MSI2zk7yI2fPzD5QCMcDAvtUtIUku9OtJlu7iJGme5BiAhIwMMvy4GYjnYOmcDDNVYTmT7e+mTJaE4uryaOZrH7QxX5UjAAIC5dyCWzgZwxwK1zqPiHeHudS1KYBgwa9eSNQwTmJSWKuqs3qDxnAJIHqU6ChaMVZIv2kkuVElt4hv4Le+ttNuNUk06CPzGinuTIkxJKjgLyhIOF2tnJLHHzLFL4iS8tSJoj5MBGci4zJMJgqkbVIGETAUnA37R3xVgmS5tb0zXtypkHkp5NmheSVQ8mxgW3qokOCVHzbhnH3Qy6u3uWnsbVXGmrJ5+dixusRZU3OQvBYhf48ZyMc5p+zjfQUZyStc63RILm+SO90a2Mkupyta6ZJdXG5ZJBuLMAeFf2PAC8Zwc+/fDXQH8PeE7S2uYLOC7kPmyrawiNRn7qnGc7VwucnOM9818vJqVnfeJLHUhFqH2iS5WOC3t1RDF8rgNGEAMhDY4wD0BbJyPrvxBrVp4d0htR1PzUt4ykbCKNpDuYgAce5AyeOeTXhZu5pRprr+nT8Qq1Od2J7u8tLaSGK6uYYpZ/ljSRwGk6A4HfGR09aqSavpwurmzN7b/abdVMse8ApuGVz9Rg4968Rthp2t6xrmq+Izqlm9xOh0+GeXbLG0hbcgzghSpU4Q/KqNnB6+iWzaDodpprXWnrJqUlssjSx2QZtiADzWAGBgEcgcZPSvPq4NUkk7t/0/wAFuN0tOtwj0i0k1EabNeXG0fvzAjlPMZm3b8gg4yCNoOMZ75J62KcQ2nyK0jRJgxp8znHseSenWs270S0vb62vf3tvd2xGyaBthYAHCt/eXk4B6ZNc54hvtP1PX9Kmsrm9j1HS7qaKdoMiGMxqGZLgkfcORg8Zz1riSddpXf8Awf8Agk/HY9CtpY5l3I2cHB9QfSuZ+KMDzeDZrqCzu7yaykjuY4Lf7zYOGyh4cBWYlWBHtTdS8UW2n6ZFrcMF1c20qr5sVtEzyhWPDhMcgAMc+n1q14J8V2XjfRLy5s7Wa3SOaS1kgvUXdkAfeUE8EHoT606dOpRarW0T/pEO8Wmcv4fnaW10+LY5sLq3Bgd7jeImzuEUYIDEsCSSScYA4worQuNK0+81EwXjxvHcxeUiSsNrAAnBHGDhzyPUVSvdOu9Ovk0eVLgWz5mtr2HiOJNxJt0BBCEICPlAOwZBGOJFlmuo/NWxZ7y5dlkUD7O58o7GlVWJOwqcggk8joDXc1d80Xa/9XOyMu2zK2s3VlD4UWFLNRZBfs8VtdxvE3yZVeCvy42AqWwD8vI6nD8O+EV8aahayazBjTdN/dRFrhpWDKQCYXDbdjMgHKZ2g4Peun1/TW1OylVJUGoR28i2ly0KM6yEZRw5HBGMZH97PGKp6V4wGm6BBZLo+pSahhUmlkjeFWf5AxaRhwfnBJxjrj0renKfsmqPxN99v67kzulZHQeKvEVt4Q0yy0vRLWMzSSLaW0aHakTEgAdD6+h9/fhre51Ky07+19ZmtpdSu7sSeVJkiOOKSRGOdvyoC5JfgFOMDIqHT9FfWIYp5hDd319cO05F7uitIBGXQB+MBGaM/IWJI5PUVj6lDNBrGi6YkFjq1va7LlbWe3kjWKFIthJBZj94F8H5lJUHIJFdFGhTguRO73b7/wBfiEEoqy17jtMgvvGbT6KL2KLS0uAvkRQGMXEZ+cBPlGIw2Sw3FsjJ5PHpfinVl+HfhKAaVZxyxWpiS4J/uswUMe5OST34GK29D0y28PeH/PudyeSjSAuFBhUjhRgBeAcZxz3rxqxun8U+MJ9bvFf7F56wW9tMqyRTkllJGwk4UkYIGVJGec5iLWMm3b93Hp3YJqo7LZHfeEvHll4suJ/D2tRGO6Z5Ig2RGXCgEHAPBII5HFcV4j8M2vhnxdbR21sDFdybNkNqdkZ5G55RgohD42/dHoAKyNYlaDxLp+rMknlm8ktUdJY9oH+qVd2cLjYjfNzwvI2k17H418Pw+LfC+6RoY47i3xKJFVhkgFTkg4KsB0I781rLlwdSLjpCe68ytKctNE/zPPprnUo4tQW3W4ZvtCWxZ54t1phNiBwzlmbgPkEk7t2NwYVh2xv9NvJotIuYtLnkt4Y0hVJAAqmQNGoEbBXLsGwSQRn5gBSeG4JNM8Qmzu3nu0tFBlAaWVr1C2+N25Kq43EAEkEAjGcZ627guILe0uVnMkn2GRZprK680Rssh3NuVcSMQz8FOWUjOTx1TtTfK9b/ANdb/wBeZqn0e5Y1CJbm9jtU/swQabM00bhLgNDJhVzhAPMfcSwGRkDOBjdUOjyyyJPFZXmpG9xHObqdbq1s9wQ7i4bYcZO5lUsSWG5yawbG7gs9WhnuGuNXvI3ItIk52bv+eU2N8wJZ/lfAGxxgiuoN/pMuomztNRs1lCr5EUkkhld8lmjJZQrZXA8vLENk8kCuapCUFy2bX9fMxkrOze5U0q0t2vI4LVtPSW6uZmkmtvPzPecS+aZPuGMbgUEhOSF2/Moqw91Nq9xomneTdmC4t2Mskgw9thSqvgZwWKkAnoAPUikkksJlu9NvVUuzFxbyxNstmU7QARnli+7nAwCexxYj0lb/AFnUi1zP5qKsU0cCFI2R0DBkf7zrztzgDOalyitZf1/V/wCkzWMeV6iatZ20GoWFvNql1NaRo6JaGQEsxAUHcQFUD5mJY5LYxnpWB4itV1+/utMGpXGlwzPG86GIyJcSqo2zRspUbtvyuDhehJIwa0/DFuYrONEtNMfZdu1uJZFklkKzbGCBQowoJ5b5jxnINX7DMLWukWRmlubZyJBblcRgq3E7g7PlJUAJz8vuapT9ns7ten39v+D6EzUZqxyfhTRLiHxBBb3MdrZXaL+/EU2DHhD5S7VB353g7iW+V9oOARSeI8aldy2msWN1qgWc2yQzzJIbZ1hKCZWY/vIztyXZV2nfuyR8vTW8d3e6fcxaLHcW+p28vmQiOc2oYRuIo1MROSuCzdkbYAeDVbVo2vLOc3mlW9nFcTpbJbyaf5ckOJP3hDJ13YKq4IHzZNX7dyqc0vT+uv8AwxEY3ZwupW8N3cWd1NLZI0KJcreahDPsufKjVFiTzQpZ2aIMOobKr823mn4btGudP1C3+y3V/p+nCO7tzb2i2sm1X+/D8xZzh5AQR8rSHKkjA7WB7O1u5bxdON1JdlYP3my4WKZmZiJT0YLIsjFi5OZCowACcHQtTj0DW4NT1S5iuY7mz8xPKZYIV2pI7QgMARGrjaF2/KXUgZJrqjVlKL5TNxs7s53xH4D07/hIri3a2TSrR2UQXP2q2kRHDYLOIfmwQUGxVXGC2cbidzVp9a029k0nxHFA9tIyW7sJ3ja/mCDE6YUhyfKjTcwJyDuOOmXr2/xH4h1S80ZobO7srSGO3je4NvLIzs0sfkh0jd2AGAMLyM/MTzBYaw+m6fDb2iT6TqUysjLLPJI8LqVwZVlwqD5BnIIJVsdCBpBSaXVrp/TMqcI82jRQuZb621G+tmt99wYPmCqJQrYDMPMGVEbM5LInyYOA3yisvTbKwiiE9xYSXkk0gmW3iacOtsMh3LB9u4hVyGPqMdKvLpN4+mX11qGtrbW90JnjSRWfK70G6YQK+CSAQpVlI5GBtJ6abwNqwjF/p11p2ricxm5mtb8lJAUkbfLsVSqlAEHGc5wctiul1acdJO3/AABRtJ2OCnaJrJ7m6tFjdC1tH5WCzRKDxkfJtHy53ZJ3YAxmtrxBo7aDZWV5b3GRqiNLDb486NC6pnzWcquSCTyi8nkkCoY7Se2v5St5p6QzI9vHHPcs8kyMTvYEYKozOcFipBJycBzVa9vLa6s/s1xLbXd5C6p9rjYu6RjaoiACH5RjYGXAywOGzmhttrlenU20jvudr+z1YRN8RtSkfTx9t0+yZ1VoRAYpHIBBAGOnAxxhie9et/G6xGoeDBGlwYJ4bmO6icIWwUySSBk8A9gedvBrw/4H6+ugfEWT7Zm8/tECwe4AIMbNIojxxl9xAByBjrwOv0J4glifxfokFxAZoWt7hixiyicqeWJA524xzztPQGvncfzxxcZ22V18rswp6Tuzw3wWPD+nLF/wlD3l9CZxL9r2SogEY2xEuMBk2hzlm6NjHevd/E2kxeIdLO2/ntY3YO0sLj95GMNtBzgKSAc9/cGvPPFotNf0GceHnGkwWb3FreW52gknAUMgYg5ALL3zxxk1qfCvWp7b4bSRS2ssj6THsjCsy+dDzt2hgCrBQflPcDHBGDGc9aKrx0ae3a+3l29fkbTTTUonoNuBFHGiKqhQFC5xgYrgvEvh6WLxg+r2cs7LCy372SoircO0XlEh8AgqEzzkEtg8HjvYwHBAPHQ4PIrO8TfY2tkS6+2xtL8ouLQAPGMqTyeMd8EHgHAzXiYapKE9OuhlDcw4bUair6TYWE9hZW2xZNsWI7mNWy6AEfKGOBz95C2PboDHYeDvDt/fW9nBbQKBM0MbpEpOFUDLFVDdB1GTXJ6B4gW1vI73XbBNEWaVl+0J++juo1URws8ucIDvCgHksMcDium8fxz3vhz7LY2Ud+9w6fu5JEELKDu/eFgflOAMqCckdOtdE0+eNOXwvf8AXX/g/cXK7kos5nRvEw8ZaBDFrdubDWEu5riziYFBMsLMDscZBIQlWI9TjHatPPL9ns5IprlnMTKzxSbnKuHCv5asBnsjkEZPTHI6L4aquq+EtLmv7NILmynlxGm5dp+ZRuB9UcHGSOhyaz9b0n+zNUit9LMdkrSb4Y42aGGZSnMcrYOQCrsQpBIAzkDjoVSEakqaVrX0Lpu14IdZambu6u1eZre381be1trriVp8uCAxOSHCjBPG5SAT1pvhufUrsWq6m0Fv5qK32dgBIZFU7gq7QVOCTgszcYGADm0mkxXmnWq3D2A1MJCWjgBMbGMgxr5rKSdrgYbHA6AVVvdWt4NQW31i1a3vproNE0oWJsqvLg7iGxGrncvACgHGRl3jK8Yr/gf13KUk1qVvEUhvEuLFopYrVbf91IIvMBZ3CZCuAhEZ55JB35wRjON8MlkfxIlzfWIjViltDeXPEs5jXDMTuZSSwXofQY4GOh1O3k1J7hnW9gXT7kWbzSRErIhZSZEUttIDBCSwbhDgZw1augXNrZ2VvIJ4dQPnG2adGJIn3FmDK3RiSW4AHTAAxWvtlGg4xWr0CU9LItfEnWY9N8O3EWwySzKEAUbiuWCg7Qcn5iBxzXn8OkyWPgO2XzZrWxkTy7z7Md5mWZnDNCW3YfLZIALEBcAng7XxUNtqGo6HY3U8NvFPdJI6y/IZEViDg8N/GhwpB/KpX8O2dpZyrdXBSBZkaNZGAiWIEjyir7htO5l9fn6jjDw8o0aEE+rvt8gpxtCyOQ1TS5fiRrotmjntdJ00/Z3h+UkXOAXKkEE8EcsoxjPPIr2XRtJls/DsWmXcv2gqmwuST/nmuL8M3kXhjX5LK++1/Y7pBLbXMvzRrJu2mEkA7WwFPXaRjAXBz38ur2ESFpLuJB6k/jWONqzk404L3VsZ1nLSMVofOniRH0Px7NHrc1zp1lctBIHlupmVyoKlM4YMhJ3bWHPAyoFb8d1Z2UdvYWsjvCxIe2MsaRqZWIkkVxJypUvJ5ZDMuXJPTHpfjbwhpXjzTLYTvE6K4ZZ0ALbQeVDDp3Ge2T61g634P0rR9Dnia/2zbHkLz3BjCqAcsWByBjjcfU+2O+nj6dWMVO/Ntb9TWFVSt0Zyll9ll0mdLx9yyXDxvNdBXiAUK29VRS5YqUXbuHCBgAAasvo9nr+jzRSwWbWM4dLNbgMLjBcqWV2BK/O6ERuckk5UYBqhZT22o6fZvd3Njc6k1yFS4tHcRqW3BVeVSGGxZCS2STnGOCw3IDpx0GLTpZLSxvbXzEmtGQ3dsVyx8pgV3bSqlsgA/L14xW1WTjte9/68zTe9jm9aludJgjsGM9rq0VkR9okunVpBGSudnBCthVyzFQinBDgitXR/D+pX+p2WpXwuJbS0cRQxyXAkaKJlKs5lV9oBdFJCgEBfuZNVvGdlNqWpPaaw88ZKCGOKJvkmEpUBxI3yMFlmdVDYByowNmTQt9AvbDUnsriZopxcyO8lrY/ZSiFHBOeN6Kdg3ghj5vB+TNW5XppppN/PcSbWx2s18HTSLKxufnaU27IPkICpuJXhQV+XHAAORx2roGay0WzkmYR2tqp3SYTgsSATgDknj61iaxDdXi29x4cFjqOr21tESm9VmQEYJYscjIHtn06Zy7O4169v5JPEKW6pbypA2mWrxs6tIF8uRt7Acs6ADO7J4AFcDpKolZ6LdX1/rsXeLjubP2eO8tY3m069k1Bw0UTC6f8AdIHDbmYk42lUbcQTwAM9K5vw5Y/8I5pSW9v4kjg0aPzrlkjG5sEcl42UsoAKFl7MxA6jPVf21b6PeQ75oYbhg22GUgSSAYL4X7xG7K9M7kPGMVz+r6pFNJcO8Ny17qytEjpZPBukePCAB0J2hEZmY8/INobmrpc7vG2j+f5meid+hwGp6PbaUt1CUOvNHpwFtHHaw29pGHZpHmhw2JAjDGw45Jb5sk1Bd6vfXuh6THfX0UklmjJcyXCm4kgZnRg3mKN24FoiQWKsQF+U/efc3WjaTqUSHWJRY6fOIoTZwF1RxEfMB8xn2xfOqbjlt+dvGBWxYaBrV5pMEzvb2mk2TNtkeG1hs4o9wzNHMwLNu27ixB+bYecAj1IuFNLnennp/X+ZhZMrapqnhaw0m4u9R+zaxf30Vss2mu0lmZIgxYSyFm4XafkBJGDH1wDTGurfXvEK6Q8VzbzW0V1DJbalcG8ezyQJI45WAbmPA25cAM2MEbjoW9imj6NHPrejxaVdb2gW4i0+Mtbgqu1pLgsRMpXdu+V+Gb5CMAcuLvXdfublJtK0y+kuykElxZMtvLdeZH5kbl2UIx2pIM7AMbjjAys00t799b/d5f12FrzpzSN3WLKyt7C2fQ9bvrPz12/ZXmIWaYBnKGRo8FdzIQXzkL+Br+Fde1Dw/eIviSNDZm3aSNbKJluQgOyKDDkfuwxLKzZyBkvgEVm6pNI2nCS5bw5LY3kYefT49SMSrsBWOZmYgOw2ooUBhwOFzzesdYN5rELRSw6leGNg9ut2JmVh8obzHLsZCHkUIm8fvDg5xTlHmg4S1/P7/wBWaycHs7FGLRbHVpryCyjuja3qzXdjbqsb3EUYUgZAIRw5KqArdFG5s5FWp/BV5prtJ4g1aVxcK9wy2VivHlqcAukbBCFKnkEBgxGTzXY6dqMl7Pctp+jRX8qmEQLbzETrGI2Vw+BjClSgA+UlcbicVz8dve6EfMXS7iysZY3ZXaJkXlQRGxUfK/3cMS2dvJwcnP29Vyte2m2l/wCvkWowdrvU5G607+x9fefR7i8SPAjliiK71lAZiZXMYUZCbsZ/vsrHA3e2eAfE8/jOObTdSs7ObS2snR2WZ5mckhCGJRRhkfPH96vPE8QXC3sFt9jtmidg8xa7R3mk8vLbmBG4bSq7zgAnaAw6egfDzUtNt7a8XT7TS7Xzbj/R3hmISVSwyGO3Ktkk4I6tjtxzZhrS1jr0dyJxunY7S08NaHbBjBpNmgKeUR5QO5AVIBHflFPPPArn/FHhVIdO16fSZp7ea+tipUYdYnAI3jPOMHBGeO3U12hJI559e2eKguiTbzN/D5bAjHHTvXgqvUTvdnMptO5EH2IzEMQozgck/SuL8Q32v6s/2fRba3gtopAI5pyHdmIOGUMCDgZJBHcYOatnU7tdXt9CvtIkvoLmNllukBaNYyrcyKQQAcEHJ6nHPSrmYbI39lAqQo5jdJkl2O8rHG3GCTgKuT0wQMVFJeyd2rv8LGkPdeoiw6v4lsFSa5isrCW3VhcQoDN5meytlduOzKD/AEo6dBcaTqkVrpRutRvbDbE9vIrWyNau4Z5FL/I7KWOACABhRjFafhfTzper3NtHJa3EQto381EZZQhLCIOSzbyQrZPqCcDdgUPC+u6dq3xK16OG9uWvYLcQrayQbUWKN9rOrd8ueh+oyCK2UmlNRV4qz2/Prt6DbWq6B4Cvbmy1W8s9WtXtLnVLl7pIgG2I5XcyHcSd+0c7fl+XIPNanjwTM1ukFoJxJFJFKXcIojbaDgk/eH3hkHgMO9bUWnxNrcl+4leRU2R79uyM4AYqOuSAAT6Diuc8XXtvYa/GuoXbpDc2rPbxj5svEcuFXjcdrAkZLEdBxUwmqlZTitbCi05pmX4fWFtDtrewu7jVUjh2RzzyRuJEIB3bh1GWPBGflbg8E3kupbuIW2pQ2+oJDbrBcXABRvMK/OFyu0gn+HPfB6AGITQ2cFuss93JKl0LYhIirSy8/KVxwnVsngAA5NW5ri5trO9D29xayKGJmQNIqrycqfl5IAyf17jdtt3t/X9djayMXU9Ikt7FrWzubu2spHSARMRC1uAAu1ZFwFQj5gHyD8y8ZAq1L4acW0T6fqN9beSxKGO4xFIGCgBwmC2FUBWByMlsknNavhFLPxDotvqllJdrDKm1PtMOA654bB+8p4IIJ+tZmoafZadqEEV3FLp88Su1tdxzEQLAH8yUkkYT77ZB4IC5I4IuNWXNyX1Xl/X69yVNN23Em0aKznvr93bzppY2i86N9kHJbq5O1cklmxgDjB5qLW9STTxcn/hHYtSukVFZbsbmlAbCgMw2ggkHGBnORVltHZLq5bTQFQJuuoREBby5HBHJw4TZyq8jg542z+I7+CRkMtp51/PHiOO3lEc0qBlLlNxwSB6gnkgEZqozcpK/vfh2NI76q6Kvi+1n1Lws91plmBfJJHJJDGoklRkJYbT3IySAeM8dDXAXdtr2q2V1LHBAunpGwkurK48yRlwM55JDjCscjPUDGTXrEcJ06S3OlzE+ZIhEMkm3cgKlyXw244LHkZJOMjrWDpsGttr2q3dzpcVkk9tGjwo32iAygyAyKNyZOGhJONxClTjKtW2GxDpxaVrLXX8he05HZF34eancQxy2mrvsu4tomjkQRmPIBVio6bh+oNeefETTBN41jmS/niivGSF4BJtQAuoZgdwydrdF64963W0ia71BrbS0tre5tS8l3a2E+8WrkM0OGAQ7WGPlIKjbxnkFbq2t4rvS73XJ4LLU7JUdorUrHBczydBM4G1mLK7ZVQcHp6703GnVdWL1a2/rp/wBwklLmXUv6Ta2+/T9KggjFpap5yvNDm5wq7Ynk3c72LOQuARz0JIrS1Y3xngtBoc8tp5EjvcvHHv3q+OGZsAoCSoYHduyMBSaguBJZXt1areadJqV0+027tK6RAjONwPyuX5AGMDpzjF+C7hkgngD3XnQ5AVgJC0auI2QK7lmOerEcjnuM805O6mlf7/vKd3a2xxF8NG1XwAdIEN4zfZg8U0VsoSd1j8yTbMqyxJuCEMy5XJYDJzXVzeJNJ8U6NAqXQ0+zjjKX7hXM1odm4osqfKgChwzk+nfpipYRXOvMDZ3IgsZLQGJlKWllBFiXJZjsA2n5kwxJAIKdRds7OZ9Ds9X05NE1K1tUKQXhudlsYNoMkkihQp2kMoUjKheWJrar7Oybbvvv39f67GLS5rN6iat8J9Pe6S6XxVq1jA6+UFjMEYK4BADBAOAinJBJxkkkmn6d4W1d5Suj3elrbWckccVxcWjvNcAEOZTIxK5JZiGVetXZdYuNeijWz0K1vngLFrpLspbxSKgbaCBk5yAOAO5xiuKmN1eayLCO51nSE1SOa5FtZho4zsbHybJMs5AAK5XPUHGMqi67XvS272f5a7BGLs1fX8D1rx54Rk1yKO90a9m07WrY745InKJPx9yUD7y+mc4PqMg+aSeFvEGsapeTmxuNPfAgm/tZ1mi+dVBliG4gFBjHL91znJr0W28XpaSaRpws7l1aOOK5nknjkktnKgBZEDFy3KknGMEtnANcXJo+sW/iPWrjVGui+nwrfCS3ldoNSVMny5Y3DYPLD5emFwPlAPZUq+5zQav3MKSqQTUiz8ONK8KWem3tppF8PEt/DJ5M17NB5/JwBz91lHAJDH3PAxj6JrWqSbr3xKboo6pbaetvHst7uF0LBljAK7kKFscMAO/yg7Gjz3GpaZqviTSrG2nur+OKKGztGYJGh6yM2wMW3ZDAdQgPGeGaXO0Xi2K+v4JEvWgbEIVzCwabbIxYMVLtkkIRldoU461wq/NLn1fm9b2/rU6FC2u/ruZutajZ654fur7T9HSDVNKIstSspbVXmeJlGwbhyvygHkgryDtNYWkrr+k+FppvD1pFHJZwo1/p01kHM0aM6RgEKSCVDqSc/KoJIO4133iu9SBNM07RtJthY6imLhbbKTQs4CxZVCAoJbG5mABIIyQAfMtG8Q6p4W1aSxj1rSft4xJeOytO8qEby6t8vmlRzksOGJHQAdOHbnSaivNJ9v6v+BMVzLl6mRr8unrEkD6Fq13cLZy2atDBFFutmbcLlY9zMzbSm0dggI2isWxitr3xBfX9no2qvIs9zdI1i6zyKUuI3DGEgKijfsIJHByR0rutQ8PXmo6lBZQRx6DqOtXC3No8MWLa4aOMkzAhmZMKWcRk4+6Dg5J6nSNE1Hwn41slfxBZpbzTLc6hH80CzSTFokCptYEsy5+8PmbOAAorpeKhBaP3rPr/l5/10WckuvqeSXsOm2V5fG41a/0cLDFJEAsiEyoULgoBuEikjaxYKThh8vy1peBNWMcVzA9/o+lnyQmLy4Wd7ghmAVkJZgNudxjCnP93k16P4PNxr+s3cl1r32LxKCGvLOS0UqVWQouMkMFyAuCRnaGA+bc3LeOfDGj3mnavqmnNqsmoQyN5hisIgsrcgu2cHBbdg54JUhTgUliYzfsp7/N/p/XYu127f1/XQ5rRpVk1iwvbfSLeOGBgTHaa0DE6CMZdzsaV1+YbgWC8nIHzMdq1V7y+i0/S/t3266Qh4vOVILSRs70SMck4LNgjC4B3da4/TtWtLbU7GawtxdNbBHhU3Bt490YCmVVLHljGAwGVYE7ehFel/Aizs7m/vtTm8+41AQIFZl3wqrOzFlkIB8zdkFdq7MEAc5oxMvZQdTdJCUuRXW57JaRm3tIoWfzGijVC2SS2BjPPWodTMkWmXcscTOywuQoPU4zjJ4yTgVYzgnJOT+OK8y+KmmWsGraVqwSfzZblIridXMmyMD7qoT8pb1QZ+U5z1r5qnD2s7N7mMEm7M0L281K3sLXWn01HuIYBI3mEJtDAblJPKnA5GM549ad4otrCx1UapfWzywqi3NvBFbs8huVLZK4BIbGzI68HGc4qHUoZvF1tayqUPhtIjM4PBvm5woBPEfB3bwMg8dcieHQdU1bTb231XUf9EuZS9uUyZI4mXg5OQG+Y47dOKuLjGzbt3/yOhNbvQ2Jxf21qmtrGWuYolD20Fs00k0W7OzHDBsHOcDkDOQMCx4W0ie01TVdSuoUtri9mO+MS+YGRQAjA8Bc4JK4zknnGMZOhXy2V99kmuZoY7W4awNvOwRI4RGWjdSQN/CoM9gx5456ObxDp1o9wt5P9mEOMtKwVW46juAMHOQMDnpWU/aRTglv+XQhqTdkZenX81tqHieyhnmvNTSSSZJJYfKgi3KrQwls4Jw45A5H0rHgOu20EVh4r0mW+025uMCVT9rkilZyVLAA7IhjO4n5QwHaqknjCTU9B8i+CWeqtIIZ44beR1ckPsUMQoDNsx1OOeuRW3o+v6tq1hLpzackWpR2nlySRlhC02wg7d3zCPdj5sk8kDpk9HJOCu4r/LzWw7NK9iSCCGwvLiG7unaXYOJJw6lCXKny1IAHLjdtydvJYrmpbHxfb/2dNa27vc6raW3mMkzqu3ORH5zA4VmAyQMnGSM8V5xa61P4kh02Ax2cur6XNJcW4JLQ3EGxkLRyBWzInmZCE5JOTnANbEEdt4nlvtNiv3kl1S0SOdbe28kQhlYiTcx+YhCoxyw7j5uN5YZJP2vT+vut/kU4qTtI19e1nxReRaXdadex6YkUJa9t0hSYyTFlUKGO7AHzE8cY/i5x1NjfrreizRIyz31uASQow7DOGHYBtp4/pgmrrVnaaPbaKlu8CG3AsYhMoMkkZVQAuBknKRk8YAySOARV8Ptb6drUSwl7aB1Nv5UmUQbULAoDxjA6j0PfNc75JQvFWtt/wSUouHNFaoZYz6I2mxC/jE1vZIsUchy8kWxSNjEfMeAeDknnrU1zrei/2bG9tpl5l8ogksZ1farYJIClwO+ccjNXdfgW01GS7EIZbtEiYAhcupPUnjJVsDp0xnmsXUtItr1IY5b1lS0YTxTXMjE2rAt5j7twOCCB8xwOf72KqPJOzbdvUtWlaS0X5GzJ4d2ajPe6ddOjzxKjqhGFdSfnQNlckEqeM4AweBjnvEHh6ddat9WmsJWusrFHNZRs8itn5DJtIygJBx0wDuOOkumxG5022srS9uG+1Rm7hhtrhomETHO9ixDBfnAbqcnpkVpme2JT5f38mU8pmaSHcuScuMHHykfMMEketOMpwe9/l0LTadk7/I4/xRdeIY5UeCNL+zNs6SrPbq9y5wGaNggVF5GB8zMexzknS0FtauDO1rYT2KTW58uCykKRRSMAD/rAMY2LyFGOcA7iTvQakLKW51D7Da2iTLHEsiykeacnauzAywJOMZJzRca9qosUZPIjuJDyZFAWMHpnLcnpxx19q19rJxUVBByPovvf6GdpvhHUk0pbfV3uLx5oVW5P21+WUEAL3/iOXyCSAeoGL1ton9l2zKpvrdFi8mFnEc6Ww243DILMTjq5b0HHFK2t6jbWsZu7yNLiU7U8yMIhY42juccjnPNTReIZY2gSe7ha4APmxKMg+4OBj8fp6VEpVpXbBqo97GJcaLo2qoBNq0l1d2EZR4IFFozqQDsjBZdu7C5IbHoVyapavpCR6zqEy3aWVj9mTzLqKQecUABxHIgDpgqQQSRg56k47Kd9OvI5SbiO1kxvl/dxgkDgtyM9vXpUEdlqOnXCXOmC01C3c5mKgJJjKhVXHBULvPJJzjHWnHESXX7/APhrCjJR+L7v+DY5hdL1Ky1KeF763t7KdpYlCxiOMb97yO2zB80kRgN15bBJJpljLqOopDDAiR29svlvcC3R5BNGVVGCSMQuCHbB3EgAg5NdBd2Wk6zqb6uUuRLCHs5YJraQY5ByUK5IO3IYAg8c8VU1eztWfzLH7W8x3LJ9ldodkb4LtjHzNlVXHB2lsYrRVua11r6GkWpRvYl8MWeo3t68OpW632ivGlxBqJbYxkAAIAz5gByxGcgDjPIAms1utS8XraSXEsdnp0AWS3kgYNMWUgMJm5YgBOVOQQcnkVJqGoanPoSWHhGSCPWY4lYreshaJc4yygnjg9OOMZqHRg/hqwEWsG71C9e4acgzCUoxzmXLsAi9toPA6DrWXNJqT76W/UwfM79+i6+ph/FSTSrjQjaX8N1bWVvcRSJsWQNLIgJHl7TgnLKMsMZ68jhvg2TS7/w7aXmofZb7TbrY88KrLcxwz5JBy+OCNmQV4IIJORVrxDbS6lEt2uoXlrczQTRtGsQaKT5kZ1CZw2VAH3uR3442TFY2nhq3tGUrHb5hf+z08vPBJIRW+XcAeDnk8ZzzopxjSUdb3LkrJRTMC1v7lPH9/Je6bDFA0Er2hsYgTfWygK3mktk7DjCgD73AbqCafwpdfD2KLUrC1tUkkn8u0WQwyCRZCX8tjho1JOe21Wx7Vr+GdO0ew0Ca48LQvdSQWsq29vMpWQGQh2RiQG5YJndkjGOOlcK41rSbKx/tuG2t7Brm6iuLaztUkW2hl3DbH8pc5k3c4XHPJWrhy1HZNq1vJu1+hEUpSt2LVt4o8P6Xdf2leW+q3h0su3228KzTWy52uI9wyEz8u5sMw6Z4q3Nq2nalbi+1651dvD3mAw6lIrW5trgnYVymG8ts5BxsXaMnoaf4F0698PSebaabqM5lEVpe+a5bzSiM++BWO1UzJt5Kr6DnjvfFGg2viTT1sNSDNaCZZmUHDEqcrgjphsH8MVFWvSjUsr273/IKqcGuhz2p/Dbw5raQS3pu7iQQGJZ/tRfcrZIbnjI3ZDDngc4FbL+H9K07QruxstKM0N3GsM8cRUSTLtCZLMRkgc5znPua09MsLfStOtrGzRktreNYo1JLEADArlfFnjDw7FpEwl1Q7jMYUe2aTckyfOoZkBKrlep+UjPUZrk9pWqvli21czi5Sfc8h8VeFtc8OxP/AGhp9rewzyPJ9rZsqCZQyq4CnCgMMq52krwThRXovwUtbqDw7dz3MUMEU1wwhijx8qoSpIwcbSc4wBx9ag0/xjeeLNH0qzSC1M1zKBrEEcTOIbVmddu1iNrP8o+bPG8joDXoNhZQaZY21lYxLFa20axRRqSQqjgDJP8AOu3FYmfsfZVFrf8AL+tAqSbdpLUi1a6ms9Hu7q0hWeeGF5I4nfYHYAkAsfu59TXm9zr1l4n0KWbxELKExwGeGCwvGmaN+q7iuMMOPbGT0r02eNLiF4bkBlkUhlBIBBHIz1PWuR1nwhp9nY3NzpgktSsM7TR7mdZkMZyCpJGeBg9QM4rlw86cb82/Rr+v0JpuCXvbnN6zqGi6dplvbXlhcRaK+FW2t5tyyRuRu2Ip+ZCWHQkkEgAdDt6h4pj8PyLY2sFnc2ogJscXHlJtRRmIkI21wcKFIGR3zkDkvDfhfVL86de3k0f2eyfyLeGe2i3lEU7TGyDMI3jcFUtgKOeSK14tM8RQzTNbx2zXFxJnzHnYTGLICruMWEGN52kH8ckVrKFJvlcr23163/q5slF6M3dK1S3j8KXWpalewaleXHy5RBEN7rhI1APfHBJyenUVmWs50O5W7vrWa3FxDtilkx5iXH2ciSSSSR+E+VFGMc4GDzWvpXhGax8OSWAv2N5IVdrmL907OAMtu5+ZjuJY9dx4rntQM2s2mm/234Wj1bU7QOJ5pThZ443dGA25XO9Q207sK2cZqKag+bld03/w3YcZRcnY7PRTqn/CAadDr0saatcxqkht9pXezZAHBXpjOPfB6Gt/RLM6bp8Nu0puJAcyzMApdu5wOg7AdhivPNJ8JTX2j2F7p19PaxyyG5W3ulKKm4N83lo2wPkjBIOO+elJ4L1vVIpb6S/1WWaO3uBDLbXkbeZGAW3SFskcngBcgbfXOM50OaMnCSdnqrdzNxurJnc6B4ds9JutQvApmvr+6a6lkclsMcABAc7QAB0/wA4TwdYhviXNHbX9sbfS2uQIAN9xtLbD5zY452bMknap6cgdrd+JtKbQ7q/gvbWS3Ee2N2mEayu6/IodiBknj1z2q94b0uPRdIt7RFXzQoM0gVQ0smBuZtoALE96hVpxhJz3ehnzNXv1Jtb05tRtR5MohvItzQSMu5QxUjDjjcp4yAR06iuL04wyazp9/eXdndS2TyW0tzCpjiD7ypK5Y4A+YHJPOemK9EVq43VrWwGoXNmkI8mRt1wJN23e3zEnIwQdwJIPXOe9LDz05X/Xc0ou94s6LxGC2ksA4RzIm3I6/MDj8s1hadcLdNKGWMByAfmBDwyI2BICMqcjkD+6OSDisadroJdun2uW8aULH57GVDIxVRs5xtzgnp74GKv2I03RbxBYSNeF7h4b8ufL+ZyfmAwAwDgLxkgMOuedlTUIct7s0jBxjZamVHd30d3eWhjluDqOnNGrunkxxLHxhgOEZhI5GRnOB0FTWtndW7YggRrSaRf3kkrMF2pltyD7vCkDGcnbwc5qzpWnXtvrtyzXt35NzJPNPazIg3RtlEJmX5gy7Rgg8JtBGeatM9okbQhoJbW4zGC024txjH+1kA55H45NayqK9oq/9fLsaxk9baXKt/qJvrjT4bG3kQzlliSUAMhXCqWA7ZJ4yOB9RXY6XpFtYqTzPOxZmuJVUuSTk9AMD2HHFcv4bhWbxVI00EJFvbiaFyoLI7fIcenyhh24c+prud1c1edrQjsc2Ik01BDs8VTvNNs7zcZ4ELsADIvyvjOcbhz6/mfWrf501WyxBB68E9651Jx1RzJtao5LXPCquty9hG0sU0ZWW0Mm0Pwx+XPAJyB1X3J4xzUd5f6fc2Mk10bEzgF4pbZ0ZiBzuOflz2LA46c16nu78YzWdq2k2uqxbblWD7SqSxnDx54yp6ZGfSuqnifs1NUdVLEte7PVHKT3MuoQTWmpJHcWbsJAsjkEkHcCrqFKkHGMZ/DpVtpba4upBNLLZPdMscby7Gi3gcAdM5xn6/hT38NXkVwq2F5C1jsIEcgKspJJBDL2/DnPbHPKXog09BbXe64nRhJDDMNrMxzggED5yCewJ785raCjP4WdUfZz+A19XT/hGvFUN9Z6RPez3MLk3CKzBlSP5o93RZGKrtBwrYIJBANV9Pe98Yy6paXcF7Y28bxhjIqIZFHO1GGTjOQWwQOg5zWja3r2ThPNk8iclxEz5I91PXgdff61G+iWEJuNWt498wBc3fmMZVAycl85IG5sDOB2AqlNRXvL3raMzs1q3r3Nbx3JqyaOlxpEUM6wyCS6ickMYgCSUx1KnB29Tj14PBtZwWXhzVNRuFsdaW7dbq7nt0KxuEVgp8tWPRTgj5iR1BxXonhS5v7jw3Y3OpOs120bMxijMfmfMdhw3Q4xnOOfSsA/ZhqOo3tnapHEJmzHF+7M8y/MXZhzhyw+oU5zms6M+S9NrZ/fr/VjKk3H3exh6Zpt1qvg7Rnef7FLDbLJbNGjxGORSBGylixKAKAQdxIbJ5xVyyE895AniCWJroxQpOIExE8rzIjMM8fePGRnuOpFdDc6Jaywyajqeo3Ub+WGWa3udkdugw7LFgcqdvO4EnHbjHOxWX9sa5oF9pyTh4phLLdeWm0wDJKsQcENhcY/iOexrVVVO76a/L5jU002uh6JbxiGCONSxWNQg3dcDAz/AFp49aaT2HTvRkc+vtXmdTmPN/iH44soEvtDji1QTmP95Nat5Tp8xACZBLE7T0B4ya4nxZd3c2q6n4Yg0EC2iMdw1rDYxurD5XMryscswz0wucjn+E+2ppGnJqUl8lnb/anIcyGJS24ZG4HGQcEiszxkb8W6iAsumyRTR30qyAGCPyn+cA4zgkHg5+X3r0cPiKcOWMI/e+v9f0jdTSskcn8IrHUNNhewkt7O30yCEMpt5Wl3zMQTmQk7iAOemM4x3r0GZ9m04bHPbnp/9auH+F8stx4WtZNM002MUUzW7RmdXWUIdu4YAA5BGMcdiea2U8Z+H7jVLewtdRjnmnZkR4wWjDqSChboCcHGeuKzxUZTrOy/r8SakXKTaWxp3t1Fp1qZb2eJGJIXtvbHCqDyScdPY1kTXdzd+C7q4urGS1uJLCR5ImYExkxtwOe36ds9K5vxtruh6naRXmlPp2u3WjzhDZrKCoeUiNScAnhgOmOh57Fvh+/1jVPCXiPU9S1eG7t5bS4C2aWwja0kEbFl8zguPQkfiaFQ/dc/9enz37GbjaNzK8a+IINM1WC303WrdL2IAPZrumZRsbAATozMwJz2Vegqx4f8SaheeMNLW7Ij0p7SfYZJv9Y4KfNgHBPOOcgDnIJIrifhX4ZtNS1eWdzthiiR40I3OokUOV3E9O3IzjvXffEWRNE0zTRp1vDG8sksCE7iqKyZfK5w2QuOeR1B9dZQhzKha7tv8rnU1GNqe7Z2eseIbDQrW4udRkKw2wVpdis5UHuQAcfj9enNQaPH5U2kNcsDcE3E0SHLuoYcNleANoIOeCzADmuJ1/W5dC8Iw+JLGCB53CpcxXAMguCHEJLHqMhc4GOcZyBg9PaMNF8YSWdtHG0N7Ek5Z9xkQltgUHONoCjjH41y+xap3Xn+G/3X+ZlZR91f10O0j2xFtoI3sWOTnJP+entXnOvWd3B4vl0lruW6sfE0Tk+Un7yxeIhhISD80e5lUrxxyT69D4x8RvoFkZYrVJnELTLvcgAjtxWP4O8QXmpaHJ4lvFhZrjTzerbqpHlAEgRq2ScYXk45Jz7UqEKlOPtLaPT59PuZMOZao07rwbp739zdapPNdaWLRQ8EpX5pELMZiFQEOAQQykHqAB3n8Ha0dd13Xru0vGvNG/0dbSVZAYs7GLqq4BBGVznOePepY/EDlrcfZ1xJHC5y3/PRyvp2xmsv4W3dtcQa6tjp8FhDHqci+VD93IAGQOAOg4FNubpSc1tZen/B0CSlZymd8pyORjPbrXI+MW1G2vYprWyhuNO8tzdTSSqn2YKpO85IyvbjpzmuqT5SePrXJ6/fz32tar4bZvKtZtLkk86PiRWyq8HpjD9COtZYe/PewqV73QzzdxjaCYRGP50OGC44PUcEgY69OPWiSa2a9QXVq1pGLuPZ5kiFZH3cbMHJ+bGAcHPY1N4c0+W60TZJf3JkjAgDEIwbbtJYqVxlucng4PGMAjE8O6x/b8wkmto4JLHUbi1bYdyyGA4RwGyV4I4B6gc9q6lre3Q6HL3mizqFsV8Ry295CZrw6ZEbi5QFFuT5hIVTkY27Omf4weKkisFtbKJ7xInMStIkgjEWB1HyDIBx1OetaHiOeb7WJInVRC0aMrLuEm9sZ7Yxz+dUbazeKIrPeXNzuVtwkfK/eI4Hb8PXGMYAuLbim2OE2opF3wLKrXt7NIzNJMsaDCsduDITnHCj3PU8egrQ1jxRZ2MzWsrz296iiTZ5Ikyu7GODjkcjJGM+vFYOjIbLWrlVdnt76BkeI4AUqGO4Hrzk559K5fxRrkF5rQtEsBDIskKvKJc7y6qAeRnKgKByRx0yaxqwUql+/wDwxtQwyr1ndXR1bfEWB5mga0a0+7umlkAMaNj59uDnGenrxXc20kckCPBJ5kbKGVw27cDyCD3zXJeHPDGlT6La3F7Abye4t08x7lt5Pf8AT1611dtDHbwRQwrtijUIgyTgAYAyeawmo7RMMV7C/LRTVtx7MVmTOSpyPYHjH8jUmajBzjNIrZ7etZI47BcxmaBolkaLOBuTqBWH4k8NQavIbiPi6IRWBfYjgNkFsA8jnB69uK2ySSVyRnPNAJH51pTnKDvEuMpQ1R5dpl06uswfMTzMsYZlZoz8wZcjIwSPXIJArf8ADk7T2twkf7+G6LoYZDny+Srpj6gj04rN8ZO9lqkqq2/zJEGSMbd2MEY7jFPtziGGFGdBy2UIBLZ5Y8dSefrXpVLTgpdzvl78fU14NVk0WdLW9gujBO7OkyRM5i+7wQAcr1JbPfpgEjM+wSadqqalp7Wd3YamUllmtyEEZVGLSg5IcM2wDHIBxyKkeC+jiZLvUZLt8K7eYCFyORhc/KeTkg88emKpCCR9A1JLSX7MlhcSSxogOxhFIyMrDI+V1xnaRgjIqIR6rrozDRakIu7W6utWBN1FDpslthJYPLhkmKlwyMrZbKugIYYGB6k11nhdrlLW4ub+CGxindfs8Pm7mWPGQGOcZ3M2AOwHrXg3iXWLHTPGVlq8emyPOtzFK8T3ReN2QGMMQykg4I5BH3ec100njfU/G3hPW3dLfTxpcLTT+Su9py0JZNhYny9vr82Tjp0PRWwc3FW2dtX0+7uyZe97vc9x6cEHjrWJ4t1tNB0lrna0kxYRxRqrPuds4G1QTzg4wPp6VX8E3F1LowhvbhrmW3by1mcfO6YBXd6sAcFu+M9axfi64sfCz38IKTtdWkUrRna0kfmbVUtjPBcsPQivOp0l7ZU5d7GUFadpGh4FuNevbP7XrNxDLDKmYGQJiQEAhwF6KckYbB9QOp6WVEnhaOVPMidSro3dT1H09a5/wDq/9t+FNNvxCYPMVlKF9/KuUJzgdSuenetDXbt7DSpLiP53TnkkZI9cYorJuq1a2uyJ1nLQq+FNDHhvR102C4aeBJXeNmQIQGO7BA4yCW571i6p4I0oyXsmlafpNrLNbPGsZs0CCY/dlOBnIGePfrXK6PqGvS+LLKebXruaA3JjmtZFXypFYZwFGNuNy7e429816fcyeTb3EuMmNGcgHG7A/wDrVtVdWjPmctXvY0qRlSlqeF+Mo7fQmlsdCsJo3twzX1w1sypcOpVht+XJRCWYAHA45wMjrfCbeZ8JNU1JxGJL6xubglPmyBG68+vzBq6Hw14gi8STeILY2RthZ3LWTuJtxmAGN3QY44xzTfEFrHo/gDWbG2LNHbaVdFC5GceU5wePeuiriHKn7Nqzdvn1/wAvkTOq5RUWf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph shows a cellular bronchiolitis, including peribronchiolar accumulations of giant cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29299=[""].join("\n");
var outline_f28_39_29299=null;
var title_f28_39_29300="Pyrazinamide: Patient drug information";
var content_f28_39_29300=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pyrazinamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     see \"Pyrazinamide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/48/16132?source=see_link\">",
"     see \"Pyrazinamide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tebrazid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat TB (tuberculosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pyrazinamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have active gout or very bad liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699013",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone, joint, or muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699621",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of suspension not used after 2 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12196 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29300=[""].join("\n");
var outline_f28_39_29300=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215773\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027972\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027971\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027976\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027977\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027979\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027974\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027975\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027980\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027981\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=related_link\">",
"      Pyrazinamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/48/16132?source=related_link\">",
"      Pyrazinamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_39_29301="Zinc sulfate: Pediatric drug information";
var content_f28_39_29301=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zinc sulfate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/57/17300?source=see_link\">",
"    see \"Zinc sulfate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/38/4708?source=see_link\">",
"    see \"Zinc sulfate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Orazinc&reg; 110 [OTC];",
"     </li>",
"     <li>",
"      Orazinc&reg; 220 [OTC];",
"     </li>",
"     <li>",
"      Zinc 15 [OTC];",
"     </li>",
"     <li>",
"      Zincate&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anuzinc;",
"     </li>",
"     <li>",
"      Rivasol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1043062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineral, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineral, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Trace Element",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F16233034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Clinical response may not occur for up to 6-8 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Oral: 2 mg",
"     <b>",
"      elemental",
"     </b>",
"     zinc/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Parenteral nutrition, maintenance requirement:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental",
"     </b>",
"     zinc:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ASPEN recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Premature neonates &lt;3 kg: 400 mcg/kg/day (Mirtallo, 2004); higher doses have been suggested in premature neonates: 450-500 mcg/kg/day (Vanek, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Term neonates &ge;3 kg: 50-250 mcg/kg/day (Mirtallo, 2004; Vanek, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer's labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Premature neonates &lt;3 kg: 300 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Term neonates &ge;3 kg: 100 mcg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1043071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/57/17300?source=see_link\">",
"      see \"Zinc sulfate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosages may be presented in units of mcg or mg; use caution to ensure correct units. Clinical response may not occur for up to 6-8 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Oral: 	Infants 1-6 months: 2 mg",
"     <b>",
"      elemental",
"     </b>",
"     zinc/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 7-12 months and Children 1-3 years: 3 mg",
"     <b>",
"      elemental",
"     </b>",
"     zinc/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-8 years: 5 mg",
"     <b>",
"      elemental",
"     </b>",
"     zinc/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents 9-13 years: 8 mg",
"     <b>",
"      elemental",
"     </b>",
"     zinc/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents 14-18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Female: 9 mg",
"     <b>",
"      elemental",
"     </b>",
"     zinc/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Male: 11 mg",
"     <b>",
"      elemental",
"     </b>",
"     zinc/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Zinc deficiency, treatment:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children: 0.5-1 mg",
"     <b>",
"      elemental",
"     </b>",
"     zinc/kg/day in divided doses 1-3 times daily; higher doses may be needed if impaired intestinal absorption or an excessive loss of zinc (eg, excessive, prolonged diarrhea, high-output intestinal fistula, burns)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: 25-50 mg",
"     <b>",
"      elemental",
"     </b>",
"     zinc (110-220 mg zinc sulfate) 3 times daily; higher doses may be needed if impaired intestinal absorption or an excessive loss of zinc (eg, excessive, prolonged diarrhea, high-output intestinal fistula, burns)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Parenteral nutrition, maintenance requirement:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental",
"     </b>",
"     zinc; higher doses may be needed if impaired intestinal absorption or an excessive loss of zinc (eg, excessive, prolonged diarrhea, high-output intestinal fistula, burns)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ASPEN recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Age-directed dosing (Vanek, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Infants &lt;3 months: 250 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Infants &ge;3 months:  50 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Children: 50 mcg/kg/day; maximum daily dose: 5000 mcg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Weight-directed dosing (Mirtallo, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Infants &lt;10 kg: 50-250 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Children 10-40 kg: 50-125 mcg/kg/day; maximum daily dose: 5000 mcg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Adolescents &gt;40 kg: 2-5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer labeling: Infants &gt;3 kg and Children &le;5 years: 100 mcg/kg/day; maximum daily dose: 5000 mcg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Diarrhea, treatment; malnourished patient",
"     </b>",
"     (WHO/UNICEF, 2004): Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental",
"     </b>",
"     zinc;",
"     <b>",
"      Note:",
"     </b>",
"     Zinc should be started in conjunction with oral rehydration solutions at first sign of diarrhea:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;6 months: 10 mg once daily for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &gt;6 months and Children: 20 mg once daily for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Female: 8 mg",
"     <b>",
"      elemental",
"     </b>",
"     zinc/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Male: 11 mg",
"     <b>",
"      elemental",
"     </b>",
"     zinc/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Zinc deficiency, treatment:",
"     </b>",
"     Oral: 25-50 mg",
"     <b>",
"      elemental",
"     </b>",
"     zinc/dose (110-220 mg zinc sulfate) 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Parenteral nutrition, maintenance requirement:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental",
"     </b>",
"     zinc:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acute metabolic states: 4.5-6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Metabolically stable: 2.5-4 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Replacement for small bowel fluid loss (metabolically stable): An additional 12.2 mg zinc/L of fluid lost, or an additional 17.1 mg zinc per kg of stool or ileostomy output",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 220 mg [elemental zinc 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orazinc&reg; 220: 220 mg [elemental zinc 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zincate&reg;: 220 mg [DSC] [elemental zinc 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: Elemental zinc 1 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]: Elemental zinc 5 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 220 mg [elemental zinc 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orazinc&reg; 110: 110 mg [elemental zinc 25 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zinc 15: 66 mg [elemental zinc 15 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16233098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with food if GI upset occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Dilute as component of daily parenteral nutrition or maintenance fluids; do not give undiluted by direct injection into a peripheral vein due to potential for phlebitis and tissue irritation and potential to increase renal losses of minerals from a bolus injection",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1043070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Capsule: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablet (Orazinc&reg;): Store at  13&deg;C to 24&deg;C (55&deg;F to 76&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store intact vial at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1043063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Dietary supplementation of zinc (OTC: FDA approved in adults); has also been used to help reduce the duration and severity of diarrhea in malnourished patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Prevention of zinc deficiency as an additive to parenteral nutrition (FDA approved in all ages)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F554161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       ZnSO",
"       <sub>",
"        4",
"       </sub>",
"       is an error-prone abbreviation (mistaken as  morphine sulfate)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F235822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16233026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zinc salts or any component",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Peripheral I.V. undiluted administration",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F16233028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration of zinc in absence of copper may decrease plasma copper levels. The parenteral product contains aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of  &gt;4-5 mcg/kg/day is associated with CNS and bone toxicity and tissue loading may occur at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16233027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer undiluted by direct injection into a peripheral vein due to potential for phlebitis, tissue irritation, and potential increased renal loss of minerals from a bolus injection; excessive intake in healthy persons may be deleterious as decreases in HDL (high-density lipoproteins) and impairment of immune system function have been reported",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ceftibuten: Zinc Salts may decrease the serum concentration of Ceftibuten.  Management: Consider administering oral zinc salts at least 3 hours after ceftibuten.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: Zinc Salts may decrease the absorption of Cephalexin.  Management: Consider administering oral zinc salts at least 3 hours after cephalexin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Zinc Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Zinc Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., zinc-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Zinc Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Zinc Salts may decrease the absorption of Tetracycline Derivatives. Only a concern when both products are administered orally.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Zinc Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Zinc Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1043069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Coffee, foods high in phytate (eg, whole grain cereals and legumes), bran, and dairy products reduce zinc absorption; avoid foods high in calcium or phosphorus",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13881520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zinc crosses the placenta and can be measured in the cord blood and placenta. Fetal concentrations are regulated by the placenta (de Moraes, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16233099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients on parenteral nutrition or chronic therapy should have periodic serum copper and serum zinc levels; alkaline phosphatase, taste acuity, mental depression",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16233029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A cofactor for more than 70 enzymes which are important to carbohydrate and protein metabolism, zinc helps to maintain normal growth and tissue repair, normal skin hydration, and senses of taste and smell",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16233030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: pH-dependent; enhanced at lower pH; (pH &lt;3); impaired by food (Anderson, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Storage sites are liver and skeletal muscle; serum levels do not adequately reflect whole-body zinc status",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 55% bound to albumin; 40% bound to alpha 1-macroglobulin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primarily in feces (Anderson, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1043077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/38/4708?source=see_link\">",
"      see \"Zinc sulfate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not exceed recommended dose.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Nutrition, \"Zinc,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1978, 62(3):408-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29301/abstract-text/704215/pubmed\" id=\"704215\" target=\"_blank\">",
"        704215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson LA, Hakojarvi SL, and Boudreaux SK, &ldquo;Zinc Acetate Treatment in Wilson's Disease,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1998, 32(1):78-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29301/abstract-text/9475826/pubmed\" id=\"9475826\" target=\"_blank\">",
"        9475826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Clinical Management of Acute Diarrhoea",
"      </i>",
"      , Geneva, NY: World Health Organization/UNICEF, 2004. Available at  file://www.unicef.org/nutrition/files/ENAcute_Diarrhoea_reprint.pdf.  Accessed 2/13/2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department Health &amp; Human Services, Food Drug Administration, \"Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,\"",
"      <i>",
"       Federal Register",
"      </i>",
"      , 2000, 65(17):4103-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2001. Available at",
"      <a href=\"file://www.nal.usda.gov/fnic/DRI//DRI_Vitamin_A/vitamin_a_full_report.pdf\">",
"       file://www.nal.usda.gov/fnic/DRI//DRI_Vitamin_A/vitamin_a_full_report.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo J, Canada T, Johnson D, et al, \"Safe Practices for Parenteral Nutrition,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2004, 28(6):S39-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29301/abstract-text/15568296/pubmed\" id=\"15568296\" target=\"_blank\">",
"        15568296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanek VW, Borum P, Buchman A, et al, \"A.S.P.E.N. Position Paper: Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi-trace Element Products,\"",
"      <i>",
"       Nutr Clin Pract",
"      </i>",
"      , 2012, 27(4):440-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29301/abstract-text/22730042/pubmed\" id=\"22730042\" target=\"_blank\">",
"        22730042",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88581 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29301=[""].join("\n");
var outline_f28_39_29301=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235812\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235813\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043062\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16233034\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043071\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235804\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235793\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16233098\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043070\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043063\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F554161\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235822\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16233026\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16233028\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16233027\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300239\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223740\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043069\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235800\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13881520\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16233099\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16233029\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16233030\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043077\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/88581\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/88581|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/57/17300?source=related_link\">",
"      Zinc sulfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/38/4708?source=related_link\">",
"      Zinc sulfate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_39_29302="Paraphimosis: Definition, pathophysiology, and clinical features";
var content_f28_39_29302=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paraphimosis: Definition, pathophysiology, and clinical features",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/39/29302/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29302/contributors\">",
"     Matthew Tews, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29302/contributors\">",
"     Jonathan I Singer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/39/29302/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29302/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29302/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/39/29302/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29302/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/39/29302/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraphimosis occurs when the foreskin in the uncircumcised or partially circumcised male is retracted behind the glans penis, develops venous and lymphatic congestion, and cannot be returned to its normal position (",
"    <a class=\"graphic graphic_picture graphicRef76100 \" href=\"UTD.htm?22/33/23057\">",
"     picture 1",
"    </a>",
"    ). This urologic emergency impedes blood flow to the glans penis with potential for permanent damage and gangrene.",
"   </p>",
"   <p>",
"    In infants and young children, paraphimosis usually results from self manipulation by the child or inappropriate retraction of the foreskin by the caretaker in misguided attempts at cleaning. In the sexually active adolescent or adult male, intercourse is a potential precipitant. Iatrogenic paraphimosis follows cystoscopy or bladder catheterization if the foreskin is not reduced back over the glans penis by the medical provider.",
"   </p>",
"   <p>",
"    Paraphimosis reduction is usually accomplished with pain control, local measures to reduce edema, and manual or minimally invasive manipulation. Emergent urologic consultation is indicated in the minority of patients in whom minimally invasive reduction fails or in patients with prolonged paraphimosis complicated by glans penis necrosis or infection.",
"   </p>",
"   <p>",
"    This review discusses the anatomy, pathophysiology, and clinical features of paraphimosis. The reduction of paraphimosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33543?source=see_link\">",
"     \"Paraphimosis reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms paraphimosis and phimosis are often confused:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paraphimosis refers to a retracted foreskin in an uncircumcised or partially circumcised male that cannot be returned to normal position.",
"     </li>",
"     <li>",
"      Phimosis is defined as a tight foreskin that cannot be retracted to expose the glans penis. In young children, phimosis is normal or physiologic. In older patients, infections such as balanoposthitis or other inflammatory conditions result in scarring and pathologic phimosis that requires urologic referral. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H172410114#H172410114\">",
"       \"Care of the uncircumcised penis\", section on 'Physiologic phimosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H172410341#H172410341\">",
"       \"Care of the uncircumcised penis\", section on 'Pathologic phimosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The penis in the uncircumcised male consists of the penile shaft, glans penis with the coronal sulcus (rim of the glans), and the foreskin (",
"    <a class=\"graphic graphic_figure graphicRef76391 \" href=\"UTD.htm?19/0/19462\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The foreskin is a physiologic covering for the glans penis. The prepuce forms during the twelfth week of fetal life as an epithelial fold that grows inward from the base of the glans penis. The squamous epithelium of the inner surface of the foreskin is continuous with the epithelium covering the glans penis. The prepuce functions to physically and immunologically protect the glans penis and external urethral orifice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At birth, the foreskin and glans penis are fused, and the prepuce is not retractable. This is a congenital or physiologic phimosis. The epithelial cells of the inner surface of the foreskin desquamate forming white pearly masses, called smegma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H29532338#H29532338\">",
"     \"Care of the uncircumcised penis\", section on 'Normal development of the foreskin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H172410114#H172410114\">",
"     \"Care of the uncircumcised penis\", section on 'Physiologic phimosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smegma works its way to the tip of the glans penis and is extruded as part of the normal separation process of the glans penis and foreskin. The adhesions gradually separate secondary to hormonal influence and intermittent erection. The foreskin becomes more retractable as the creation of the space between the glans penis and inner foreskin develops.",
"   </p>",
"   <p>",
"    Several studies of prepuce development have found that approximately half of uncircumcised males have fully retractable foreskins by age 10 years. By the age of 17, 95 to 99 percent of foreskins are fully retractable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H86213584#H86213584\">",
"     \"Care of the uncircumcised penis\", section on 'Foreskin retraction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraphimosis is caused by foreskin entrapment behind the coronal sulcus (",
"    <a class=\"graphic graphic_picture graphicRef76100 \" href=\"UTD.htm?22/33/23057\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76391 \" href=\"UTD.htm?19/0/19462\">",
"     figure 1",
"    </a>",
"    ). Impairment of lymphatic and venous flow from the constricting ring of foreskin causes venous engorgement of the glans penis with swelling. Ultimately, arterial flow to the glans penis becomes compromised over a period of hours to days [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/2\">",
"     2",
"    </a>",
"    ]. Bulbar, urethral, and pudendal vessels may be sequentially impaired. If paraphimosis is not corrected in a timely fashion, penile necrosis, infarction of the glans, or gangrene may occur, followed by autoamputation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraphimosis is an uncommon emergency department (ED) complaint [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/6\">",
"     6",
"    </a>",
"    ]. The majority of the penile conditions are traumatic (bites, penile tourniquet syndrome, zipper entrapment) or infectious (balanitis, balanoposthitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Predisposing factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Phimosis",
"      </strong>",
"      &ndash; Patients at the greatest risk for developing paraphimosis typically have a partial phimosis (the preputial opening is too small to easily fit over the coronal sulcus of the glans penis). Subsequent retraction of the foreskin leads to entrapment and paraphimosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H172410114#H172410114\">",
"       \"Care of the uncircumcised penis\", section on 'Physiologic phimosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H172410341#H172410341\">",
"       \"Care of the uncircumcised penis\", section on 'Pathologic phimosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In the infant and young boy, this phimosis is usually physiologic. Retraction with paraphimosis typically occurs during cleaning by a caretaker. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H172410114#H172410114\">",
"       \"Care of the uncircumcised penis\", section on 'Physiologic phimosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H9377172#H9377172\">",
"       \"Care of the uncircumcised penis\", section on 'Routine care and hygiene'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Pathologic phimosis may follow balanoposthitis or other penile inflammation in adolescents and older men, or may relate to loss of skin elasticity and decreased frequency of erection with aging in elderly men [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/23/24953?source=see_link\">",
"       \"Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H172410341#H172410341\">",
"       \"Care of the uncircumcised penis\", section on 'Pathologic phimosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Genitourinary procedures",
"      </strong>",
"      &ndash; Paraphimosis is frequently caused by failure of medical personnel to return a fully retractable foreskin to normal position after cystoscopy or bladder catheterization [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Sexual activity",
"      </strong>",
"      &ndash; There are numerous case reports in the literature about sexual causes of paraphimosis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. Activities such as erotic dancing have also caused paraphimosis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Penile trauma",
"      </strong>",
"      &ndash; Paraphimosis following body piercing of the genitals in which the pierced glans or foreskin is too painful to allow foreskin retraction has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Other",
"      </strong>",
"      &ndash; Paraphimosis may occur in a male who forgets to replace the foreskin after cleaning or after urination [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/4\">",
"       4",
"      </a>",
"      ]. Paraphimosis has also developed in association with Plasmodium falciparum infection [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Swelling of the penis and penile pain are the two most common complaints in males with paraphimosis. Paraphimosis is also an important cause of irritability in the preverbal infant.",
"   </p>",
"   <p>",
"    Occasionally, a nonretractable foreskin may be an incidental finding by the parents when changing a diaper or when giving their child a bath. Dysuria or decreased urinary stream may also be described.",
"   </p>",
"   <p>",
"    Urinary obstruction is a late feature of paraphimosis and indicates the need for urgent reduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33543?source=see_link\">",
"     \"Paraphimosis reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In sexually active individuals who are uncircumcised, erections alone may precipitate paraphimosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/14\">",
"     14",
"    </a>",
"    ]. Paraphimosis may also occur in uncircumcised men who forget to reduce the foreskin after sex, cleaning, or urination. The timing of the presenting paraphimosis may be variable. Sexually active men may fall asleep after intercourse without replacing the foreskin, only to wake up with paraphimosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;On physical examination, the patient is typically in significant pain. The examiner should ensure that no constricting foreign body, including hair, clothing, rubber bands, or metal objects from piercing are present. The following findings are typically evident on inspection of the penis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Edema and tenderness of the glans penis",
"     </li>",
"     <li>",
"      Painful swelling of the distal retracted foreskin",
"     </li>",
"     <li>",
"      A constricting band of tissue proximal to the head of the penis at the coronal sulcus (",
"      <a class=\"graphic graphic_picture graphicRef76100 \" href=\"UTD.htm?22/33/23057\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The penile shaft appears flaccid and unaffected",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With ischemia of the glans penis, the skin color will change from the normal pink color to blue or black. In addition, the ischemic glans penis will be firm to palpation rather than soft.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tourniquet syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain, swelling, and edema of the distal penis and foreskin may occur with a constriction of the proximal penis and appears similar to paraphimosis. In the infant, a human hair or fiber of clothing may inadvertently wrap around the penis, causing venous congestion and reduced lymphatic flow and is called the hair tourniquet syndrome. A careful inspection at the normal to abnormal interface of the penis will reveal the constricting hair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/18\">",
"     18",
"    </a>",
"    ]. Rarely, such bands may be intentionally placed on the young as an abusive event [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13044?source=see_link\">",
"     \"Hair entrapment removal techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the adolescent or adult, rings, studs or constricting bands intentionally placed to sustain erections, prevent ejaculation, or heighten sexual pleasure should also be visible with inspection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Balanoposthitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balanoposthitis, an inflammation of the glans penis and the foreskin, creates complaints of irritation, burning, or itching. Pain is less frequent than in paraphimosis, and drainage is typically present. Physical findings may be similar to paraphimosis with an inflamed surface and a moist, glistening transudate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/23/24953?source=see_link\">",
"     \"Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Insect bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonvenomous and venomous insect bites to the glans penis cause penile swelling, erythema, genital itching, and mild discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29302/abstract/21\">",
"     21",
"    </a>",
"    ]. Causative agents include bed bugs, chiggers, mosquitoes, fleas, spiders, and hymenoptera (eg, bees, wasps). On examination, asymmetric soft tissue swelling that is more lateral or ventral and a small punctate lesion should give clues to the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43556?source=see_link\">",
"     \"Chigger bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=see_link\">",
"     \"Insect bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=see_link\">",
"     \"Approach to the patient with a suspected spider bite: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Generalized edematous state",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painless penile edema may occur as a manifestation of an edematous state secondary to cardiac, renal, or hepatic problems. The diagnosis is suggested by evidence of organ dysfunction on the general examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7288?source=see_link\">",
"     \"Evaluation and management of edema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painless penile swelling also develops in patients with angioedema. Angioedema generally develops over minutes to hours and resolves in 24 to 48 hours. The skin is either normal in color or erythematous. Pruritus is usually absent, unless the angioedema is associated with urticarial lesions (which are intensely pruritic). Pain and warmth are variably present.",
"   </p>",
"   <p>",
"    Etiologies include allergy, C1 inhibitor deficiency, and adverse drug effect of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary management of paraphimosis consists of timely reduction of the foreskin back over the glans penis and requires appropriate pain control, adjuncts to reduce swelling, and judicious selection of reduction technique. This procedure can usually be accomplished by the primary care or emergency physician and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33543?source=see_link\">",
"     \"Paraphimosis reduction\"",
"    </a>",
"    .) Most patients fully recover from paraphimosis without sequelae.",
"   </p>",
"   <p>",
"    If signs of glans penis arterial compromise are present (eg, blue or black skin coloration with firmness to palpation), immediate reduction and urologic consultation are warranted. If subspecialty care is not emergently available, the medical provider should proceed to reduce the paraphimosis with the understanding that minimally invasive techniques may fail and that a dorsal slit procedure may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33543?source=see_link\">",
"     \"Paraphimosis reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma to the foreskin during paraphimosis reduction may lead to phimosis. For this reason, many advocate referral of all patients to an urologist after paraphimosis reduction to determine the need for circumcision. In addition, patients who have a repeated episode of paraphimosis warrant referral for circumcision.",
"   </p>",
"   <p>",
"    In patients for whom paraphimosis reduction is uneventful, circumcision may not be necessary and follow-up may occur with the primary care provider in one to two weeks in order to evaluate for secondary infection and to reinforce proper hygiene.",
"   </p>",
"   <p>",
"    Emergent urologic consultation is indicated for patients in whom initial attempts at reduction are unsuccessful and for patients with signs of glans penis ischemia, infection, or gangrene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents of young, uncircumcised boys should be educated not to forcefully retract the phimotic foreskin. Adolescents and adults should be reminded to return the foreskin to normal position after cleaning and sexual activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/48/41729?source=see_link\">",
"       \"Patient information: Caring for an uncircumcised penis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paraphimosis refers to a retracted foreskin in an uncircumcised male that cannot be returned to normal position (",
"      <a class=\"graphic graphic_picture graphicRef76100 \" href=\"UTD.htm?22/33/23057\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In infants and young children, paraphimosis usually results from inappropriate retraction of the physiologically phimotic foreskin by the caretaker in misguided attempts at cleaning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H86213584#H86213584\">",
"       \"Care of the uncircumcised penis\", section on 'Foreskin retraction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H172410114#H172410114\">",
"       \"Care of the uncircumcised penis\", section on 'Physiologic phimosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the sexually active adolescent or adult, intercourse is a potential precipitant. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iatrogenic paraphimosis follows cystoscopy or bladder catheterization if the foreskin is not reduced back over the glans penis by the medical provider. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Swelling of the penis and penile pain are the two most common complaints in uncircumcised males with paraphimosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On inspection, the glans penis and distal foreskin appear swollen with a constricting band present at the coronal sulcus (",
"      <a class=\"graphic graphic_picture graphicRef76100 \" href=\"UTD.htm?22/33/23057\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef76391 \" href=\"UTD.htm?19/0/19462\">",
"       figure 1",
"      </a>",
"      ). Blue or black skin discoloration of the glans penis and firmness of the glans to palpation indicate ischemia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary management of paraphimosis consists of timely reduction of the foreskin back over the glans penis and requires appropriate pain control, adjuncts to reduce swelling, and judicious selection of reduction technique. This procedure can usually be accomplished by the primary care or emergency physician and is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33543?source=see_link\">",
"       \"Paraphimosis reduction\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If signs of glans penis arterial compromise are present, (eg, blue or black skin coloration with firmness to palpation), immediate reduction and urologic consultation are warranted. If subspecialty care is not emergently available, the medical provider should proceed to reduce the paraphimosis with the understanding that minimally invasive techniques may fail and that a dorsal slit procedure may be necessary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33543?source=see_link\">",
"       \"Paraphimosis reduction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/1\">",
"      Porter WM, Bunker CB. The dysfunctional foreskin. Int J STD AIDS 2001; 12:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/2\">",
"      Reynard JM, Barua JM. Reduction of paraphimosis the simple way - the Dundee technique. BJU Int 1999; 83:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/3\">",
"      McCollough M, Sharieff GQ. Abdominal surgical emergencies in infants and young children. Emerg Med Clin North Am 2003; 21:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/4\">",
"      Hollowood AD, Sibley GN. Non-painful paraphimosis causing partial amputation. Br J Urol 1997; 80:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/5\">",
"      Raman SR, Kate V, Ananthakrishnan N. Coital paraphimosis causing penile necrosis. Emerg Med J 2008; 25:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/6\">",
"      Barone JG, Fleisher MH. Treatment of paraphimosis using the \"puncture\" technique. Pediatr Emerg Care 1993; 9:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/7\">",
"      Gausche M. Genitourinary surgical emergencies. Pediatr Ann 1996; 25:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/8\">",
"      Williams JC, Morrison PM, Richardson JR. Paraphimosis in elderly men. Am J Emerg Med 1995; 13:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/9\">",
"      Fari&ntilde;a LA, Alonso MV, Horjales M, Zungri ER. [Contact-derived allergic balanoposthitis and paraphimosis through topical application of celandine juice]. Actas Urol Esp 1999; 23:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/10\">",
"      Verma S. Coital penile trauma with severe paraphimosis. J Eur Acad Dermatol Venereol 2005; 19:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/11\">",
"      Berk DR, Lee R. Paraphimosis in a middle-aged adult after intercourse. Am Fam Physician 2004; 69:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/12\">",
"      Finkelstein JA. \"Puncture\" technique for treating paraphimosis. Pediatr Emerg Care 1994; 10:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/13\">",
"      Ramdass MJ, Naraynsingh V, Kuruvilla T, Maharaj D. Case report. Paraphimosis due to erotic dancing. Trop Med Int Health 2000; 5:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/14\">",
"      Higgins SP. Painful swelling of the prepuce occurring during penile erection. Genitourin Med 1996; 72:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/15\">",
"      Jones SA, Flynn RJ. An unusual (and somewhat piercing) cause of paraphimosis. Br J Urol 1996; 78:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/16\">",
"      Hansen RB, Olsen LH, Langkilde NC. Piercing of the glans penis. Scand J Urol Nephrol 1998; 32:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/17\">",
"      Gozal D. Paraphimosis apparently associated with Plasmodium falciparum infection. Trans R Soc Trop Med Hyg 1991; 85:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/18\">",
"      Garty BZ, Mimouni M, Varsano I. Penile tourniquet syndrome. Cutis 1983; 31:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/19\">",
"      Tournel G, Desurmont M, B&eacute;cart A, et al. Child barbarity and torture: a case report. Am J Forensic Med Pathol 2006; 27:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/20\">",
"      Greenspan L. Tourniquet syndrome caused by metallic bands: a new tool for removal. Ann Emerg Med 1982; 11:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29302/abstract/21\">",
"      Smith GA, Sharma V, Knapp JF, Shields BJ. The summer penile syndrome: seasonal acute hypersensitivity reaction caused by chigger bites on the penis. Pediatr Emerg Care 1998; 14:116.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6482 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29302=[""].join("\n");
var outline_f28_39_29302=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tourniquet syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Insect bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Generalized edematous state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6482\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6482|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/0/19462\" title=\"figure 1\">",
"      Penis anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6482|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/33/23057\" title=\"picture 1\">",
"      Paraphimosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=related_link\">",
"      Approach to the patient with a suspected spider bite: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/23/24953?source=related_link\">",
"      Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=related_link\">",
"      Care of the uncircumcised penis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43556?source=related_link\">",
"      Chigger bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7288?source=related_link\">",
"      Evaluation and management of edema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13044?source=related_link\">",
"      Hair entrapment removal techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=related_link\">",
"      Insect bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33543?source=related_link\">",
"      Paraphimosis reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/48/41729?source=related_link\">",
"      Patient information: Caring for an uncircumcised penis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_39_29303="Esterified estrogens: Drug information";
var content_f28_39_29303=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Esterified estrogens: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/56/7046?source=see_link\">",
"    see \"Esterified estrogens: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Menest&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F167701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Estragyn;",
"     </li>",
"     <li>",
"      Estratab&reg;;",
"     </li>",
"     <li>",
"      Menest&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F167718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Estrogen Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F167704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer, advanced:",
"     </b>",
"     Oral: 1.25-2.5 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Female hypoestrogenism due to hypogonadism:",
"     </b>",
"     Oral: 2.5-7.5 mg/day in divided doses for 20 days followed by a 10-day rest period. Administer cyclically (3 weeks on and 1 week off). If bleeding does not occur by the end of the 10-day period, repeat the same dosing schedule; the number of courses dependent upon the responsiveness of the endometrium. If bleeding occurs before the end of the 10-day period, begin an estrogen-progestin cyclic regimen of 2.5-7.5 mg/day in divided doses for 20 days; during the last 5 days of estrogen therapy, give an oral progestin. If bleeding occurs before regimen is concluded, discontinue therapy and resume on the fifth day of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Female hypoestrogenism due to castration and primary ovarian failure:",
"     </b>",
"     Oral: 1.25 mg/day, cyclically. Adjust dosage upward or downward, according to the severity of symptoms and patient response. For maintenance, adjust dosage to lowest level that will provide effective control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vasomotor symptoms associated with menopause:",
"     </b>",
"     Oral: 1.25 mg/day administered cyclically (3 weeks on and 1 week off). If patient has not menstruated within the last 2 months or more, cyclic administration is started arbitrary. If the patient is menstruating, cyclical administration is started on day 5 of the bleeding. For short-term use only and should be discontinued as soon as possible. Re-evaluate at 3- to 6-month intervals for tapering or discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vulvar and vaginal atrophy associated with menopause:",
"     </b>",
"     Oral: 0.3 to &ge;1.25 mg/day, depending on the tissue response of the individual patient. Administer cyclically. For short-term use only and should be discontinued as soon as possible. Re-evaluate at 3- to 6-month intervals for tapering or discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, metastatic (appropriately selected patients):",
"     </b>",
"     Males and postmenopausal females: Oral: 10 mg 3 times/day for at least 3 months",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F167705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15837998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15837999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F167679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menest&reg;: 0.3 mg, 0.625 mg, 1.25 mg, 2.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F167663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9518183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food at same time each day.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F167680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate-to-severe vasomotor symptoms associated with menopause; treatment of moderate-to-severe vulvar and vaginal atrophy associated with menopause; hypoestrogenism (due to hypogonadism, castration, or primary ovarian failure); advanced prostatic cancer (palliation), metastatic breast cancer (palliation) in men and postmenopausal women",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F167725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [oral]; Strength of recommendation - strong [oral]).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F167716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, hypertension, MI, stroke, venous thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dementia exacerbation, dizziness, epilepsy exacerbation, headache, irritability, mental depression, migraine, mood disturbances, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, chloasma, erythema multiforme, erythema nodosum, hemorrhagic eruption, hirsutism, pruritus, loss of scalp hair, melasma, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast cancer, breast enlargement, breast tenderness, carbohydrate intolerance, fibrocystic breast changes, galactorrhea, hypocalcemia, libido (changes in), nipple discharge, premenstrual like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, bloating, gallbladder disease, nausea, pancreatitis, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Alterations in frequency and flow of menstrual patterns, breakthrough bleeding,  changes in cervical secretions, cervical ectropion changes, cystitis-like syndrome, dysmenorrhea, endometrial hyperplasia, endometrial cancer, increased size of uterine leiomyomata, ovarian cancer, vaginal candidiasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Aggravation of porphyria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hemangioma enlargement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, chorea, leg cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Contact lens intolerance, corneal curvature steepening, retinal vascular thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation, pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid/anaphylactic reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F167683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to estrogens or any component of the formulation; undiagnosed abnormal vaginal bleeding; DVT or PE (current or history of); active or recent (within 1 year) arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast (known, suspected or history of), except in appropriately selected patients being treated for metastatic disease; estrogen-dependent tumor; hepatic dysfunction or disease; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F167667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012).  An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may also lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.",
"     </b>",
"     Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Adverse cardiovascular events have also been reported in males taking estrogens for prostate cancer. Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with severe hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use caution with migraine; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of oral estrogen (with or without progestins) in this age group due to potential of increased risk of breast and endometrial cancers, and lack of proven cardioprotection and cognitive protection (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Prior to puberty, estrogens may cause premature closure of the epiphyses, premature breast development in girls or gynecomastia in boys. Vaginal bleeding and vaginal cornification may also be induced in girls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, estrogens should be discontinued at least 4-6  weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vulvar and vaginal atrophy use: Moderate-to-severe symptoms of vulvar and vaginal atrophy include vaginal dryness, dyspareunia, and atrophic vaginitis. When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F167714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2B6 (minor), CYP2C9 (minor), CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F167672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F167695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (routine use increases estrogen plasma concentrations and risk of breast cancer). Ethanol may also increase the risk of osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Folic acid absorption may be decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F167687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, the use of estrogen and progestin as in combination hormonal contraceptives have not been associated with teratogenic effects when inadvertently taken early in pregnancy. This product is contraindicated for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F167709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F167688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogen has been shown to decrease the quantity and quality of human milk; use only if clearly needed; monitor the growth of the infant closely.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F167689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food at same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F167686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Menest Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg (100): $94.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.625 mg (100): $133.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg (100): $186.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (50): $173.92",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F167677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Routine physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer in female patients with uterus. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menopausal symptoms; vulvar and vaginal atrophy: Assess need for therapy at 3- to 6-month intervals",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F167690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Estratab (CA);",
"     </li>",
"     <li>",
"      Menest (AR, CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F167666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not &lt;90%. Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. In males and following menopause in females, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F167682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed; high concentrations in the sex hormone target organs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Bound to sex hormone-binding globulin and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; partial metabolism via CYP3A4 enzymes; estradiol is reversibly converted to estrone and estriol; oral estradiol also undergoes enterohepatic recirculation by conjugation in the liver, followed by excretion of sulfate and glucuronide conjugates into the bile, then hydrolysis in the intestine and estrogen reabsorption. Sulfate conjugates are the primary form found in postmenopausal women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as estradiol, estrone, estriol, and their glucuronide and sulfate conjugates)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grodstein F, Stampfer MJ, Colditz GA, et al, &ldquo;Postmenopausal Hormone Therapy and Mortality,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 336(25):1769-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/9187066/pubmed\" id=\"9187066\" target=\"_blank\">",
"        9187066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hulley S, Grady D, Bush T, et al, &ldquo;Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 280(7):605-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/9718051/pubmed\" id=\"9718051\" target=\"_blank\">",
"        9718051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, Department of Health and Human Services, &ldquo;WHIMS Study on Estrogen/Progestin,&rdquo; May 27, 2003. Available at",
"      <a href=\"file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winship KA, &ldquo;Unopposed Oestrogens,&rdquo;",
"      <i>",
"       Adverse Drug React Acute Poisoning Rev",
"      </i>",
"      , 1987, 6(1):37-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/39/29303/abstract-text/3303864/pubmed\" id=\"3303864\" target=\"_blank\">",
"        3303864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9425 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29303=[""].join("\n");
var outline_f28_39_29303=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708757\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167700\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167701\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167718\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167704\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167705\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837998\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837999\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167679\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167663\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518183\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167680\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167725\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167716\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167683\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167667\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167714\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167672\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167695\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167687\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167709\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167688\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167689\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167686\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167677\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167690\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167666\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167682\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9425\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9425|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/56/7046?source=related_link\">",
"      Esterified estrogens: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_39_29304="Iliac artery aneurysm";
var content_f28_39_29304=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Iliac artery aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/39/29304/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29304/contributors\">",
"     Melissa L Kirkwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/39/29304/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29304/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29304/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/39/29304/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29304/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/39/29304/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H544011285\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysmal degeneration of the iliac arteries (common, internal, external iliac) can occur in isolation, or in association with other large vessel aneurysms (eg, abdominal aorta, femoral artery).",
"   </p>",
"   <p>",
"    Iliac artery aneurysms (IAAs) are often diagnosed as a result of screening or other imaging studies. Symptoms do not typically occur unless the aneurysm is large and are primarily related to compression of surrounding structures. Like abdominal aortic aneurysms, IAAs have a propensity for life-threatening rupture as diameter increases. On occasion, aneurysm thrombosis may lead to peripheral thromboembolism or acute limb ischemia.",
"   </p>",
"   <p>",
"    The management of asymptomatic IAAs depends upon the size of the aneurysm, the presence or absence of coexisting abdominal aortic aneurysm or other aneurysm (eg, femoral, popliteal), and patient comorbidities. Patients with symptomatic IAAs should be referred for prompt vascular evaluation and repair.",
"   </p>",
"   <p>",
"    The diagnosis and management of IAAs will be reviewed here. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8809?source=see_link\">",
"     \"Surgical and endovascular repair of iliac artery aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20024761\">",
"    <span class=\"h1\">",
"     ANATOMIC ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seventy percent of iliac aneurysms occur in the common iliac artery, while 20 and 10 percent are found in the internal and external iliac arteries, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/1\">",
"     1",
"    </a>",
"    ]. About two-thirds of patients with IAA have involvement or more than one segment of the iliac arterial tree; one-third of IAAs are bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The common iliac arteries are the terminal branches of the abdominal aorta and arise at the level of the 4",
"    <sup>",
"     th",
"    </sup>",
"    lumbar vertebra (",
"    <a class=\"graphic graphic_figure graphicRef51087 \" href=\"UTD.htm?42/14/43234\">",
"     figure 1",
"    </a>",
"    ). The common iliac artery bifurcates into the external iliac and internal iliac arteries at the pelvic inlet. The internal iliac artery gives off branches to the pelvic viscera and also supplies the musculature of the pelvis. The external iliac artery passes beneath the inguinal ligament to become the common femoral artery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20024768\">",
"    <span class=\"h2\">",
"     Definition of iliac aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any vessel, a true IAA is defined as a focal dilation of the artery with a diameter that is increased more than 50 percent compared with the normal diameter of the artery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/4\">",
"     4",
"    </a>",
"    ]. In men, the common iliac artery normally averages 1.2 &plusmn; 0.2 cm, whereas in women it is smaller, averaging 1.0 &plusmn; 0.2 cm. The internal iliac artery in both genders averages 0.54 &plusmn; 0.15 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/5\">",
"     5",
"    </a>",
"    ]. Based upon these values, for the common iliac artery, an aneurysm is generally present if the artery measures &gt;1.85 cm in males and &gt;1.5 cm in females [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/6\">",
"     6",
"    </a>",
"    ]. An internal iliac artery with a diameter more than 0.8 cm is likely aneurysmal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107323044\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solitary iliac artery aneurysms (IAAs) are uncommon. The overall incidence of solitary IAA in the general population is estimated to be about 0.03 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/7\">",
"     7",
"    </a>",
"    ]. Solitary IAA represents approximately 0.4 to 1.9 percent of all cases of aneurysmal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/8\">",
"     8",
"    </a>",
"    ]. The incidence of IAA associated with abdominal aortic aneurysm (AAA) is higher. Given an incidence of AAA of about 5 percent based upon screening studies, and that about 25 percent of patients with AAA have an IAA, the incidence of IAA associated with AAA in the general population is about 1 percent.",
"   </p>",
"   <p>",
"    Risk factors for degenerative IAA are the similar risk factors for other degenerative large vessel aneurysms (abdominal aortic aneurysm, popliteal aneurysm) and include male gender, white race, advancing age, history of smoking, hypertension and other risk factors for atherosclerotic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=see_link&amp;anchor=H1460375#H1460375\">",
"     \"Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H1382371318#H1382371318\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective study evaluating surgical treatment for isolated IAA in 56 patients, 96 percent of the patients were men, 60 percent had a significant smoking history, 79 percent had hypertension, 50 percent had coronary artery disease, and 27 percent of patients had prior AAA repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large retrospective review examining 715 common IAAs, 94 percent of patients were men, the mean age was 72 years, and 69 percent of patients had hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/10\">",
"     10",
"    </a>",
"    ]. In this series, hypertension predicted faster iliac artery expansion compared with normotensive patients (0.32 versus 0.14",
"    <span class=\"nowrap\">",
"     cm/year)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20024782\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of IAAs are true aneurysms that are the result of arterial wall degeneration. Less commonly, a pseudoaneurysm is the cause of iliac artery dilation and can be due to para-anastomotic graft failure following a prior aortic graft repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/6\">",
"     6",
"    </a>",
"    ], vascular injury from penetrating mechanisms (gunshot, knife), or iatrogenic injury during hip replacement, lumbar disc surgery or other pelvic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IAAs have also been associated with Behcet&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/13\">",
"     13",
"    </a>",
"    ], fibromuscular dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/14\">",
"     14",
"    </a>",
"    ], Takayasu&rsquo;s arteritis and other connective tissue disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/15\">",
"     15",
"    </a>",
"    ]. In rare cases, infected aneurysm can develop in the iliac arteries and organisms including Salmonella, Staphylococcus aureus, Klebsiella and Candida have been isolated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/6,16\">",
"     6,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=see_link\">",
"     \"Overview of infected (mycotic) arterial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20026244\">",
"    <span class=\"h2\">",
"     Aneurysm formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;True aneurysm formation is due to a loss of the mechanical integrity of the vessel wall due to an altered balance between the production and degradation of the vascular wall constituents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/17\">",
"     17",
"    </a>",
"    ]. The etiology of this imbalance is multifactorial and likely a complex interplay of inflammatory, immunologic and potentially mechanical and genetic factors. A common systemic etiology for large vessel aneurysm formation is supported by the occurrence of multiple large vessel aneurysms in the same patient. The pathogenesis of abdominal aortic aneurysm is discussed in detail elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H431203144#H431203144\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Aneurysm diameter and rupture risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20026251\">",
"    <span class=\"h2\">",
"     Iliac artery expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of isolated IAAs and those in association with an AAA is continued expansion over time with the observed rate of expansion related to iliac artery diameter on initial diagnosis. Data for the expansion of IAA come mostly from studies evaluating the much more prevalent common iliac artery aneurysm. There are few studies relating to the natural history of internal and external IAAs to help guide their management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H721247733\">",
"    <span class=\"h2\">",
"     Isolated iliac artery aneurysms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective review evaluating aneurysm growth rates, isolated IAAs &lt;3 cm in diameter expanded at an average rate of 1.1 mm per year, whereas aneurysms &gt;3 cm expanded by 2.6 mm per year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/18\">",
"     18",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20025038\">",
"    <span class=\"h3\">",
"     Iliac artery aneurysms with coexistent abdominal aortic aneurysms",
"    </span>",
"    &nbsp;&mdash;&nbsp;IAA is frequently associated with abdominal aortic aneurysm (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72488 \" href=\"UTD.htm?26/54/27490\">",
"     image 1",
"    </a>",
"    ). Between 15 to 40 percent of patients who present with abdominal aortic aneurysm have at least one IAA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/10,19-24\">",
"     10,19-24",
"    </a>",
"    ]. In a retrospective review of 439 patients with 715 common IAAs, 86 percent had an abdominal aortic aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/10\">",
"     10",
"    </a>",
"    ]. Iliac aneurysm was bilateral in 70 percent of those who had an associated AAA.",
"   </p>",
"   <p>",
"    In a review of 190 patients with abdominal aortic aneurysm (AAA), surveillance found that 41 percent of the patients had a concomitant common IAA defined by a diameter &gt;16 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/24\">",
"     24",
"    </a>",
"    ]. In this study, a regression model was developed to determine iliac artery growth rates. Iliac artery expansion depended upon baseline iliac diameter. A common iliac artery measuring 16 mm could be expected to expand to 25 mm within 10 years, and a 23 mm common iliac artery would reach 35 mm. Expansion of an IAA was more likely in patients who had AAA that also expanded. No correlation was found between AAA growth rate and CIA growth rate, or AAA diameter and CIA growth rate. The authors concluded the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A common iliac artery measuring &lt;16 mm when diagnosed and associated with AAA &lt;4 cm could reasonably be reevaluated when intervention for the AAA is planned because of the slower growth rates",
"     </li>",
"     <li>",
"      A common iliac artery measuring of &gt;16 mm should be followed independent of the AAA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although this model is helpful in guiding surveillance of small iliac artery aneurysms, it does not predict growth for common IAA &gt;26 mm. It also does not reflect the impact of smoking and hypertension on common IAA growth rates.",
"   </p>",
"   <p>",
"    Other clinical studies have found increased expansion rates for larger versus smaller iliac artery diameters.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review of 201 patients found that after elective open infra-renal abdominal aortic aneurysm repair with a tube graft, aneurysmal common IAAs measuring 19 to 25 mm in diameter expanded more compared with normal caliber common iliac arteries over an average follow-up of 7.1 years (mean growth 2.4 mm versus 1.1 mm) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Expansion of IAAs following endovascular repair of abdominal aortic aneurysm was 1.5 mm for larger (&gt;16 mm) and 1.1 mm with smaller (&le;16 mm) iliac arteries over a mean follow-up of 44 months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lastly, in a review of 438 patients with 715 common IAAs, 377 patients with 633 common IAAs had current or previously repaired AAA. Expansion rates were measured in 15 percent of the treated iliac aneurysms (n = 104). Of the common IAAs that were monitored for growth, 51 percent were &gt;3cm. The median growth rate for common IAAs &gt;3 cm was 3.2",
"      <span class=\"nowrap\">",
"       mm/year",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108704530\">",
"    <span class=\"h2\">",
"     Site of aneurysm and association with other aneurysms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an IAA also have a high incidence of aneurysms in the contralateral iliac artery and femoral arteries. The presence of these other aneurysms, particularly abdominal aortic aneurysm, impacts the management of the IAA. (See",
"    <a class=\"local\" href=\"#H108756454\">",
"     'Indications for repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus, it is important to perform a full arterial assessment when iliac aneurysm is detected because of the high rate of coexistent aneurysm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3065?source=see_link\">",
"     \"Popliteal artery aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H544011328\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of iliac artery aneurysm (IAA) depends upon its size and location. Larger aneurysms (diameter &gt;6 cm) are more likely to be associated with the development of symptoms (compression, thrombosis, thromboembolism) or iliac artery rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/2,27,28\">",
"     2,27,28",
"    </a>",
"    ]. In a study of internal IAAs, the mean size at diagnosis was 7.7 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About half of patients are asymptomatic and the IAA discovered incidentally at the time of",
"    <span class=\"nowrap\">",
"     abdominal/pelvic",
"    </span>",
"    imaging for a different indication. Plain abdominal and pelvic radiography may show the calcified wall of an aneurysm in the lower pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iliac artery aneurysms behave more like abdominal aortic aneurysm with symptoms more commonly due to expansion, compression, erosion of surrounding structures or rupture compared with symptoms related to thrombosis or thromboembolism as is seen with popliteal artery aneurysm.",
"   </p>",
"   <p>",
"    Most available studies have evaluated symptoms related to common or internal iliac artery aneurysm. The clinical presentation of external iliac artery aneurysm may be similar. A retrospective review found 11 cases of isolated true external iliac artery aneurysms. Of these, three patients were asymptomatic, three had a painful pulsatile mass, four presented with rupture, and one with peripheral embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/29\">",
"     29",
"    </a>",
"    ]. The diameter of each of the ruptured aneurysms was &gt;4 cm, and there were no cases of acute arterial thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41367772\">",
"    <span class=\"h2\">",
"     Compression of surrounding structures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms related to compression may lead to one or more of the following clinical manifestations (",
"    <a class=\"graphic graphic_figure graphicRef50540 \" href=\"UTD.htm?2/42/2727\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/8,30-33\">",
"     8,30-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compression of the ureter can lead to urinary retention, ureteric colic, pyelonephritis, and renal failure due to ureteral obstruction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"       \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Compression of the colon can cause pain with defecation, tenesmus and constipation secondary to rectal compression.",
"     </li>",
"     <li>",
"      Compression of the lumbar plexus can result in paresthesia, paresis, sciatic neuralgia, or lumbosacral pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H544011335\">",
"    <span class=\"h2\">",
"     Rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported five-year rupture rates for IAA range from 14 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/2\">",
"     2",
"    </a>",
"    ], and as many as 33 percent of patients with isolated iliac aneurysms present with rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/2,8,34\">",
"     2,8,34",
"    </a>",
"    ]. The average size of ruptured isolated iliac aneurysms is between 5 and 7 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/2,10,27\">",
"     2,10,27",
"    </a>",
"    ]. The size of ruptured external IAA may be slightly smaller at 4 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iliac aneurysm rupture causes acute abdominal, and thigh or groin pain, often accompanied by hemodynamic instability. Retroperitoneal rupture may be contained but intraperitoneal rupture can lead to rapid exsanguination. Rupture into the rectum, ureter, bladder, iliac veins and rectus sheath have all been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. Rupture into adjacent veins can cause high output heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=see_link\">",
"     \"High-output heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mortality from iliac aneurysm rupture is high with a mortality rate of about 30 percent following open repair with reports ranging from zero to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/1,3,40,41\">",
"     1,3,40,41",
"    </a>",
"    ]. Worse outcomes are related to a delay in diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/30,42,43\">",
"     30,42,43",
"    </a>",
"    ]. Endovascular stent grafting for emergent repair has lowered perioperative mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8809?source=see_link\">",
"     \"Surgical and endovascular repair of iliac artery aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41367779\">",
"    <span class=\"h2\">",
"     Aneurysm thrombosis and thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms related to aneurysm thrombosis or thromboembolism are less common, occurring in 5 to 13 percent of patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that identified 16 aneurysms in 11 patients, only 1 patient presented with distal embolization and there were no cases of thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a review of the literature that identified 94 internal IAAs, thrombosis of the internal iliac artery did not occur [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 53 patients with isolated iliac artery aneurysm (common and internal), seven patients presented with lower extremity peripheral ischemia. Four patients had iliac aneurysm thrombosis causing symptoms of intermittent claudication and three patients had peripheral embolization as the cause of ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41368874\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of iliac artery aneurysm (IAA) may be suggested in a patient with risk factors or based upon clinical presentation. Although abdominal palpation may demonstrate a pulsatile mass that confirms the diagnosis, a negative examination does not exclude IAA. Imaging is required to definitively exclude IAA and, if an aneurysm is found, accurately determine the extent and dimensions of the aneurysm to guide further management. (See",
"    <a class=\"local\" href=\"#H544011372\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H544011342\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical exam including abdominal examination, rectal examination, and a complete peripheral arterial examination is performed to identify suspected IAA based upon the presence of risk factors, or the diagnosis of another large vessel aneurysm.",
"   </p>",
"   <p>",
"    Physical exam detects a pulsatile mass in up to 70 percent of patients with IAA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/2\">",
"     2",
"    </a>",
"    ]; however, undetected IAAs with diameters up to 11 cm have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/27\">",
"     27",
"    </a>",
"    ]. As with the diagnosis of abdominal aortic aneurysm, the sensitivity of abdominal and rectal palpation in detecting IAA is probably dependent upon the size of the aneurysm. In a retrospective review that identified 71 IAAs, a mass was detected on physical examination with abdominal palpation and rectal exam in 70 percent of patients; the mean diameter of IAA was 5.5 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/2\">",
"     2",
"    </a>",
"    ]. In another study in which the mean diameter of IAA was 3.7 cm, physical exam identified the presence of IAA in 55 percent of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An audible bruit can also indicate the presence of IAA. In a review of 53 isolated iliac artery aneurysms, a bruit was present in 18 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/33\">",
"     33",
"    </a>",
"    ]. Only 17 percent of patients in this study had a palpable mass (by abdominal exam in seven patients and rectal exam in two).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41368223\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging provides the diagnosis of IAA in patients with risk factors or physical examination findings suggestive of IAA. Abdominal and pelvic ultrasound is the screening test of choice for asymptomatic patients, whereas for patients with symptoms, abdominal and pelvic computed tomography provides a more accurate diagnosis. The diagnostic accuracy of vascular imaging for iliac aneurysm is based upon sensitivities and specificities measured using these modalities to diagnose other vascular diseases, most notably, abdominal aortic aneurysm, which is often co-existent with iliac artery aneurysm. Specific considerations for imaging the iliac artery are discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H15828721#H15828721\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultrasound of the abdomen and pelvis is a good noninvasive technique to demonstrate iliac artery disease but imaging may be limited if the iliac vessels are tortuous or deep, and overlying bowel gas may obscure the examination [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/31,47,48\">",
"       31,47,48",
"      </a>",
"      ]. The precise location of the aneurysm (common, external, internal iliac artery) may be difficult to determine on ultrasound. If the IAA can be adequately imaged with ultrasound, then ultrasound is generally used to follow the aneurysm over time for expansion. (See",
"      <a class=\"local\" href=\"#H20037944\">",
"       'Surveillance ultrasound'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Computed tomography (CT) angiography (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60706 graphicRef74061 \" href=\"UTD.htm?25/12/25801\">",
"       image 2A-B",
"      </a>",
"      ) is very accurate for diagnosing IAAs and provides extensive detail of aorto-iliac anatomy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/33\">",
"       33",
"      </a>",
"      ]. It also allows characterization of coexistent abdominal aortic aneurysm or other peripheral artery aneurysm. If ultrasound cannot make the diagnosis, we prefer to obtain CT imaging to diagnose suspected IAA [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/33\">",
"       33",
"      </a>",
"      ]. Disadvantages of CT angiography include the need for intravenous contrast and radiation exposure.",
"     </li>",
"     <li>",
"      Magnetic resonance (MR) imaging and MR angiography are equal to CT in providing an accurate diagnosis and anatomic detail; however, given its expense and other issues (metal implants, gadolinium-related nephrogenic systemic fibrosis), MR is not typically used as the study to diagnose or follow up IAA.",
"     </li>",
"     <li>",
"      Arteriography (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72488 \" href=\"UTD.htm?26/54/27490\">",
"       image 1",
"      </a>",
"      ) is invasive and inaccurate for determining the true diameter of iliac artery aneurysm because thrombus often lines the aneurysm sac obscuring the true iliac artery diameter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H544011372\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of iliac artery aneurysm (IAA) is based on published outcomes of retrospective reviews and expert consensus. Ruptured and symptomatic aneurysms are repaired to reduce mortality associated with rupture, to relieve symptoms, and reduce the risk of future rupture. Early diagnosis, careful surveillance of small iliac aneurysms and repair of symptomatic and larger iliac aneurysms reduces the morbidity and mortality associated with IAA. Multiple studies have found that mortality ranges from 20 to 55 percent for emergent repair of IAA compared with about 1 percent for elective repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/10,27,33,40,49\">",
"     10,27,33,40,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic iliac artery aneurysm (IAA) is managed conservatively with serial imaging studies, or repaired. A conservative approach is appropriate for small asymptomatic IAAs and a subset of patients with symptomatic aneurysm who have a low life expectancy or limited functional status [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/50\">",
"     50",
"    </a>",
"    ]. The decision for elective repair is based on rupture risk, which depends upon aneurysm size and upon the expected expansion rate of the aneurysm relative to the patient&rsquo;s life expectancy. The presence of other aneurysms and the risk of rupture associated with them, particularly abdominal aortic aneurysm (AAA), also impacts decision-making.",
"   </p>",
"   <p>",
"    All patients with IAA should be treated to manage their risk factors for cardiovascular disease. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H3592986#H3592986\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Conservative management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41368706\">",
"    <span class=\"h2\">",
"     Aneurysm size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the results of retrospective reviews of ruptured IAA and expert consensus opinion, an iliac artery aneurysm diameter of 3.0 cm is the traditional threshold above which asymptomatic iliac aneurysm repair is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/1,2,18,27,51\">",
"     1,2,18,27,51",
"    </a>",
"    ]. A more recent retrospective review of 715 common iliac aneurysms found that ruptured iliac aneurysms had a median diameter of 6 cm (438 patients), and no aneurysm &lt;3.8 cm in diameter ruptured [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/10\">",
"     10",
"    </a>",
"    ]. Given the natural history of iliac artery aneurysm with relatively slow growth rates and low rupture rates for iliac aneurysms &lt;3.5 cm, aneurysms up to 3.5 cm can probably be safely observed but more data is needed before confirming a higher threshold. (See",
"    <a class=\"local\" href=\"#H20037944\">",
"     'Surveillance ultrasound'",
"    </a>",
"    below.) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/10,27,33,40,49\">",
"     10,27,33,40,49",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41368713\">",
"    <span class=\"h2\">",
"     Coexistent AAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a coexisting AAA is present that meets criteria for repair, an iliac artery aneurysm that is smaller than 3.0 cm may be considered for treatment. In a multicenter study, 147 patients who previously underwent open repair of abdominal aortic aneurysm (AAA) with a tube graft were included and divided into three groups based upon common iliac artery diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Group A (n = 59): normal common iliac artery diameter &le;12 mm",
"     </li>",
"     <li>",
"      Group B (n = 53): ectatic iliac arteries with a diameter that was 12 to 18 mm",
"     </li>",
"     <li>",
"      Group C (n = 35): aneurysmal iliac arteries with a diameter &ge;18 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After 5.5 years, common iliac arteries in Group A or B remained &le;25 mm and no patient experienced significant iliac artery growth. In group C, 10 of 35 patients had a common iliac artery diameter &ge;25 mm; three patients required surgery to treat the IAA during follow-up. If the preoperative iliac artery diameter is &ge;25 mm, a bifurcated graft should be used when treating AAA and IAA simultaneously. For patients with a life expectancy of more than 8 years, taking into account iliac artery expansion rates (discussed above), repair of AAA with a bifurcated graft is justified for an IAA with a diameter &ge;18 mm.",
"   </p>",
"   <p>",
"    For patients with AAA undergoing endovascular repair, it is essential to provide adequate distal fixation of the iliac limb into the iliac artery. If appropriate apposition of the iliac endograft limb to the common iliac artery cannot be achieved due to aneurysmal dilatation, then the iliac aneurysm should be treated simultaneously. This is usually accomplished by extending the iliac limb of the AAA endograft into the external iliac artery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8809?source=see_link\">",
"     \"Surgical and endovascular repair of iliac artery aneurysm\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108756454\">",
"    <span class=\"h2\">",
"     Indications for repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taking into account expansion rates (which are about 1",
"    <span class=\"nowrap\">",
"     mm/year",
"    </span>",
"    for a 1.0 cm aneurysm and 3",
"    <span class=\"nowrap\">",
"     mm/year",
"    </span>",
"    for a 3.0 cm aneurysm), risk of rupture and the high mortality rate associated with emergent (20 to 55 versus 1 percent) compared with elective repair, indications for IAA repair include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/10,27,33,40,49\">",
"     10,27,33,40,49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20026251\">",
"     'Iliac artery expansion'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H544011335\">",
"     'Rupture'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ruptured IAA &ndash; Ruptured IAA is a surgical emergency and repair should be performed without delay. (See",
"      <a class=\"local\" href=\"#H544011335\">",
"       'Rupture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic IAA &ndash; Patients who present with symptoms generally have larger aneurysms that are at a high risk for rupture and IAA should be repaired urgently. (See",
"      <a class=\"local\" href=\"#H544011328\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapidly expanding IAA &ndash; Rapidly expanding IAA (&ge;7 mm in six months or &gt;1 cm in one year) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/10,51\">",
"       10,51",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H20026251\">",
"       'Iliac artery expansion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic IAA &ge;3.0 cm. (See",
"      <a class=\"local\" href=\"#H41368706\">",
"       'Aneurysm size'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coexistent AAA repair &ndash; Patients with AAA associated with common iliac arteries &ge;2.5 cm are treated by using a bifurcated graft rather than a tube graft. In association with endovascular aneurysm repair of AAA, common iliac aneurysms of any size are treated to obtain an adequate distal seal zone. (See",
"      <a class=\"local\" href=\"#H41368713\">",
"       'Coexistent AAA'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20037944\">",
"    <span class=\"h2\">",
"     Surveillance ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies to help guide the follow-up of IAA. Patients who do not have an indication for iliac aneurysm repair should be followed with serial physical examination and computed tomography or B-mode ultrasound at six-month intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/18\">",
"     18",
"    </a>",
"    ]. If a patient has a coexistent AAA, both aneurysms should be followed by the same modality. If the IAA remains stable over several exams, it may be reasonable to undergo follow-up annually.",
"   </p>",
"   <p>",
"    Computed tomography (CT) is the standard diagnostic technique used to follow IAA but has the disadvantages of exposing the patient to radiation and intravenous contrast. B-mode ultrasonography is a good alternative to CT if the aneurysm can be adequately imaged. Studies comparing the sensitivities of CT and ultrasound specifically for IAA are few. One study found that IAA size may be slightly underestimated using B-mode ultrasound compared with CT scan but the difference between the modalities was not found to be significant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29304/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H41368223\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20025243\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The iliac artery is defined as aneurysmal when a localized diameter is 1.5 times normal artery diameter. True aneurysms involve all layers of the vessel wall, whereas false aneurysms do not. The majority of aneurysms of the iliac arteries are true aneurysms. The common iliac artery is likely to be aneurysmal when it measures &gt;1.85 cm in adult males and &gt;1.5 cm in adult females. An internal iliac artery with a diameter more than 0.8 cm is consistent with aneurysm in most individuals. (See",
"      <a class=\"local\" href=\"#H544011285\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20024761\">",
"       'Anatomic issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H108704530\">",
"       'Site of aneurysm and association with other aneurysms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iliac artery aneurysms (IAAs) are most closely associated with abdominal aortic aneurysm. Up to 40 percent of patients who present with abdominal aortic aneurysm have at least one IAA. The common iliac artery is affected in 70 percent of patients who have IAA. (See",
"      <a class=\"local\" href=\"#H108704530\">",
"       'Site of aneurysm and association with other aneurysms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk factors for true aneurysm of the iliac artery are similar to other degenerative large vessel aneurysms and include smoking, hypertension, male sex, advancing age, and other large vessel aneurysm. Other causes are generally due to trauma, or iatrogenic instrumentation. (See",
"      <a class=\"local\" href=\"#H107323044\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20024782\">",
"       'Pathogenesis and natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural history of IAAs, either isolated or in association with an abdominal aortic aneurysm (AAA), is continued expansion over time. Similar to abdominal aortic aneurysm (AAA), growth rates for IAAs depend upon diameter, with larger aneurysms having greater rates of expansion. (See",
"      <a class=\"local\" href=\"#H20024782\">",
"       'Pathogenesis and natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonruptured IAAs do not usually cause symptoms unless the aneurysm is large enough to compress surrounding structures. Less commonly, patients can present with symptoms of lower extremity ischemia due to arterial obstruction from iliac aneurysm thrombosis or distal embolization of intraluminal thrombus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3065?source=see_link&amp;anchor=H1231035344#H1231035344\">",
"       \"Popliteal artery aneurysm\", section on 'Clinical presentation'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H20024782\">",
"       'Pathogenesis and natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IAA rupture can be the initial presentation with acute abdominal, thigh, or groin pain, accompanied by hemodynamic instability. Rupture into adjacent structures (eg, rectum, ureter, bladder, iliac vein) can also occur. The average size of ruptured isolated iliac aneurysms is 5.5 cm. Mortality with rupture ranges from 50 to 100 percent with poor outcomes often related to a delay in diagnosis. (See",
"      <a class=\"local\" href=\"#H544011335\">",
"       'Rupture'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8809?source=see_link\">",
"       \"Surgical and endovascular repair of iliac artery aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IAAs are often diagnosed incidentally as a result of imaging tests performed in patients being evaluated for other problems such as abdominal or pelvic pain, other aneurysm, or peripheral artery disease. IAA is reliably diagnosed using ultrasonography, computed tomography, or magnetic resonance imaging. (See",
"      <a class=\"local\" href=\"#H544011342\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ruptured IAA undergo emergent repair of the aneurysm to reduce mortality. Symptomatic IAA is repaired to relieve symptoms. Patients who have symptoms typically have larger aneurysms and are also at high risk for rupture. (See",
"      <a class=\"local\" href=\"#H544011372\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For IAA &ge;3.0 cm in diameter, we suggest elective repair over conservative management in patients with a good operative risk and life expectancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with IAA &lt;3.0 cm are typically observed; however, repair of asymptomatic IAA below this threshold may be prudent or required during the course of managing other aneurysmal disease in the aorta or femoropopliteal segments. Rapid aneurysmal expansion, ie, &ge;7 mm in six months or &gt;10 mm in one year, increases the risk of IAA rupture and also indicates the need for repair. (See",
"      <a class=\"local\" href=\"#H544011372\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no studies to help guide the follow-up of IAA. For patients who do not have an indication for iliac aneurysm repair, we perform serial physical examination imaging at six-month intervals. If the size of the aneurysm is stable over several examinations, annual follow-up is reasonable. (See",
"      <a class=\"local\" href=\"#H20037944\">",
"       'Surveillance ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/1\">",
"      Krupski WC, Selzman CH, Floridia R, et al. Contemporary management of isolated iliac aneurysms. J Vasc Surg 1998; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/2\">",
"      Richardson JW, Greenfield LJ. Natural history and management of iliac aneurysms. J Vasc Surg 1988; 8:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/3\">",
"      Sandhu RS, Pipinos II. Isolated iliac artery aneurysms. Semin Vasc Surg 2005; 18:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/4\">",
"      Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg 1991; 13:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/5\">",
"      Horejs D, Gilbert PM, Burstein S, Vogelzang RL. Normal aortoiliac diameters by CT. J Comput Assist Tomogr 1988; 12:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/6\">",
"      Bacharach JM, Slovut DP. State of the art: management of iliac artery aneurysmal disease. Catheter Cardiovasc Interv 2008; 71:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/7\">",
"      Brunkwall J, Hauksson H, Bengtsson H, et al. Solitary aneurysms of the iliac arterial system: an estimate of their frequency of occurrence. J Vasc Surg 1989; 10:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/8\">",
"      Levi N, Schroeder TV. Isolated iliac artery aneurysms. Eur J Vasc Endovasc Surg 1998; 16:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/9\">",
"      Patel NV, Long GW, Cheema ZF, et al. Open vs. endovascular repair of isolated iliac artery aneurysms: A 12-year experience. J Vasc Surg 2009; 49:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/10\">",
"      Huang Y, Gloviczki P, Duncan AA, et al. Common iliac artery aneurysm: expansion rate and results of open surgical and endovascular repair. J Vasc Surg 2008; 47:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/11\">",
"      Appel N, Duncan JR, Schuerer DJ. Percutaneous stent-graft treatment of superior mesenteric and internal iliac artery pseudoaneurysms. J Vasc Interv Radiol 2003; 14:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/12\">",
"      Ijaz S, Geroulakos G. Ruptured internal iliac artery aneurysm mimicking a hip fracture. Int Angiol 2001; 20:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/13\">",
"      Kalko Y, Basaran M, Aydin U, et al. The surgical treatment of arterial aneurysms in Beh&ccedil;et disease: a report of 16 patients. J Vasc Surg 2005; 42:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/14\">",
"      Atsuta Y, Inaba M, Goh K, et al. Isolated iliac artery aneurysm caused by fibromuscular dysplasia: report of a case. Surg Today 2003; 33:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/15\">",
"      Crivello MS, Porter DH, Kim D, et al. Isolated external iliac artery aneurysm secondary to cystic medial necrosis. Cardiovasc Intervent Radiol 1986; 9:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/16\">",
"      Woodrum DT, Welke KF, Fillinger MF. Candida infection associated with a solitary mycotic common iliac artery aneurysm. J Vasc Surg 2001; 34:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/17\">",
"      Jacob T, Hingorani A, Ascher E. Examination of the apoptotic pathway and proteolysis in the pathogenesis of popliteal artery aneurysms. Eur J Vasc Endovasc Surg 2001; 22:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/18\">",
"      Santilli SM, Wernsing SE, Lee ES. Expansion rates and outcomes for iliac artery aneurysms. J Vasc Surg 2000; 31:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/19\">",
"      Armon MP, Wenham PW, Whitaker SC, et al. Common iliac artery aneurysms in patients with abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1998; 15:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/20\">",
"      Henretta JP, Karch LA, Hodgson KJ, et al. Special iliac artery considerations during aneurysm endografting. Am J Surg 1999; 178:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/21\">",
"      Parlani G, Zannetti S, Verzini F, et al. Does the presence of an iliac aneurysm affect outcome of endoluminal AAA repair? An analysis of 336 cases. Eur J Vasc Endovasc Surg 2002; 24:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/22\">",
"      Wyers MC, Schermerhorn ML, Fillinger MF, et al. Internal iliac occlusion without coil embolization during endovascular abdominal aortic aneurysm repair. J Vasc Surg 2002; 36:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/23\">",
"      Kritpracha B, Pigott JP, Price CI, et al. Distal internal iliac artery embolization: a procedure to avoid. J Vasc Surg 2003; 37:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/24\">",
"      Richards T, Dharmadasa A, Davies R, et al. Natural history of the common iliac artery in the presence of an abdominal aortic aneurysm. J Vasc Surg 2009; 49:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/25\">",
"      Ballotta E, Da Giau G, Gruppo M, et al. Natural history of common iliac arteries after aorto-aortic graft insertion during elective open abdominal aortic aneurysm repair: a prospective study. Surgery 2008; 144:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/26\">",
"      Falkensammer J, Hakaim AG, Andrew Oldenburg W, et al. Natural history of the iliac arteries after endovascular abdominal aortic aneurysm repair and suitability of ectatic iliac arteries as a distal sealing zone. J Endovasc Ther 2007; 14:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/27\">",
"      McCready RA, Pairolero PC, Gilmore JC, et al. Isolated iliac artery aneurysms. Surgery 1983; 93:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/28\">",
"      Lowry SF, Kraft RO. Isolated aneurysms of the iliac artery. Arch Surg 1978; 113:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/29\">",
"      Kato T, Takagi H, Kawai N, et al. Ruptured isolated external iliac artery true aneurysm associated with cystic medial necrosis: report of a case. Surg Today 2009; 39:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/30\">",
"      Kasulke RJ, Clifford A, Nichols WK, Silver D. Isolated atherosclerotic aneurysms of the internal iliac arteries: report of two cases and review of literature. Arch Surg 1982; 117:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/31\">",
"      Nelson RP. Isolated internal iliac artery aneurysms and their urological manifestations. J Urol 1980; 124:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/32\">",
"      Srirangam SJ, Manikandan R, Ross D, Collins GN. Ureteric obstruction caused by aneurysm of the hypogastric artery. Scand J Urol Nephrol 2003; 37:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/33\">",
"      Nachbur BH, Inderbitzi RG, B&auml;r W. Isolated iliac aneurysms. Eur J Vasc Surg 1991; 5:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/34\">",
"      Bolin T, Lund K, Skau T. Isolated aneurysms of the iliac artery: what are the chances of rupture? Eur J Vasc Surg 1988; 2:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/35\">",
"      JACKMAN RJ, McQUARRIE HB, EDWARDS JE. Fatal rectal hemorrhage caused by aneurysm of the internal iliac artery; report of case. Proc Staff Meet Mayo Clin 1948; 23:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/36\">",
"      JOSHI DM, KELLY M. Rectally palpable aneurysm as a cause of bleeding per rectum. Br J Clin Pract 1963; 17:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/37\">",
"      Krupski WC, Bass A, Rosenberg GD, et al. The elusive isolated hypogastric artery aneurysm: novel presentations. J Vasc Surg 1989; 10:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/38\">",
"      de Donato G, Neri E, Baldi I, Setacci C. Rupture of internal iliac artery aneurysm presenting as rectus sheath hematoma: case report. J Vasc Surg 2004; 39:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/39\">",
"      FRANK IN, THOMPSON HT, ROB C, SCHWARTZ SI. Aneurysm of the internal iliac artery. Arch Surg 1961; 83:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/40\">",
"      Desiron Q, Detry O, Sakalihasan N, et al. Isolated atherosclerotic aneurysms of the iliac arteries. Ann Vasc Surg 1995; 9 Suppl:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/41\">",
"      Schroeder RA, Flanagan TL, Kron IL, Tribble CG. A safe approach to the treatment of iliac artery aneurysms. Aortobifemoral bypass grafting with exclusion of the aneurysm. Am Surg 1991; 57:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/42\">",
"      Verta MJ Jr, Janevicius RV. Isolated hypogastric artery aneurysms. J Cardiovasc Surg (Torino) 1982; 23:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/43\">",
"      Boyarsky AH, Burks WP, Davidson JT, Chandler JJ. Ruptured aneurysm of the internal iliac artery. South Med J 1985; 78:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/44\">",
"      Hechelhammer L, Rancic Z, Pfiffner R, et al. Midterm outcome of endovascular repair of ruptured isolated iliac artery aneurysms. J Vasc Surg 2010; 52:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/45\">",
"      Ferreira J, Canedo A, Brand&atilde;o D, et al. Isolated iliac artery aneurysms: six-year experience. Interact Cardiovasc Thorac Surg 2010; 10:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/46\">",
"      Dix FP, Titi M, Al-Khaffaf H. The isolated internal iliac artery aneurysm--a review. Eur J Vasc Endovasc Surg 2005; 30:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/47\">",
"      Parry DJ, Kessel D, Scott DJ. Simplifying the internal iliac artery aneurysm. Ann R Coll Surg Engl 2001; 83:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/48\">",
"      P&auml;iv&auml;nsalo M, L&auml;hde S, Leinonen A. Bilateral isolated internal iliac aneurysms presenting as pelvic tumours. Rontgenblatter 1987; 40:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/49\">",
"      Weimann S, Tauscher T, Flora G. Isolated iliac artery aneurysms. Ann Vasc Surg 1990; 4:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/50\">",
"      Schellack J, Smith RB 3rd, Perdue GD. Nonoperative management of selected popliteal aneurysms. Arch Surg 1987; 122:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/51\">",
"      Kasirajan V, Hertzer NR, Beven EG, et al. Management of isolated common iliac artery aneurysms. Cardiovasc Surg 1998; 6:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/52\">",
"      Hassen-Khodja R, Feugier P, Favre JP, et al. Outcome of common iliac arteries after straight aortic tube-graft placement during elective repair of infrarenal abdominal aortic aneurysms. J Vasc Surg 2006; 44:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29304/abstract/53\">",
"      Kirkwood ML, Saunders A, Jackson BM, et al. Aneurysmal iliac arteries do not portend future iliac aneurysmal enlargement after endovascular aneurysm repair for abdominal aortic aneurysm. J Vasc Surg 2011; 53:269.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15703 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29304=[""].join("\n");
var outline_f28_39_29304=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20025243\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544011285\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20024761\">",
"      ANATOMIC ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20024768\">",
"      Definition of iliac aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107323044\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20024782\">",
"      PATHOGENESIS AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20026244\">",
"      Aneurysm formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20026251\">",
"      Iliac artery expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H721247733\">",
"      Isolated iliac artery aneurysms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20025038\">",
"      - Iliac artery aneurysms with coexistent abdominal aortic aneurysms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108704530\">",
"      Site of aneurysm and association with other aneurysms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544011328\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41367772\">",
"      Compression of surrounding structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H544011335\">",
"      Rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41367779\">",
"      Aneurysm thrombosis and thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41368874\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H544011342\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41368223\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544011372\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41368706\">",
"      Aneurysm size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41368713\">",
"      Coexistent AAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108756454\">",
"      Indications for repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20037944\">",
"      Surveillance ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20025243\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15703\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15703|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/54/27490\" title=\"diagnostic image 1\">",
"      Aortoiliac aneurysm on arteriography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/38/34407\" title=\"diagnostic image 2A\">",
"      Left iliac artery aneurysm on abdominal CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/35/30256\" title=\"diagnostic image 2B\">",
"      Left iliac artery aneurysm on 3D computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15703|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/14/43234\" title=\"figure 1\">",
"      Normal abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/42/2727\" title=\"figure 2\">",
"      Iliac aneurysm symptoms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=related_link\">",
"      Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=related_link\">",
"      High-output heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=related_link\">",
"      Overview of infected (mycotic) arterial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3065?source=related_link\">",
"      Popliteal artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8809?source=related_link\">",
"      Surgical and endovascular repair of iliac artery aneurysm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_39_29305="Clostridium difficile in adults: Clinical manifestations and diagnosis";
var content_f28_39_29305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clostridium difficile in adults: Clinical manifestations and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/39/29305/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29305/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/39/29305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29305/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/39/29305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29305/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/39/29305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clostridium difficile causes antibiotic-associated colitis; it colonizes the human intestinal tract after the normal gut flora have been altered by antibiotic therapy. It is one of the most common healthcare-associated infections and a significant cause of morbidity and mortality among elderly hospitalized patients.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of C. difficile infection will be reviewed here. The treatment, pathophysiology, and epidemiology of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Watery diarrhea is the cardinal clinical symptom of C. difficile infection, although it can cause a spectrum of manifestations ranging from the asymptomatic carrier state to severe fulminant disease with toxic megacolon (",
"    <a class=\"graphic graphic_table graphicRef80697 \" href=\"UTD.htm?16/26/16812\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/1\">",
"     1",
"    </a>",
"    ]. The basis for this range of symptomatic responses is not fully understood but may be related to various host and pathogen factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Carrier state",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 20 percent of hospitalized adults are C. difficile carriers who shed C. difficile in their stools but do not have diarrhea; in long term care facilities, carriage rate may approach 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Although asymptomatic, these individuals serve as a reservoir for environmental contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The host immune response to C. difficile may play a role in determining an individual's carrier status. Data on treatment of asymptomatic carriers are limited and routine treatment is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=see_link\">",
"     \"Prevention and control of Clostridium difficile in hospital and institutional settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diarrhea with colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of C. difficile-associated diarrhea with colitis include watery diarrhea up to 10 or 15 times daily with lower abdominal pain and cramping, low grade fever, and leukocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/5\">",
"     5",
"    </a>",
"    ]. Fever (T&gt;38.5) is a sign of severe C. difficile-associated diarrhea (CDAD); fever is associated with CDAD in about 15 percent of cases. Leukocytosis in the setting of CDAD is common; CDAD is reported to routinely be associated with a WBC on average of 15K. These symptoms generally occur in the setting of antibiotic administration; they may begin during antibiotic therapy or 5 to 10 days following antibiotic administration. Infrequently, symptoms present as late as 10 weeks after cessation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The antibiotics most frequently implicated in predisposition to C. difficile infection are fluoroquinolones,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , cephalosporins, and penicillins, but virtually all antibiotics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , can predispose to C. difficile (",
"    <a class=\"graphic graphic_table graphicRef55479 \" href=\"UTD.htm?24/35/25147\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Physical examination generally demonstrates lower abdominal tenderness. Sigmoidoscopic or colonoscopic examination may demonstrate a spectrum of findings, from patchy mild erythema and friability to severe pseudomembranous colitis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pseudomembranous colitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Unexplained leukocytosis in hospitalized patients (even in the absence of diarrhea) may reflect underlying C. difficile infection. In a prospective study of 60 patients with unexplained leukocytosis (white blood cell count",
"    <span class=\"nowrap\">",
"     &gt;15,000/microL),",
"    </span>",
"    for example, positive stool C. difficile toxin was observed in 58 percent of cases compared with 12 percent in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/7\">",
"     7",
"    </a>",
"    ]. When unexplained leukocytosis is due to CDAD, most often diarrhea develops in the next one to two days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=see_link&amp;anchor=H19#H19\">",
"     \"Causes of neutrophilia\", section on 'Acute infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pseudomembranous colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pseudomembranous colitis usually present with clinical manifestations of CDAD with colitis. In addition, sigmoidoscopic examination in these patients demonstrates the presence of pseudomembranes, which is sufficient to make a presumptive diagnosis of C. difficile infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Endoscopic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. difficile toxin-induced cytoskeleton disruption manifests with gross findings of shallow ulcerations on the intestine mucosal surface [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/8\">",
"     8",
"    </a>",
"    ]. Ulcer formation allows release of serum proteins, mucus, and inflammatory cells, which manifest grossly on the colorectal mucosal surface as pseudomembranes (virtually pathognomonic for C. difficile infection; there are rare reports of Klebsiella and other pathogens also capable of causing pseudomembranous colitis).",
"   </p>",
"   <p>",
"    Pseudomembranes manifest as raised yellow or off-white plaques up to 2 cm in diameter, scattered over the colorectal mucosa (",
"    <a class=\"graphic graphic_picture graphicRef53774 \" href=\"UTD.htm?38/28/39363\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62422 \" href=\"UTD.htm?4/15/4337\">",
"     picture 2",
"    </a>",
"    ). Some patients with pseudomembranous colitis have scattered lesions with relatively normal appearing intervening mucosa, whereas others have a confluent pseudomembrane covering the entire mucosa. Other gross findings include may include bowel wall edema, erythema, friability, and inflammation; these may be observed with or without presence of pseudomembranes.",
"   </p>",
"   <p>",
"    In some cases, pseudomembranes may be absent in the rectosigmoid area but may be visualized more proximally with colonoscopy, although colonoscopy is not indicated for diagnosis of C. difficile [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/9\">",
"     9",
"    </a>",
"    ]. Colonoscopy may demonstrate pseudomembranes even if sigmoidoscopy does not [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic features of pseudomembranous colitis (PMC) have been classified into three distinct types [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 PMC is the mildest form and the major inflammatory changes are confined to the superficial epithelium and immediately subjacent lamina propria. Typical pseudomembranes are present, and crypt abscesses are occasionally present.",
"     </li>",
"     <li>",
"      Type 2 PMC is characterized by more severe disruption of glands, marked mucin secretion, and more intense inflammation of basal lamina.",
"     </li>",
"     <li>",
"      Type 3 PMC is characterized by severe, intense necrosis of the full thickness of the mucosa with a confluent pseudomembrane.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal computed tomography (CT) scan in patients with pseudomembranous colitis demonstrates pronounced thickening of the colonic wall (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57812 \" href=\"UTD.htm?41/42/42656\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recurrent disease: relapse vs reinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of symptoms after successful initial therapy for C. difficile, due to relapse of the initial infecting strain or due to reinfection with a new strain, develops in 10 to 25 percent of cases; patients may experience several episodes of recurrence. Recurrence may present within days or weeks of completing treatment; the clinical presentation may be similar to or more severe than the initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/13\">",
"     13",
"    </a>",
"    ]. Recurrence may be related to variability in the host immune response to C. difficile infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link&amp;anchor=H9#H9\">",
"     \"Clostridium difficile in adults: Treatment\", section on 'Management of initial recurrence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrent C. difficile infection often represents relapse rather than reinfection, regardless of the interval between episodes. Among 134 paired stool isolates from 102 patients with recurrent C. difficile infections, isolates obtained two to eight weeks apart were identical in 88 percent of cases; isolates obtained 8 weeks to 11 months apart were identical in 65 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with recurrent diarrhea, cramping, and bloating after treatment of C. difficile may have postinfectious irritable bowel syndrome or other inflammatory colitides including collagenous or microscopic colitis, concomitant ulcerative colitis or Crohn&rsquo;s disease, or celiac disease (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=see_link\">",
"     \"Pathophysiology of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fulminant colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manifestations of fulminant colitis typically include severe lower quadrant or diffuse abdominal pain, diarrhea, abdominal distention, fever, hypovolemia, lactic acidosis, hypoalbuminemia, and marked leukocytosis (up to 40,000 white blood",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    or higher) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/7,15,16\">",
"     7,15,16",
"    </a>",
"    ]. Diarrhea may be less prominent in patients with prolonged ileus due to pooling of secretions in the dilated, atonic colon. Other potential complications of fulminant colitis include toxic megacolon and bowel perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toxic megacolon is a clinical diagnosis based upon the finding of colonic dilatation (&gt;7 cm in its greatest diameter) accompanied by severe systemic toxicity. Abdominal plain films may also demonstrate small bowel dilatation, air-fluid levels (mimicking an intestinal obstruction or ischemia), and \"thumb printing\" (scalloping of the bowel wall) due to submucosal edema (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59217 \" href=\"UTD.htm?10/11/10416\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52929 \" href=\"UTD.htm?32/51/33598\">",
"     image 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link\">",
"     \"Toxic megacolon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bowel perforation presents with abdominal rigidity, involuntary guarding, diminished bowel sounds, rebound tenderness, and severe localized tenderness in the left or right lower quadrants. Abdominal radiographs may demonstrate free abdominal air.",
"   </p>",
"   <p>",
"    Aggressive diagnostic and therapeutic interventions are warranted in the setting of fulminant C. difficile infection. Bedside sigmoidoscopy or colonoscopy may be performed to make a presumptive diagnosis of C. difficile infection by evaluating for presence of pseudomembranes. Given the risk of perforation, care should be taken to introduce minimal amounts of air to avoid exacerbating ileus or distention. Prompt surgical consultation is warranted to assess the requirement for colectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link&amp;anchor=H18#H18\">",
"     \"Clostridium difficile in adults: Treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     UNUSUAL PRESENTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other manifestations of C. difficile include protein-losing enteropathy with ascites, C. difficile infection in the setting of chronic inflammatory bowel disease, and extracolonic involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Protein-losing enteropathy with ascites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with C. difficile infection develop protein-losing enteropathy with hypoalbuminemia, and a few may exhibit ascites and peripheral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Inflammation of the bowel wall allows leakage of albumin into the lumen, causing colonic loss of albumin with inadequate compensatory hepatic synthesis. As a result, serum albumin levels may drop below 2.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     g/L).",
"    </span>",
"    The protein-losing enteropathy responds to appropriate medical therapy of the infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clostridium difficile and inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with C. difficile (as well as other enteric pathogens) may complicate the course of inflammatory bowel disease (IBD) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Enteric infections account for about 10 percent of symptomatic relapses in patients with IBD; C. difficile accounts for about one-half of these infections [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/23\">",
"     23",
"    </a>",
"    ]. Rates of C. difficile among IBD patients appear to be increasing in some institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The association between IBD and C. difficile may be due to a variety of factors, including antibiotic use for treatment of other gastrointestinal pathogens and frequent hospitalization for management of IBD flares. Rarely, C. difficile can trigger an initial bout of IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C. difficile infection in IBD patients requires prompt diagnosis and management, since failure to diagnose the infection can lead to inappropriate treatment with glucocorticoids or immunosuppressive therapy. Furthermore, C. difficile may be difficult to distinguish from an IBD relapse given the similar symptoms of diarrhea, abdominal pain, and low grade fever. Thus, a high index of suspicion is required when evaluating IBD patients with apparent flares, especially those who have recently received antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    been hospitalized.",
"   </p>",
"   <p>",
"    The diagnosis requires the use of laboratory tools; endoscopy is usually not helpful because IBD patients generally do not develop pseudomembranes. Given the preexisting colonic pathology, patients with IBD who develop C. difficile colitis more frequently may require colectomy (20 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/25\">",
"     25",
"    </a>",
"    ]. Specific antibiotic and surgical management is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also a high prevalence of C. difficile carriage in patients with IBD. This was illustrated in a study of 122 patients with longstanding IBD in which the frequency of C. difficile carriage was higher in IBD patients than in healthy volunteers (8 versus 1 percent, respectively), in the absence of recent antibiotics or hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/26\">",
"     26",
"    </a>",
"    ]. Despite this observation, none developed symptomatic disease in the subsequent six months. The reason for this observation is not certain; possibilities include altered colonic microbial flora, mucosal inflammation, and impaired mucosal innate immunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Extracolonic involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare cases of C. difficile appendicitis, small bowel enteritis, and extraintestinal involvement have been described.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appendicitis due to C. difficile is unusual; three cases have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/27\">",
"       27",
"      </a>",
"      ]. The association may be underdiagnosed because milder cases might respond to antibiotic therapy alone.",
"     </li>",
"     <li>",
"      Small bowel involvement with C. difficile enteritis is unusual [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. Manifestations may include increased ileostomy output; in some cases such patients have had prior colectomy with ileostomy, allowing direct visualization of pseudomembranes on the ileostomy mucosa. Patients with C. difficile involvement of the small bowel tend to be elderly or have multiple comorbidities. Therefore such patients may be at increased risk for fulminant disease with a high mortality rate [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rare cases of C. difficile cellulitis, soft tissue infection, and reactive arthritis have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/28,31\">",
"       28,31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although C. difficile is the major infectious cause of antibiotic-associated diarrhea, it must be distinguished from other infectious and noninfectious causes of diarrhea. Staphylococcus aureus was previously implicated as an important cause of antibiotic-associated pseudomembranous colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Other potential pathogens include Klebsiella oxytoca, Clostridium perfringens, Candida spp, and Salmonella [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/34-39\">",
"     34-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among noninfectious causes, antibiotic-associated diarrhea may be attributable to osmotic mechanisms rather than C. difficile infection. Differentiation of this noninfectious form of antibiotic-associated diarrhea may be difficult, especially in patients who also may be asymptomatic C. difficile carriers. Cessation of symptoms with discontinuation of oral intake is a distinguishing feature of osmotic diarrhea (",
"    <a class=\"graphic graphic_figure graphicRef69745 \" href=\"UTD.htm?37/28/38349\">",
"     figure 1",
"    </a>",
"    ). The presence of fever and leukocytosis favor C. difficile or other infectious etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link\">",
"     \"Approach to the adult with chronic diarrhea in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postinfectious irritable bowel syndrome occurs in about 10 percent of patients who have been successfully treated for an initial bout of C. difficile. These patients may have up to 10 watery stools per day and are often convinced that they are suffering from a relapse of their original C. difficile infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=see_link\">",
"     \"Pathophysiology of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15443523\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of C. difficile infection requires the presence of moderate to severe diarrhea or ileus, and either [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A stool test positive for C. difficile toxins or toxigenic C. difficile",
"     </li>",
"     <li>",
"      Endoscopic or histologic findings of pseudomembranous colitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnostic stool evaluation for the presence of C. difficile toxins should be pursued in the setting of clinically significant diarrhea (usually defined as three or more loose stools per day for at least two days); suspicion is warranted if many stools (10 to 15) occur with fever or nocturnal diarrhea even if only one day in duration.",
"   </p>",
"   <p>",
"    In general, only loose, watery, or semi-formed stool should be tested for C. difficile [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. Diagnosis via swab may be warranted for patients with suspected C. difficile infection and ileus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/45,46,50,51\">",
"     45,46,50,51",
"    </a>",
"    ]. C. difficile toxin degrades at room temperature and may be undetectable within two hours after collection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/44\">",
"     44",
"    </a>",
"    ]; specimens should be kept at 4&ordm;C if delay is anticipated. A suspected outbreak should prompt freezing of stool samples for later investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15443551\">",
"    <span class=\"h2\">",
"     Laboratory diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory diagnosis of C. difficile infection requires demonstration of C. difficile toxin(s) or detection of toxigenic C. difficile organism(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/40\">",
"     40",
"    </a>",
"    ]. A number of tests are available, including [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/44,46,52\">",
"     44,46,52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Polymerase chain reaction (PCR)",
"     </li>",
"     <li>",
"      Enzyme immunoassay (EIA) for C. difficile glutamate dehydrogenase (GDH)",
"     </li>",
"     <li>",
"      Enzyme immunoassay (EIA) for C. difficile toxins A and B",
"     </li>",
"     <li>",
"      Cell culture cytotoxicity assay",
"     </li>",
"     <li>",
"      Selective anaerobic culture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tests are discussed in further detail below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCR testing &mdash; Real-time PCR tests that detect toxin A and B genes are highly sensitive and specific [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/53-56\">",
"       53-56",
"      </a>",
"      ]. The sensitivity of PCR is greater than enzyme immunoassay and comparable to cytotoxicity assay [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/46,57-61\">",
"       46,57-61",
"      </a>",
"      ]. In addition, PCR results can be available within as little as one hour. Given its high sensitivity and potential for false positive results, some favor use of PCR in an algorithm together with other assays such as EIA for GHD and EIA for toxins A and B. (See",
"      <a class=\"local\" href=\"#H15451180\">",
"       'Clinical approach'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      EIA for C. difficile GDH &mdash; GDH antigen is an essential enzyme produced constitutively by all C. difficile isolates; its detection cannot distinguish between toxigenic and nontoxigenic strains [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/62-64\">",
"       62-64",
"      </a>",
"      ]. Therefore, testing for GDH antigen is useful as an initial screening step in a multistep approach, which also consists of subsequent testing with more specific assays such as PCR on specimens that are GDH antigen positive [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/46,65\">",
"       46,65",
"      </a>",
"      ]. GDH antigen testing is highly sensitive, and results are available in less than one hour.",
"     </li>",
"     <li>",
"      EIA for C. difficile toxins A and B &mdash; Most C. difficile strains produce both toxins A and B, although some strains produce toxin A or B only [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/66-70\">",
"       66-70",
"      </a>",
"      ]. The sensitivity of EIA for toxins A and B is about 75 percent; the specificity is high (up to 99 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/46,71,72\">",
"       46,71,72",
"      </a>",
"      ]. There is a relatively high false negative rate since 100 to 1000 pg of toxin must be present for the test to be positive [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/32\">",
"       32",
"      </a>",
"      ]. A number of inexpensive assays are commercially available, and test results are available within hours [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the initial EIA test is negative, the value of repeating the test is limited and repeat testing is generally discouraged [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/46,73-75\">",
"     46,73-75",
"    </a>",
"    ]. Three studies found fewer than 10 percent more cases by repeated testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/76-78\">",
"     76-78",
"    </a>",
"    ], while two others found 19 percent and 20 percent more cases with one or two further tests [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/73,79\">",
"     73,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cell culture cytotoxicity assay &mdash; The cell culture cytotoxicity assay is the &lsquo;gold standard&rsquo; test for diagnosis of C. difficile, and is the standard against which other tests should be compared [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/80,81\">",
"       80,81",
"      </a>",
"      ]. It performed by adding a prepared stool sample (diluted, buffered, and filtered) to a monolayer of cultured cells [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/82\">",
"       82",
"      </a>",
"      ]. If C. difficile toxin is present, it exerts a cytopathic effect characterized by rounding of fibroblasts in tissue culture (",
"      <a class=\"graphic graphic_figure graphicRef73568 \" href=\"UTD.htm?25/24/25988\">",
"       figure 2",
"      </a>",
"      ). The cytotoxicity assay is more sensitive than enzyme immunoassays, but is labor intensive and takes approximately two days [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/40,44,83\">",
"       40,44,83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Selective anaerobic culture &mdash; Culture on selective medium with toxin testing of isolated C. difficile is the most sensitive diagnostic method, although it cannot distinguish toxin-producing strains from non-toxin producing strains [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/81\">",
"       81",
"      </a>",
"      ]. Prior treatment with heat or alcohol to select spores is sometimes used to improve yield. Culture is useful for epidemiologic studies, but is generally too slow and labor-intensive for clinical use [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of multistep algorithms have been developed in an attempt to improve the accuracy of diagnostic testing for C. difficile infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/46,62-65,84\">",
"     46,62-65,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15451180\">",
"    <span class=\"h3\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We favor use of PCR for diagnosis of C. difficile, either alone or as part of an algorithm (including initial EIA screening for GDH, with or without EIA screening for toxins A and B) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. The high sensitivity and specificity of PCR, together with its rapid turn-around time, allow prompt isolation and treatment of patients with C. difficile infection, likely reducing opportunity for nosocomial spread and improving patient outcomes. An algorithmic approach may be less expensive but take slightly longer and may have reduced sensitivity compared with PCR alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study comparing the Cepheid Xpert C. difficile PCR assay with cell culture cytotoxicity assay for diagnosis of CDAD, the sensitivity and specificity of the Cepheid assay were 97 and 93 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/87\">",
"     87",
"    </a>",
"    ]. Using the PCR ribotyping as a reference for the hypervirulent 027 strain, the sensitivity and specificity were 100 and 98.1 percent, respectively. A previous study compared PCR and EIA techniques with anaerobic culture (the \"most sensitive\") in 618 stool samples; sensitivity and specificity were better for PCR than EIA (93 and 97 percent versus 73 and 97 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic approach for suspected recurrent C. difficile is the same as the approach for initial infection. There is no clinical role for laboratory diagnosis among asymptomatic patients or among patients on treatment for acute disease, whose stool assays may remain positive during or after clinical recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy or sigmoidoscopy and biopsy (in the setting of diagnostic uncertainty) can be a useful adjunctive tool for diagnosis of C. difficile in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High clinical suspicion for C. difficile with negative laboratory assay(s)",
"     </li>",
"     <li>",
"      Prompt C. difficile diagnosis needed before laboratory results can be obtained",
"     </li>",
"     <li>",
"      Failure of C. difficile infection to respond to antibiotic therapy",
"     </li>",
"     <li>",
"      Atypical presentation with ileus or minimal diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/10,38\">",
"       10,38",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the appropriate clinical setting, visualization of pseudomembranes on sigmoidoscopy nearly always reflects C. difficile infection. However, pseudomembranes are not observed in 10 to 20 percent of patients with C. difficile, particularly in the setting of recurrent infection; in such cases biopsy is useful for diagnosis of C. difficile infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29305/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. In addition, pseudomembranes may not be observed in the setting of other forms of colitis. For example, pseudomembranes are rarely seen in patients with inflammatory bowel disease and superimposed C. difficile infection; in such cases, biopsy is also useful for diagnosis of C. difficile infection.",
"   </p>",
"   <p>",
"    Endoscopy is not warranted in patients with classic clinical findings and a positive stool toxin assay. In the setting of fulminant colitis, care should be taken to introduce minimal amounts of air given the risk of perforation. Gross and histologic findings obtained by endoscopic evaluation are discussed in detail above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Endoscopic findings'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Pseudomembranous colitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/47/28402?source=see_link\">",
"       \"Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=see_link\">",
"       \"Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clostridium difficile colonizes the human intestinal tract after the normal gut flora have been altered by antibiotic therapy and causes antibiotic-associated colitis; a spectrum of manifestations is observed (",
"      <a class=\"graphic graphic_table graphicRef80697 \" href=\"UTD.htm?16/26/16812\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Manifestations of C. difficile-associated diarrhea (CDAD) with colitis include watery diarrhea up to 10 or 15 times daily with lower abdominal pain and cramping, low grade fever, and leukocytosis. The antibiotics most frequently implicated in predisposition to C. difficile infection are fluoroquinolones,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      , cephalosporins, and penicillins (",
"      <a class=\"graphic graphic_table graphicRef55479 \" href=\"UTD.htm?24/35/25147\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diarrhea with colitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relapse or reinfection develops in 10 to 25 percent of treated C. difficile cases, and patients may experience several episodes of relapsing colitis. Relapse may present within days or weeks of completing treatment for C. difficile; the clinical presentation may be similar to or more severe than the initial presentation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Recurrent disease: relapse vs reinfection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Manifestations of fulminant colitis include severe lower quadrant or diffuse abdominal pain, diarrhea, abdominal distention, fever, hypovolemia, lactic acidosis, and marked leukocytosis. Diarrhea may be less prominent in patients with prolonged ileus due to pooling of secretions in the dilated, atonic colon. Potential complications include toxic megacolon and bowel perforation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Fulminant colitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis should be based on results from a laboratory diagnostic test detecting toxin-producing strains (via enzyme immunoassay or polymerase chain reaction) or an endoscopic evaluation that demonstrates pseudomembranes in the colon. (See",
"      <a class=\"local\" href=\"#H15443523\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We favor use of polymerase chain reaction (PCR) for diagnosis of C. difficile, either alone or as part of an algorithm (including initial enzyme immunoassay [EIA] screening for glutamate dehydrogenase [GDH], with or without EIA screening for toxins A and B). (See",
"      <a class=\"local\" href=\"#H15451180\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/1\">",
"      Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med 2008; 359:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/2\">",
"      Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/3\">",
"      McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/4\">",
"      Riggs MM, Sethi AK, Zabarsky TF, et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007; 45:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/5\">",
"      Wanahita A, Goldsmith EA, Musher DM. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by clostridium difficile. Clin Infect Dis 2002; 34:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/6\">",
"      Tedesco FJ. Pseudomembranous colitis: pathogenesis and therapy. Med Clin North Am 1982; 66:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/7\">",
"      Wanahita A, Goldsmith EA, Marino BJ, Musher DM. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 2003; 115:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/8\">",
"      Riegler M, Sedivy R, Pothoulakis C, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995; 95:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/9\">",
"      Sepp&auml;l&auml; K, Hjelt L, Sipponen P. Colonoscopy in the diagnosis of antibiotic-associated colitis. A prospective study. Scand J Gastroenterol 1981; 16:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/10\">",
"      Tedesco FJ. Antibiotic associated pseudomembranous colitis with negative proctosigmoidoscopy examination. Gastroenterology 1979; 77:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/11\">",
"      Price AB, Davies DR. Pseudomembranous colitis. J Clin Pathol 1977; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/12\">",
"      Valiquette L, P&eacute;pin J, Do XV, et al. Prediction of complicated Clostridium difficile infection by pleural effusion and increased wall thickness on computed tomography. Clin Infect Dis 2009; 49:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/13\">",
"      Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/14\">",
"      Kamboj M, Khosa P, Kaltsas A, et al. Relapse versus reinfection: surveillance of Clostridium difficile infection. Clin Infect Dis 2011; 53:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/15\">",
"      Bulusu M, Narayan S, Shetler K, Triadafilopoulos G. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol 2000; 95:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/16\">",
"      Walk ST, Micic D, Jain R, et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 2012; 55:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/17\">",
"      Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/18\">",
"      Lamontagne F, Labb&eacute; AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/19\">",
"      Dansinger ML, Johnson S, Jansen PC, et al. Protein-losing enteropathy is associated with Clostridium difficile diarrhea but not with asymptomatic colonization: a prospective, case-control study. Clin Infect Dis 1996; 22:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/20\">",
"      Rybolt AH, Bennett RG, Laughon BE, et al. Protein-losing enteropathy associated with Clostridium difficile infection. Lancet 1989; 1:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/21\">",
"      LaMont JT, Trnka YM. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet 1980; 1:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/22\">",
"      Greenfield C, Aguilar Ramirez JR, Pounder RE, et al. Clostridium difficile and inflammatory bowel disease. Gut 1983; 24:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/23\">",
"      Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004; 16:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/24\">",
"      Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/25\">",
"      Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/26\">",
"      Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009; 104:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/27\">",
"      Brown TA, Rajappannair L, Dalton AB, et al. Acute appendicitis in the setting of Clostridium difficile colitis: case report and review of the literature. Clin Gastroenterol Hepatol 2007; 5:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/28\">",
"      Jacobs A, Barnard K, Fishel R, Gradon JD. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2001; 80:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/29\">",
"      Hayetian FD, Read TE, Brozovich M, et al. Ileal perforation secondary to Clostridium difficile enteritis: report of 2 cases. Arch Surg 2006; 141:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/30\">",
"      Vesoulis Z, Williams G, Matthews B. Pseudomembranous enteritis after proctocolectomy: report of a case. Dis Colon Rectum 2000; 43:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/31\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 19-1998. A 70-year-old man with diarrhea, polyarthritis, and a history of Reiter's syndrome. N Engl J Med 1998; 338:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/32\">",
"      Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/33\">",
"      Gravet A, Rondeau M, Harf-Monteil C, et al. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-lukD. J Clin Microbiol 1999; 37:4012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/34\">",
"      H&ouml;genauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006; 355:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/35\">",
"      Sparks SG, Carman RJ, Sarker MR, McClane BA. Genotyping of enterotoxigenic Clostridium perfringens fecal isolates associated with antibiotic-associated diarrhea and food poisoning in North America. J Clin Microbiol 2001; 39:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/36\">",
"      Forbes D, Ee L, Camer-Pesci P, Ward PB. Faecal candida and diarrhoea. Arch Dis Child 2001; 84:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/37\">",
"      Hovius SE, Rietra PJ. Salmonella colitis clinically presenting as a pseudomembranous colitis. Neth J Surg 1982; 34:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/38\">",
"      Triadafilopoulos G, Hallstone AE. Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology 1991; 101:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/39\">",
"      Bauer TM, Lalvani A, Fehrenbach J, et al. Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adults. JAMA 2001; 285:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/40\">",
"      Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/41\">",
"      Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/42\">",
"      Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009; 15:1053.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Health. Health Protection Agency. Clostridium difficile infection: How to deal with the problem. Department of Health London 2008. Available at: www.hpa.org.uk/webw/HPAweb&amp;HPAwebStandard/HPAweb_C/1204186173530?p=1263812760663 (Accessed on April 01, 2010).",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Clostridium difficile. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LJ.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/45\">",
"      Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/46\">",
"      Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/47\">",
"      Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006; 73:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/48\">",
"      Gerding DN. Diagnosis of Clostridium difficile--associated disease: patient selection and test perfection. Am J Med 1996; 100:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/49\">",
"      Katz DA, Lynch ME, Littenberg B. Clinical prediction rules to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea. Am J Med 1996; 100:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/50\">",
"      Peterson LR, Robicsek A. Does my patient have Clostridium difficile infection? Ann Intern Med 2009; 151:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/51\">",
"      Kundrapu S, Sunkesula VC, Jury LA, et al. Utility of perirectal swab specimens for diagnosis of Clostridium difficile infection. Clin Infect Dis 2012; 55:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/52\">",
"      Kufelnicka AM, Kirn TJ. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection. Clin Infect Dis 2011; 52:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/53\">",
"      Luo RF, Banaei N. Is repeat PCR needed for diagnosis of Clostridium difficile infection? J Clin Microbiol 2010; 48:3738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/54\">",
"      B&eacute;langer SD, Boissinot M, Clairoux N, et al. Rapid detection of Clostridium difficile in feces by real-time PCR. J Clin Microbiol 2003; 41:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/55\">",
"      van den Berg RJ, Bruijnesteijn van Coppenraet LS, Gerritsen HJ, et al. Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile-associated diarrhea in hospitalized patients. J Clin Microbiol 2005; 43:5338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/56\">",
"      Longtin Y, Trottier S, Brochu G, et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis 2013; 56:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/57\">",
"      Kvach EJ, Ferguson D, Riska PF, Landry ML. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. J Clin Microbiol 2010; 48:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/58\">",
"      Stamper PD, Babiker W, Alcabasa R, et al. Evaluation of a new commercial TaqMan PCR assay for direct detection of the clostridium difficile toxin B gene in clinical stool specimens. J Clin Microbiol 2009; 47:3846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/59\">",
"      Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol 2009; 47:3211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/60\">",
"      Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol 2009; 47:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/61\">",
"      van den Berg RJ, Vaessen N, Endtz HP, et al. Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study. J Med Microbiol 2007; 56:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/62\">",
"      Ticehurst JR, Aird DZ, Dam LM, et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006; 44:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/63\">",
"      Reller ME, Lema CA, Perl TM, et al. Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol 2007; 45:3601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/64\">",
"      Fenner L, Widmer AF, Goy G, et al. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol 2008; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/65\">",
"      Wilkins TD, Lyerly DM. Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol 2003; 41:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/66\">",
"      Limaye AP, Turgeon DK, Cookson BT, Fritsche TR. Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile. J Clin Microbiol 2000; 38:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/67\">",
"      Barbut F, Lalande V, Burghoffer B, et al. Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. J Clin Microbiol 2002; 40:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/68\">",
"      Johnson S, Kent SA, O'Leary KJ, et al. Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med 2001; 135:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/69\">",
"      Knapp CC, Sandin RL, Hall GS, et al. Comparison of vidas Clostridium difficile toxin-A assay and premier C. difficile toxin-A assay to cytotoxin-B tissue culture assay for the detection of toxins of C. difficile. Diagn Microbiol Infect Dis 1993; 17:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/70\">",
"      Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/71\">",
"      Blossom DB, McDonald LC. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 2007; 45:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/72\">",
"      Swindells J, Brenwald N, Reading N, Oppenheim B. Evaluation of diagnostic tests for Clostridium difficile infection. J Clin Microbiol 2010; 48:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/73\">",
"      Manabe YC, Vinetz JM, Moore RD, et al. Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med 1995; 123:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/74\">",
"      Deshpande A, Pasupuleti V, Patel P, et al. Repeat stool testing to diagnose Clostridium difficile infection using enzyme immunoassay does not increase diagnostic yield. Clin Gastroenterol Hepatol 2011; 9:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/75\">",
"      Cardona DM, Rand KH. Evaluation of repeat Clostridium difficile enzyme immunoassay testing. J Clin Microbiol 2008; 46:3686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/76\">",
"      Mohan SS, McDermott BP, Parchuri S, Cunha BA. Lack of value of repeat stool testing for Clostridium difficile toxin. Am J Med 2006; 119:356.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/77\">",
"      Renshaw AA, Stelling JM, Doolittle MH. The lack of value of repeated Clostridium difficile cytotoxicity assays. Arch Pathol Lab Med 1996; 120:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/78\">",
"      Aichinger E, Schleck CD, Harmsen WS, et al. Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol 2008; 46:3795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/79\">",
"      Gade R, Turett G. The utility of repeated stool toxin testing for diagnosing Clostridium difficile colitis. South Med J 2009; 102:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/80\">",
"      Laughon BE, Viscidi RP, Gdovin SL, et al. Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis 1984; 149:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/81\">",
"      Shanholtzer CJ, Willard KE, Holter JJ, et al. Comparison of the VIDAS Clostridium difficile toxin A immunoassay with C. difficile culture and cytotoxin and latex tests. J Clin Microbiol 1992; 30:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/82\">",
"      Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of Clostridium difficile infection. BMJ 2010; 340:c1296.",
"     </a>",
"    </li>",
"    <li>",
"     Singh N, Hyun DY. Clostridium difficile. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.977.",
"    </li>",
"    <li>",
"     Ferry G, Versalovic J. Antibiotic-associated colitis. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.653.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/85\">",
"      Goldenberg SD, Cliff PR, Smith S, et al. Two-step glutamate dehydrogenase antigen real-time polymerase chain reaction assay for detection of toxigenic Clostridium difficile. J Hosp Infect 2010; 74:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/86\">",
"      Novak-Weekley SM, Marlowe EM, Miller JM, et al. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol 2010; 48:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/87\">",
"      Huang H, Weintraub A, Fang H, Nord CE. Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of clostridium difficile infections. J Clin Microbiol 2009; 47:3729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/88\">",
"      Peterson LR, Manson RU, Paule SM, et al. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin Infect Dis 2007; 45:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/89\">",
"      Goodhand JR, Alazawi W, Rampton DS. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29305/abstract/90\">",
"      Ananthakrishnan AN, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2010; 4:589.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2699 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-99A7E1262A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29305=[""].join("\n");
var outline_f28_39_29305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Carrier state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diarrhea with colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pseudomembranous colitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Endoscopic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Histopathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recurrent disease: relapse vs reinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fulminant colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      UNUSUAL PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Protein-losing enteropathy with ascites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clostridium difficile and inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Extracolonic involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15443523\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15443551\">",
"      Laboratory diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15451180\">",
"      - Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2699\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2699|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/42/42656\" title=\"diagnostic image 1\">",
"      C difficile colitis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/11/10416\" title=\"diagnostic image 2\">",
"      Toxic megacolon in C diff",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/51/33598\" title=\"diagnostic image 3\">",
"      Thumbprinting C difficile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2699|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/28/38349\" title=\"figure 1\">",
"      Osmotic v C difficile diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/24/25988\" title=\"figure 2\">",
"      Diagnostic test C difficile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2699|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/28/39363\" title=\"picture 1\">",
"      Pseudomembranous colitis scope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/15/4337\" title=\"picture 2\">",
"      Pseudomembranous colitis Gross",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2699|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/26/16812\" title=\"table 1\">",
"      Variants of C difficile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/35/25147\" title=\"table 2\">",
"      Antibiotics C diff diarrhea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=related_link\">",
"      Causes of neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=related_link\">",
"      Pathophysiology of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/47/28402?source=related_link\">",
"      Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=related_link\">",
"      Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=related_link\">",
"      Prevention and control of Clostridium difficile in hospital and institutional settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=related_link\">",
"      Toxic megacolon",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_39_29306="Supportive care after hematopoietic cell transplantation";
var content_f28_39_29306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Supportive care after hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/39/29306/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29306/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/39/29306/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29306/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/39/29306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/39/29306/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/39/29306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H875589\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients undergoing hematopoietic cell transplantation (HCT), advances in hematopoietic support; improvements in antibiotics, antifungal agents, and antiviral drugs; and better medications to control side effects of treatment such as nausea, vomiting, diarrhea and pain have all had a major impact on the clinical course.",
"   </p>",
"   <p>",
"    In terms of decreased morbidity and mortality after autologous transplantation, probably the single most important advance has been the introduction of mobilized peripheral blood progenitor cells (PBPCs) as the source of hematopoietic stem cells. This approach results in more rapid recovery, which has significantly reduced the duration of antibiotic therapy, the degree of mucositis, the length of hospitalization, and the risk of the transplant procedure itself. These positive developments have resulted in a marked decline in the discomfort that patients experience in the transplant setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, umbilical cord blood). Otherwise, the source of such cells will be specified (eg, autologous PBPC transplantation).",
"   </p>",
"   <p>",
"    General supportive care measures for patients following HCT and long term complications of HCT will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Hematopoietic support after HCT and the prevention and treatment of acute and chronic graft versus host disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=see_link\">",
"     \"Treatment of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and treatment of pulmonary, renal, and infectious complications following HCT are also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14745?source=see_link\">",
"     \"Pulmonary complications after autologous hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=see_link\">",
"     \"Kidney disease following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1511687\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous and allogeneic hematopoietic cell transplantation (HCT) are associated with neutropenia, anemia, and thrombocytopenia in the peri-transplant period. The degree of myelosuppression and the time to hematopoietic recovery differ with multiple factors including the preparative regimen and graft source. Blood product transfusions and hematopoietic growth factors are essential components of transplant care. This is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598154\">",
"    <span class=\"h1\">",
"     MUCOSITIS AND NUTRITIONAL SUPPORT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598162\">",
"    <span class=\"h2\">",
"     Overview and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients who undergo either autologous or allogeneic hematopoietic cell transplantation (HCT) develops significant mucositis and has difficulty maintaining an adequate caloric intake, with the degree of mucositis related to the cytotoxic regimen used, as well as a number of patient characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link&amp;anchor=H4#H4\">",
"     \"Oral toxicity associated with chemotherapy\", section on 'Etiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of patients undergoing allogeneic HCT for chronic myeloid leukemia, adverse risk factors for developing more significant degrees of oral mucositis (OM) included conditioning regimens utilizing total body irradiation, a body mass index &ge;25, non-use of multivitamins prior to transplantation, as well as the presence of the methylenetetrahydrofolate reductase 677TT genotype [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 197 patients with multiple myeloma or non-Hodgkin lymphoma receiving high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      or BEAM conditioning chemotherapy, respectively, prior to autologous HCT, severe OM occurred in 42 to 46 percent, with a mean duration of 5.3 to 5.5 days [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/6\">",
"       6",
"      </a>",
"      ]. The time from start of conditioning to peak OM was 12 to 15 days; risk factors for severe OM included higher chemotherapy doses and poor performance status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598169\">",
"    <span class=\"h2\">",
"     Total parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;If mucositis is severe enough to impair oral intake, patients generally receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN) until they are able to maintain adequate nutrition orally [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/7\">",
"     7",
"    </a>",
"    ]. Grading scales to define the severity of mucositis are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link&amp;anchor=H5#H5\">",
"     \"Oral toxicity associated with chemotherapy\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unfortunately, randomized studies are far from clear on the benefits of TPN in this setting, as exemplified by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of prophylactic therapy in 137 patients, TPN significantly improved overall survival, time to relapse, and disease-free survival compared with hydration with 5 percent dextrose [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a double-blinded study of 258 patients who were randomly assigned to receive either TPN or hydration in an outpatient setting, the patients who received TPN had a delay in the resumption of &gt;85 percent of their caloric requirement, suggesting that the administration of TPN may suppress normal appetite [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/9\">",
"       9",
"      </a>",
"      ]. There was no effect of TPN on hospital readmission, disease relapse, or survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of TPN in general, and particularly in patients undergoing HCT for malignant diseases, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=see_link&amp;anchor=H9#H9\">",
"     \"The role of parenteral and enteral/oral nutritional support in patients with cancer\", section on 'Hematopoietic cell transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=see_link\">",
"     \"Nutrition support in critically ill patients: Parenteral nutrition\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=see_link\">",
"     \"Nutrition support in critically ill patients: Enteral nutrition\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the potential benefits of TPN, mucositis remains an important clinical problem. Current management approaches include the use of topical and intravenous pain medications. Many patients who undergo transplantation require opioid pain medications and the length of time of IV opiate need is one of the best indicators of the degree of mucositis. New approaches are greatly needed, since the severity of mucositis (and the attendant requirement for pain medications) is one of the principal reasons that these patients require prolonged hospitalization with attendant increases in hospital costs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598176\">",
"    <span class=\"h3\">",
"     Glutamine supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of glutamine, either alone or as a supplement to TPN is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=see_link&amp;anchor=H11#H11\">",
"     \"The role of parenteral and enteral/oral nutritional support in patients with cancer\", section on 'Glutamine supplementation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link&amp;anchor=H18#H18\">",
"     \"Oral toxicity associated with chemotherapy\", section on 'Glutamine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598183\">",
"    <span class=\"h2\">",
"     Growth factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598191\">",
"    <span class=\"h3\">",
"     Palifermin",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach has been the use of growth factors such as recombinant human keratinocyte growth factor (KGF,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36084?source=see_link\">",
"     palifermin",
"    </a>",
"    , Kepivance). KGF reduces the degree of mucositis and improves survival in animal models in which the degree of mucositis and associated risk of infection are associated with measurable mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A placebo-controlled randomized clinical trial has demonstrated that treatment with this agent reduced the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic cancers. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A significant reduction in grade 3-4 mucositis from 98 percent in the control group to 63 percent in the KGF-treated group.",
"     </li>",
"     <li>",
"      Reduction of the median duration of mucositis from 9 days (range: 1-22) in the placebo group to 6 days (range: 1-27) in the KGF-treated group.",
"     </li>",
"     <li>",
"      A reduction in the use of opioid analgesics and TPN in KGF-treated patients was also noted. There were no differences in event-free or overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this study the preparative regimen of fractionated total body irradiation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    was utilized, which causes significant mucositis. Whether similar results will be obtained in patients receiving less intensive regimens remains to be determined. In two studies using historical controls, the use of KGF also resulted in positive benefits in terms of both oral and intestinal mucositis following preparative transplant regimens that did not contain radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link&amp;anchor=H16#H16\">",
"     \"Oral toxicity associated with chemotherapy\", section on 'Palifermin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon this registration trial, KGF was approved by the United States FDA to decrease the incidence and severity of severe oral mucositis associated with hematologic malignancies in patients receiving myelotoxic therapy requiring hematopoietic stem cell support.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36084?source=see_link\">",
"     Palifermin",
"    </a>",
"    has also been recommended by the American Society of Clinical Oncology to decrease severe mucositis in autologous transplantation for hematologic malignancies with total-body irradiation-containing (TBI) conditioning regimens, and should be considered for patients undergoing myeloablative allogeneic transplantation with TBI-based conditioning regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although KGF was able to reduce the risk of GVHD as well as mucositis in an animal transplant model [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/17\">",
"     17",
"    </a>",
"    ], a retrospective analysis, as well as a randomized, placebo-controlled phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    clinical trial of KGF in the allogeneic setting in man did not uncover any significant effect on engraftment, acute GVHD, or survival [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A randomized trial has been completed and results are awaited comparing the use of KGF to placebo following allogeneic transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598198\">",
"    <span class=\"h3\">",
"     Interleukin-11",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another agent with cytoprotective effects on the gastrointestinal tract is interleukin (IL)-11 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Use of this agent has been shown to protect against neutropenic sepsis in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In one study, a double-blind, placebo-controlled trial in 40 patients undergoing chemotherapy for malignant hematologic disease, use of recombinant human IL-11 reduced the incidence of bacteremia, predominantly of enteric origin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/23\">",
"     23",
"    </a>",
"    ]. However, due to toxicity and cost as well as limited efficacy, this agent is rarely used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17962?source=see_link&amp;anchor=H12#H12\">",
"     \"Investigational therapies in the medical management of Crohn's disease\", section on 'Interleukin-11'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598205\">",
"    <span class=\"h2\">",
"     Amifostine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     Amifostine",
"    </a>",
"    is a phosphorylated aminothiol capable of protecting normal tissues from radiation and alkylating agent toxicity. A retrospective study of mucosal damage was performed in 68 patients receiving high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    followed by autologous HCT, with (35 patients) or without (33 patients) concomitant amifostine (740",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    IV 30 minutes before starting the melphalan infusion) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients receiving amifostine had a significantly lower median number of days of analgesic therapy (zero versus six days), lower incidence of diarrhea (3 versus 25 percent) and emesis (9 versus 34 percent), and a lower incidence of grades 3 to 4 mucositis (21 versus 53 percent). No differences in hematologic recovery were seen between the two groups. A randomized study is warranted to confirm these observations and the usefulness of amifostine in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598212\">",
"    <span class=\"h2\">",
"     Nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention and treatment of nausea and vomiting in patients following HCT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link&amp;anchor=H27#H27\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\", section on 'High-dose chemotherapy regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90227195\">",
"    <span class=\"h1\">",
"     DIARRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 80 percent of patients will have at least one episode of acute diarrhea within the first 100 days following allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/25\">",
"     25",
"    </a>",
"    ]. The initial assessment should assess the quantity and quality of the stool and evaluate for possible causes. The initial management begins with general measures including the correction of volume depletion and metabolic derangements, followed by a search for the underlying etiology. Acute graft-versus-host disease is the most serious cause of persistent acute diarrhea following allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/25\">",
"     25",
"    </a>",
"    ]. Other causes of diarrhea include infections, medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil), mucosal damage due to the conditioning regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/26\">",
"     26",
"    </a>",
"    ], neutropenic enterocolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/27\">",
"     27",
"    </a>",
"    ], and, infrequently, post-transplantation lymphoproliferative disease involving the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, recipients of umbilical cord blood transplantation may develop a culture-negative, antibiotic-responsive diarrhea termed cord colitis syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90227203\">",
"    <span class=\"h2\">",
"     Graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute graft-versus-host disease (GVHD) is the most common cause of persistent acute diarrhea following allogeneic HCT, accounting for 64 percent of episodes in one prospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/25\">",
"     25",
"    </a>",
"    ]. Involvement of the gastrointestinal tract with acute GVHD varies widely, and is characterized by diarrhea and abdominal cramping. The diarrhea may initially be watery with high volumes. The diarrhea frequently becomes bloody, resulting in significant transfusion requirements. While the diagnosis can often be made on clinical grounds, histologic confirmation may be helpful to corroborate a clinical impression of acute GVHD. The diagnosis and management of acute GVHD is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\", section on 'Gastrointestinal tract'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90227211\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious diarrhea is a less common cause of diarrhea post-HCT but is important to exclude prior to the initiation of immunosuppressive agents for the treatment of presumed GVHD. Common causes of infectious diarrhea in this setting include clostridium difficile, cytomegalovirus, adenovirus, and many enteric viruses (eg, coxsackie, echovirus, rotavirus, norovirus). Parasitic infections, such as giardiasis, are less common, possibly due to the strict hygienic practices employed by transplant centers. Infections following HCT are discussed in more detail separately. In culture negative diarrhea where GVHD has been ruled out, occasionally a course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H90227219\">",
"     'Cord colitis syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90227219\">",
"    <span class=\"h2\">",
"     Cord colitis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cord colitis syndrome is a culture-negative, antibiotic-responsive diarrhea that has been described solely among recipients of umbilical cord blood (UCB) transplantation. An initial retrospective case series of 104 patients who underwent UCB transplantation at a single institution described the occurrence of cord colitis syndrome in approximately 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients with cord colitis most commonly presented with a persistent (&gt;7 days) watery, nonbloody diarrhea starting a median of 131 days after HCT. The diarrhea was associated with weight loss (91 percent) and fever (64 percent), and the majority of patients required hospitalization. As with other forms of colitis, computed tomography of the abdomen demonstrated focal or diffuse thickening of the colonic wall. Colonoscopy revealed erythematous mucosa with or without ulcerations, but no pseudomembranes. Cord colitis was distinguished from other causes of diarrhea by negative viral and bacterial cultures and a colon biopsy that demonstrated chronic active colitis, frequently with associated granulomas. All cases demonstrated a response to antibacterial treatment (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    with or without a fluoroquinolone) with a median treatment duration of 14 days. While approximately half of the patients relapsed after the discontinuation of antibiotics, all responded to subsequent courses of antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598219\">",
"    <span class=\"h1\">",
"     HEPATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disordered liver function is a common complication of both myeloablative and nonmyeloablative HCT, ranging from increased concentrations of bilirubin and hepatic enzymes to hepatic graft-versus-host disease, hepatic veno-occlusive disease, and death due to liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\", section on 'Liver'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\", section on 'Liver'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=see_link\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598226\">",
"    <span class=\"h2\">",
"     Hepatic veno-occlusive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic sinusoidal obstruction syndrome (SOS) is a syndrome characterized by painful hepatomegaly, weight gain, ascites, and jaundice, which can progress to fulminant hepatic failure. Pathologic changes include necrosis of hepatocytes and perivenular fibrosis with cholestasis, which are presumably due to injury induced by the preparative regimen, although no single regimen or agent has been more likely to be associated with this disorder.",
"   </p>",
"   <p>",
"    Mild SOS is generally self-limited, whereas severe disease is extremely difficult to treat, and efforts have been aimed at prevention. The prevention and treatment of hepatic sinusoidal obstruction syndrome are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7081?source=see_link\">",
"     \"Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598233\">",
"    <span class=\"h2\">",
"     Ursodeoxycholic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     Ursodeoxycholic acid",
"    </a>",
"    (UDCA), a hydrophilic bile salt, has been studied as treatment for several liver problems, including primary biliary cirrhosis, prevention of rejection episodes after liver transplantation, graft versus host disease (GVHD), and hepatic sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic cell transplantation (HCT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43526?source=see_link\">",
"     \"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7081?source=see_link\">",
"     \"Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=see_link\">",
"     \"Treatment of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective randomized, open-label study, 244 patients undergoing allogeneic HCT were randomly assigned to receive or not to receive UDCA (12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into two oral doses), starting one day before the first conditioning dose, continuing until day 90 following HCT. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly fewer patients in the group given UDCA developed a serum bilirubin concentration &gt;2.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       micromol/L;",
"      </span>",
"      15 versus 26 percent) or a serum alanine aminotransferase concentration &gt;100",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"      (52 versus 67 percent).",
"     </li>",
"     <li>",
"      The combined incidence of severe liver problems (ie, stage III to IV liver GVHD, SOS, fatal non-GVHD liver failure) was significantly lower in the UDCA group (4.8 versus 16.0 percent).",
"     </li>",
"     <li>",
"      The incidence of grade III to IV acute GVHD was significantly lower in the URSO group (4.1 versus 14.2 percent).",
"     </li>",
"     <li>",
"      The incidence of non-relapse mortality at one year was significantly lower in the URSO group (19 versus 34 percent).",
"     </li>",
"     <li>",
"      Overall survival at one year was significantly better for the URSO group (71 versus 55 percent). This survival advantage was significant among low-risk patients (ie, acute leukemia in first remission, chronic myeloid leukemia in first chronic phase, aplastic anemia, or hereditary disorder; 77 versus 58 percent), but was not different for the high-risk patients (ie, all others; 60 versus 52 percent).",
"     </li>",
"     <li>",
"      There were no significant differences between the two groups in the incidence of hepatic SOS, chronic GVHD at one year after HCT, or the rate of disease relapse. No adverse event caused by URSO was identified other than mild diarrhea. Despite difficulties with oral intake, the proportion of all prescribed URSO doses actually taken ranged from 71 to 94 percent during the first month of treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The improved survival noted for low-risk patients is particularly noteworthy, as survival in this group has been difficult to improve upon utilizing mobilized peripheral blood precursor cells and other interventions. These results suggest a role for this agent in the prevention of transplant-related complications in allogeneic HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598240\">",
"    <span class=\"h1\">",
"     PREVENTION OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo HCT are at risk for bacterial, viral, and fungal infections, the time course of which varies in the post-transplant period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/35\">",
"     35",
"    </a>",
"    ], according to the degree of immune deficiency and cytopenia induced by the transplantation procedure, as well as whether the transplantation is autologous (",
"    <a class=\"graphic graphic_figure graphicRef64491 \" href=\"UTD.htm?4/7/4223\">",
"     figure 1",
"    </a>",
"    ) or allogeneic (",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"UTD.htm?8/10/8362\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, prophylactic therapies to prevent infection, according to institutional practices and including use of neutropenic precautions, antibiotics, immunoglobulin infusions, antiviral drugs, antifungal drugs, and vaccinations are recommended during the period of increased risk. These issues differ from one institution to another, and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H18#H18\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines for preventing opportunistic infections in these subjects, cosponsored by the CDC, Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation, and a discussion of the use of immunizations in the post-HCT period are presented separately. The IDSA clinical practice guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, as well as other IDSA guidelines, can be accessed through the Infectious Diseases Society of America's web site [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599675\">",
"    <span class=\"h1\">",
"     NEURO-PSYCHIATRIC MORBIDITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599683\">",
"    <span class=\"h2\">",
"     Psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the transplant procedure itself can be physically and emotionally stressful, there does not appear to be a substantially increased risk of a long-term psychiatric disorder due to the procedure itself. Few studies have examined this issue prospectively.",
"   </p>",
"   <p>",
"    A three-year prospective study of 220 patients undergoing HCT for a hematologic malignancy at a single institution found an incidence of a psychiatric disorder (eg, depressive, anxiety, or adjustment disorder) at the time of hospital admission for the transplant of 21 percent, and an incidence of 22 percent during post-admission follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On multivariate analysis, the following factors were significantly associated with psychiatric disorder risk:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Younger age",
"     </li>",
"     <li>",
"      Women",
"     </li>",
"     <li>",
"      Past psychiatric history",
"     </li>",
"     <li>",
"      Lower functional status",
"     </li>",
"     <li>",
"      Presence of pain",
"     </li>",
"     <li>",
"      Smoking cessation",
"     </li>",
"     <li>",
"      Higher regimen-related toxicity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another report compared the psychiatric well-being of 1065 long-term HCT survivors with that of healthy siblings as part of the Bone Marrow Transplant Survivor Study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/39\">",
"     39",
"    </a>",
"    ]. Psychiatric disorders were seen in 22 percent of HCT survivors and 8 percent of siblings. Factors associated with an increased risk of psychiatric disorder in HCT survivors included exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , self-reported poor health, and a low household income.",
"   </p>",
"   <p>",
"    While clinicians should continue to screen patients for psychiatric morbidity following HCT, these studies suggest that the majority of long-term survivors will be psychologically healthy after HCT. Nonetheless, psychiatric issues are relatively common and often not diagnosed in the post-transplant setting. Attention to the potential for psychiatric problems is important for the overall well-being of surviving patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599690\">",
"    <span class=\"h2\">",
"     Encephalopathy and delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 50 percent of patients undergoing myeloablative HCT experience an acute confusional state consistent with delirium at some point during the first 30 days post-HCT. Delirium can be distressing to the patient, family, and medical team and can result in decreased performance status and longer hospital stays. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delirium in the peri-HCT period was evaluated in a prospective single-center cohort study of 90 patients undergoing autologous or allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/40\">",
"     40",
"    </a>",
"    ]. The presence and severity of delirium was assessed using standardized rating scales administered three times a week. Delirium occurred in 45 patients (50 percent). The patients who experienced an episode of delirium during the acute phase of their first myeloablative HCT, compared with those who did not, had impaired neurocognitive abilities and persistent distress 80 days following HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/41\">",
"     41",
"    </a>",
"    ]. Risk factors for the development of delirium included higher pre-HCT levels of alkaline phosphatase",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood urea nitrogen and the use of high dose opioids post-HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/42\">",
"     42",
"    </a>",
"    ]. Delirium was more severe in patients with these risk factors, those who had poorer pre-HCT executive function, and those suffering from pain. Although these risks of delirium are higher than our own experience, delirium remains a significant clinical problem associated with potential adverse outcomes (eg, aspiration, falls, and diagnostic challenges). Medications should be suspected as a potential cause in patients who develop delirium (",
"    <a class=\"graphic graphic_table graphicRef70449 \" href=\"UTD.htm?1/11/1214\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Transient, profound encephalopathy, with concurrent cardiac and gastrointestinal effects, has been reported very rarely following infusions of the hematopoietic stem cell product, perhaps due to acute systemic toxicity from the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"     dimethylsulfoxide",
"    </a>",
"    (DMSO) used as a cryopreservative [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599697\">",
"    <span class=\"h2\">",
"     Social and psychological support",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have emphasized the importance of social and psychological support during and after HCT and its effect on quality of life and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/2,46-49\">",
"     2,46-49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=see_link\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study examined whether the consistent presence of an in-hospital lay care-partner (ie, someone present at the bedside during the patient's hospitalization for &ge;7",
"    <span class=\"nowrap\">",
"     hours/day",
"    </span>",
"    at least 5",
"    <span class=\"nowrap\">",
"     days/week)",
"    </span>",
"    had a significant effect on overall survival following HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/47\">",
"     47",
"    </a>",
"    ]. Results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      45 percent of the patients had an in-hospital lay care-partner. Spouses and parents constituted 61 and 34 percent of these care-partners, respectively.",
"     </li>",
"     <li>",
"      At one year post-HCT, overall survivals were 26 versus 75 percent for those without or with a care-partner as defined above (hazard ratio 3.1; 95% CI 1.9-4.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results require replication in other well constructed clinical trials before one can advocate for the need for such support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599704\">",
"    <span class=\"h1\">",
"     FUNCTIONAL RECOVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients who have successfully undergone autologous or allogeneic HCT return to some aspects of a normal lifestyle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43719?source=see_link\">",
"     \"Functional problems in the patient with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=see_link\">",
"     \"Quality of life following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 320 patients responding to a series of questionnaires following transplantation, the following observations were made at one year of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than 80 percent of survivors saw a physician once per month or less.",
"     </li>",
"     <li>",
"      Approximately 60 percent of patients had returned to work, school, or homemaking and agreed with the statement: \"Life has returned to normal.\"",
"     </li>",
"     <li>",
"      Forty-six percent of autologous HCT patients and 39 percent of allogeneic HCT patients agreed with the statement: \"In general, my health is very good to excellent.\"",
"     </li>",
"     <li>",
"      Forty-three percent of autologous and 25 percent of allogeneic HCT patients were off all transplant-related medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599711\">",
"    <span class=\"h2\">",
"     Patient expectations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the improvements noted above, informed consent guidelines mandate that patients have an accurate understanding of the risks of HCT. A single institution study of patients undergoing HCT indicated that patients and their physicians had the most concordant and accurate pre-transplant expectations of post-transplant survival when outcomes were most likely to be favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/51\">",
"     51",
"    </a>",
"    ]. Thus, for autologous transplants, in which the actual treatment-related mortality at one year was 10 percent, patient and physician estimates were 12 and 10 percent, respectively.",
"   </p>",
"   <p>",
"    This was not true when one year treatment-related mortality was significantly higher. As an example, in patients with intermediate or advanced disease receiving a transplant from an unrelated donor (actual one-year mortality 44 to 67 percent), physician expectations were appropriately modified (estimated mortality of 38 to 55 percent), while those of patients were overly optimistic (15 to 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599718\">",
"    <span class=\"h2\">",
"     End-of-life and advanced care planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high probability for morbidity and mortality post-transplant, advance care planning (ie, having a living will, a power of attorney for health care, or life-support instructions) should be completed while the patient is competent, to insure that care is consistent with the patient's wishes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14473?source=see_link&amp;anchor=H14#H14\">",
"     \"Legal aspects of end of life care\", section on 'Advance directives'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This issue was explored in all patients at least 19 years of age who underwent their first HCT for a hematologic malignancy between the years 2001 and 2003 at a single medical center. The following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 343 patients in this study, 172 (50 percent) did not have advanced care planning (ACP), as defined above.",
"     </li>",
"     <li>",
"      Of those with ACP, 22, 68, and 10 percent completed ACP before cancer diagnosis, after cancer diagnosis but before HCT, or following HCT, respectively.",
"     </li>",
"     <li>",
"      Of interest, patients without ACP before HCT had a significantly greater risk of death compared with patients with ACP (hazard ratio 2.1; 95% CI 1.3-3.3). Stated otherwise, in this exploratory study the patients least likely to have planned for poor outcomes were the ones most likely to face them.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599725\">",
"    <span class=\"h2\">",
"     Estimating mortality risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk scores are available for estimating mortality risk in patients considering allogeneic HCT. Of these, the three most commonly used assessments are the European Group for Blood and Marrow Transplantation (EGBMT) risk assessment score for allogeneic transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/53\">",
"     53",
"    </a>",
"    ], the Pretransplant Assessment of Mortality (PAM) score [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/54\">",
"     54",
"    </a>",
"    ], and the Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potentially important issue is that mortality rates after allogeneic HCT have decreased since these tools were created. A retrospective single-center study of 1418 patients who underwent allogeneic HCT from 1993 through 1997 and 1148 patients who were transplanted from 2003 through 2007 reported a significant decrease in non-relapse mortality (odds ratio 0.48, 95% CI 0.40-0.57) and overall mortality (odds ratio 0.59, 95% CI 0.52-0.67) in the patients in the latter group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/57\">",
"     57",
"    </a>",
"    ]. Similar results were reported in a study of 5972 patients younger than age 50 years undergoing myeloablative conditioning and allogeneic HCT for acute myeloid leukemia in first or second complete remission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/58\">",
"     58",
"    </a>",
"    ]. This benefit probably reflects shifts in conditioning regimens, preferred stem cell source, graft-versus-host disease prophylaxis, and other supportive measures.",
"   </p>",
"   <p>",
"    The European Group for Blood and Marrow Transplantation (EGBMT) devised a risk score based on five separate characteristics, which predicted treatment-related mortality and five-year overall survival following allogeneic HCT for patients with CML (",
"    <a class=\"graphic graphic_table graphicRef67260 \" href=\"UTD.htm?35/31/36348\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/53\">",
"     53",
"    </a>",
"    ]. This risk score was later validated for CML using separate data from the International Bone Marrow Transplant Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/59\">",
"     59",
"    </a>",
"    ] and subsequently for predicting survival, treatment-related mortality, and death from relapse for those transplanted for hematologic disease in general (ie, CML, AML, ALL, MDS, myeloma, NHL, aplastic anemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link&amp;anchor=H4#H4\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Investigators at Seattle constructed a Pretransplantation Assessment of Mortality (PAM) score incorporating the following eight pre-transplant clinical variables (factors associated with a significantly increased risk of death at two years are shown in parentheses) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient age (&gt;50)",
"     </li>",
"     <li>",
"      Donor type (unrelated or mismatched related)",
"     </li>",
"     <li>",
"      Disease risk (all conditions with the exception of chronic myeloid leukemia in chronic phase, refractory anemia, aplastic anemia, Blackfan-Diamond syndrome)",
"     </li>",
"     <li>",
"      Conditioning regimen (all regimens except nonmyeloablative)",
"     </li>",
"     <li>",
"      Serum creatinine (&gt;1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or &gt;106",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Serum alanine aminotransferase level (&gt;49",
"      <span class=\"nowrap\">",
"       U/L)",
"      </span>",
"     </li>",
"     <li>",
"      FEV1 (&le;80 percent of normal)",
"     </li>",
"     <li>",
"      Carbon monoxide diffusing capacity (&lt;70 percent of normal)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By applying weighting factors derived from a multivariate analysis, they obtained a score ranging from 8 to 50, which was found to predict two-year mortality in early and late validation groups as well as three separate groups of patients with CML, AML, or MDS. As an example, the estimated two-year mortality for patients with CML and the following risk scores were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Score 9 to 16 &mdash; 14 percent two-year mortality; HR 1.0",
"     </li>",
"     <li>",
"      Score 17 to 23 &mdash; 32 percent mortality; HR 2.5, 95% CI 1.8-3.6",
"     </li>",
"     <li>",
"      Score 24 to 30 &mdash; 60 percent mortality; HR 5.8, 95% CI 4.1-8.3",
"     </li>",
"     <li>",
"      Score 30 to 44 &mdash; 83 percent mortality; HR 12.0, 95% CI 7.6-19",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Charlson Comorbidity Index (CCI) is commonly used to predict the impact of comorbidities on mortality from various medical conditions including solid malignancies. However, many of the comorbidities assessed in the original CCI are exclusion criteria for allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/61\">",
"     61",
"    </a>",
"    ]. As such, a modified hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was created for this patient population (",
"    <a class=\"graphic graphic_table graphicRef59272 \" href=\"UTD.htm?7/48/7950\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. This index weighs 17 possible comorbidities for a score ranging from 0 to 29. In a validation cohort of 346 patients undergoing allogeneic HCT, rates of two-year non-relapse mortality for patients with scores of 0, 1, 2, 3, and 4 or more were 14, 22, 19, 41, and 40 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/55\">",
"     55",
"    </a>",
"    ]. The HCT-CI has also been used to predict non-relapse mortality and overall survival in pediatric patients undergoing a first allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While future studies will be needed to validate these scoring systems and other available comorbidity scores [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/55,56,61\">",
"     55,56,61",
"    </a>",
"    ], including the Karnofsky performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/63\">",
"     63",
"    </a>",
"    ], all can serve to help patients better appreciate their mortality risk after allogeneic HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link&amp;anchor=H5#H5\">",
"     \"Comprehensive geriatric assessment for patients with cancer\", section on 'Comorbidity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599732\">",
"    <span class=\"h2\">",
"     Intensive care unit admission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Admission to an intensive care unit (ICU) is an ominous clinical event post-HCT and is associated with high rates of mortality as well as worsened long-term survival for those successfully discharged from an ICU. Admission to an ICU appears to be more common, and ICU mortality higher, in those receiving myeloablative allo-HCT than in those undergoing nonmyeloablative allo-HCT or autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While short-term and long-term survivals have differed greatly among published studies, the following factors present at the time of ICU admission were reported to adversely affect survival in more than one study:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endotracheal intubation and mechanical ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/65-67\">",
"       65-67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Use of vasopressors [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/64,68\">",
"       64,68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence of multi-organ failure [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/64,66\">",
"       64,66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated bilirubin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/64,65,67\">",
"       64,65,67",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since overall survival of transplant patients admitted to an ICU has been increasing over the past decades, it is not possible to easily determine whether admission to an ICU will be futile for any one individual patient. However, in a study of 865 mechanically ventilated patients who had received a HCT between 1980 and 1992, there were no survivors among an estimated 398 patients who had lung injury and either required more than four hours of vasopressor support or had sustained hepatic and renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/60/26565?source=see_link\">",
"     \"Ethics in the intensive care unit: Informed consent\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Decisions concerning which patients are appropriate for ICU care and how long to continue aggressive therapy are complex issues requiring significant deliberation. At our program we divide patients into those for whom ICU care is recommended, short term therapy advised, and those for whom ICU care is not recommended. Utilizing the ICU staff to perform consultations on the appropriateness of ICU care prior to the time when critical interventions are required has been helpful in aligning appropriate care with the expectations of patients and their families.",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) statement on withholding and withdrawing life-sustaining therapy, as well as other ATS guidelines, can be accessed through the ATS website at",
"    <span class=\"nowrap\">",
"     www.thoracic.org/statements.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599739\">",
"    <span class=\"h1\">",
"     LONG-TERM COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing hematopoietic cell transplantation have an increased risk of long-term complications. Secondary malignancy is of particular concern and most often occurs many years following the transplantation procedure. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28280?source=see_link\">",
"     \"Malignancy after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=see_link\">",
"     \"The approach to hematopoietic cell transplantation survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term complications that have been described after HCT include, but are not limited to, the following [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/70-75\">",
"     70-75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Late relapse of the primary disease",
"     </li>",
"     <li>",
"      Increased overall mortality",
"     </li>",
"     <li>",
"      Graft versus host disease and its sequelae",
"     </li>",
"     <li>",
"      Effects of long-term immune deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/76\">",
"       76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neutrophil dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/77\">",
"       77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Disorders of taste [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/78\">",
"       78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      End-organ damage from chemotherapy and radiation therapy (eg, cataracts, lung and liver damage)",
"     </li>",
"     <li>",
"      Congestive failure [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/79\">",
"       79",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Metabolic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/80\">",
"       80",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chronic kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pulmonary dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/83\">",
"       83",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Iron overload from multiple blood transfusions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/84\">",
"       84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased risk factors for cardiovascular disease (eg, diabetes, hypertension, dyslipidemia, obesity) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/85-88\">",
"       85-88",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Development of secondary malignancies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28280?source=see_link\">",
"       \"Malignancy after hematopoietic cell transplantation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Growth and development issues in children and adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/89\">",
"       89",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Gonadal function, fertility, and sexual functioning issues [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/90-93\">",
"       90-93",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neuropsychiatric functioning; quality of life issues [",
"      <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/94,95\">",
"       94,95",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=see_link\">",
"       \"Quality of life following hematopoietic cell transplantation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Osteoporosis/osteopenia/osteonecrosis",
"      </span>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=see_link\">",
"       \"Osteoporosis after solid organ or stem cell transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link&amp;anchor=H12#H12\">",
"       \"Osteonecrosis (avascular necrosis of bone)\", section on 'Transplantation'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The largest study of long-term follow-up evaluated 10,632 patients who were alive and disease-free two years after receiving a myeloablative allogeneic HCT for acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic syndrome, lymphoma, or severe aplastic anemia before 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/96\">",
"     96",
"    </a>",
"    ]. After a median follow-up of nine years, there was an estimated 10-year overall survival rate of 85 percent. The most common causes of death after HCT for malignancy were late relapse, graft versus host disease, and infection. When compared with persons from the general population, relative rates of mortality were higher among HCT recipients at two years. The relative risk of death declined with increasing time from HCT, but did not return to that of the general population, except among patients who underwent HCT for lymphoma.",
"   </p>",
"   <p>",
"    Another report from the Bone Marrow Transplant Survivor Study included 1479 individuals who had survived two or more years after allogeneic HCT and were followed for a median time of 9.5 years. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using age-, sex-, and calendar-specific rates from the general United States population, the standardized mortality ratio (SMR) for the entire group was increased almost 10-fold. It was highest in the second through the fifth year post-HCT (78-fold), in those transplanted for inborn errors of metabolism (37-fold), and in those &lt;18 years of age at the time of transplant (16-fold).",
"     </li>",
"     <li>",
"      Mortality rates remained high as long as 16 to 20 years post-diagnosis (SMR 2.9; 95% CI 1.8-4.3).",
"     </li>",
"     <li>",
"      Relapse of the primary disease (29 percent) and chronic GVHD (22 percent) were the most common causes of premature death.",
"     </li>",
"     <li>",
"      Compared with those &lt;18 years of age at the time of HCT, non-relapse mortality (NRM) was increased 1.7-fold and 3.7-fold for those who were 18 to 45 or &ge;46 years of age at the time of HCT, respectively, and was increased 2.7-fold for those with chronic GVHD, compared with those without chronic GVHD.",
"     </li>",
"     <li>",
"      HCT survivors were more likely than their siblings to report difficulty in holding jobs (odds ratio 14) and in obtaining life insurance (OR 10) or health insurance (OR 7). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=see_link\">",
"       \"Quality of life following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar study of life expectancy was conducted in 2574 patients who had survived without recurrence of their original disease for at least five years after allogeneic or autologous HCT. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?28/39/29306/abstract/97\">",
"     97",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estimated survival of the cohort at 20 years after HCT was 80 percent (95% CI 78-83).",
"     </li>",
"     <li>",
"      Mortality rates remained four- to ninefold higher than the expected population rate for at least 30 years following HCT, yielding a 30 percent lower life expectancy compared with those in the general population, regardless of current age.",
"     </li>",
"     <li>",
"      The leading causes of death were second malignancies and recurrent disease, followed by infection, chronic GVHD, respiratory disease, and cardiovascular disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies suggest that patients who are alive two years after allogeneic HCT have a very good prognosis with the majority of patients surviving for more than 10 years post-HCT. Relapse and graft-versus-host disease are the most common causes of death in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599816\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients undergoing hematopoietic cell transplantation (HCT), advances in hematopoietic support, improvements in antibiotics, antifungal agents, and antiviral drugs, and better medications to control side effects of treatment such as nausea, vomiting, diarrhea and pain have all had a major impact on the clinical course.",
"     </li>",
"     <li>",
"      The majority of patients who undergo myeloablative HCT develop significant mucositis and have difficulty maintaining an adequate caloric intake, with the degree of mucositis related to the cytotoxic regimen used, as well as a number of patient characteristics. Despite the potential benefits of TPN, mucositis remains an important clinical problem. Current management approaches include the use of topical and intravenous pain medications. In addition, growth factors may be of benefit in a subset of patients. (See",
"      <a class=\"local\" href=\"#H598154\">",
"       'Mucositis and nutritional support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disordered liver function is a common complication of both myeloablative and nonmyeloablative HCT, ranging from increased concentrations of bilirubin and hepatic enzymes to hepatic graft-versus-host disease, hepatic veno-occlusive disease, and death due to liver failure. (See",
"      <a class=\"local\" href=\"#H598219\">",
"       'Hepatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who undergo HCT are at risk for bacterial, viral, and fungal infections, the time course of which varies in the post-transplant period, according to the degree of immune deficiency and cytopenia induced by the transplantation procedure, as well as whether the transplantation is autologous (",
"      <a class=\"graphic graphic_figure graphicRef64491 \" href=\"UTD.htm?4/7/4223\">",
"       figure 1",
"      </a>",
"      ) or allogeneic (",
"      <a class=\"graphic graphic_figure graphicRef52716 \" href=\"UTD.htm?8/10/8362\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"       \"Overview of infections following hematopoietic cell transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"       \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prophylactic therapies to prevent infection, according to institutional practices and including use of neutropenic precautions, antibiotics, immunoglobulin infusions, antiviral drugs, antifungal drugs, and vaccinations are recommended during the period of increased risk. These issues differ from one institution to another, and are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"       \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H18#H18\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Infections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Social and psychological support during and after HCT have important effects on quality of life and survival. The majority of patients who have successfully undergone autologous or allogeneic HCT return to some aspects of a normal lifestyle. (See",
"      <a class=\"local\" href=\"#H599675\">",
"       'Neuro-psychiatric morbidity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of risk scores are available for estimating mortality risk in patients considering allogeneic HCT. (See",
"      <a class=\"local\" href=\"#H599725\">",
"       'Estimating mortality risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Admission to an intensive care unit (ICU) is an ominous clinical event post-HCT and is associated with increased mortality as well as worsened long-term survival for those successfully discharged from an ICU. (See",
"      <a class=\"local\" href=\"#H599732\">",
"       'Intensive care unit admission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/1\">",
"      Roeland E, Mitchell W, Elia G, et al. Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 1: Physical symptoms. J Support Oncol 2010; 8:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/2\">",
"      Roeland E, Mitchell W, Elia G, et al. Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 2: psychosocial concerns. J Support Oncol 2010; 8:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/3\">",
"      Wardley AM, Jayson GC, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000; 110:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/4\">",
"      Robien K, Schubert MM, Bruemmer B, et al. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004; 22:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/5\">",
"      Fanning SR, Rybicki L, Kalaycio M, et al. Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. Br J Haematol 2006; 135:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/6\">",
"      Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/7\">",
"      Scolapio JS, Tarrosa VB, Stoner GL, et al. Audit of nutrition support for hematopoietic stem cell transplantation at a single institution. Mayo Clin Proc 2002; 77:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/8\">",
"      Weisdorf SA, Lysne J, Wind D, et al. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation 1987; 43:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/9\">",
"      Charuhas PM, Fosberg KL, Bruemmer B, et al. A double-blind randomized trial comparing outpatient parenteral nutrition with intravenous hydration: effect on resumption of oral intake after marrow transplantation. JPEN J Parenter Enteral Nutr 1997; 21:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/10\">",
"      Jones JA, Qazilbash MH, Shih YC, et al. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer 2008; 112:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/11\">",
"      Playford RJ, Marchbank T, Mandir N, et al. Effects of keratinocyte growth factor (KGF) on gut growth and repair. J Pathol 1998; 184:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/12\">",
"      Farrell CL, Bready JV, Rex KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/13\">",
"      Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/14\">",
"      Tsirigotis P, Triantafyllou K, Girkas K, et al. Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. Bone Marrow Transplant 2008; 42:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/15\">",
"      Kobbe G, Bruns I, Schroeder T, et al. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol 2010; 21:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/16\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/17\">",
"      Krijanovski OI, Hill GR, Cooke KR, et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999; 94:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/18\">",
"      Blazar BR, Weisdorf DJ, Defor T, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108:3216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/19\">",
"      Langner S, Staber P, Schub N, et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008; 42:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/20\">",
"      Du X, Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use. Blood 1997; 89:3897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/21\">",
"      Opal SM, Jhung JW, Keith JC Jr, et al. Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis. Blood 1999; 93:3467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/22\">",
"      Opal SM, Keith JC Jr, Jhung J, et al. Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis. J Infect Dis 2003; 187:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/23\">",
"      Ellis M, Zwaan F, Hedstr&ouml;m U, et al. Recombinant human interleukin 11 and bacterial infection in patients with [correction of] haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/24\">",
"      Capelli D, Santini G, De Souza C, et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study. Br J Haematol 2000; 110:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/25\">",
"      van Kraaij MG, Dekker AW, Verdonck LF, et al. Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant 2000; 26:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/26\">",
"      Bow EJ, Loewen R, Cheang MS, et al. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997; 15:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/27\">",
"      Davila ML. Neutropenic enterocolitis. Curr Opin Gastroenterol 2006; 22:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/28\">",
"      Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/29\">",
"      Herrera AF, Soriano G, Bellizzi AM, et al. Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med 2011; 365:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/30\">",
"      McDonald GB, Schoch HG, Gooley TA. Liver dysfunction and mortality after allogeneic marrow transplantation: Analysis of 1419 consecutive patients (abstract). Hepatology 1999; 30:162A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/31\">",
"      Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/32\">",
"      Arai S, Lee LA, Vogelsang GB. A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res 2002; 11:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/33\">",
"      Gooley TA, Rajvanshi P, Schoch HG, McDonald GB. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology 2005; 41:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/34\">",
"      Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/35\">",
"      van der Meer JW, Guiot HF, van den Broek PJ, van Furth R. Infections in bone marrow transplant recipients. Semin Hematol 1984; 21:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/36\">",
"      Peggs KS, Mackinnon S. Immune reconstitution following haematopoietic stem cell transplantation. Br J Haematol 2004; 124:407.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.idsociety.org/Content.aspx?id=9088 (Accessed on February 26, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/38\">",
"      Prieto JM, Blanch J, Atala J, et al. Stem cell transplantation: risk factors for psychiatric morbidity. Eur J Cancer 2006; 42:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/39\">",
"      Sun CL, Francisco L, Baker KS, et al. Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood 2011; 118:4723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/40\">",
"      Fann JR, Roth-Roemer S, Burington BE, et al. Delirium in patients undergoing hematopoietic stem cell transplantation. Cancer 2002; 95:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/41\">",
"      Fann JR, Alfano CM, Roth-Roemer S, et al. Impact of delirium on cognition, distress, and health-related quality of life after hematopoietic stem-cell transplantation. J Clin Oncol 2007; 25:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/42\">",
"      Fann JR, Hubbard RA, Alfano CM, et al. Pre- and post-transplantation risk factors for delirium onset and severity in patients undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2011; 29:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/43\">",
"      Higman MA, Port JD, Beauchamp NJ Jr, Chen AR. Reversible leukoencephalopathy associated with re-infusion of DMSO preserved stem cells. Bone Marrow Transplant 2000; 26:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/44\">",
"      Bauwens D, Hantson P, Laterre PF, et al. Recurrent seizure and sustained encephalopathy associated with dimethylsulfoxide-preserved stem cell infusion. Leuk Lymphoma 2005; 46:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/45\">",
"      Chen-Plotkin AS, Vossel KA, Samuels MA, Chen MH. Encephalopathy, stroke, and myocardial infarction with DMSO use in stem cell transplantation. Neurology 2007; 68:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/46\">",
"      Siegel SD. Psychosocial considerations in hematopoietic stem cell transplantation: implications for patient quality of life and post-transplant survival. J Psychosoc Oncol 2008; 5:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/47\">",
"      Foster LW, McLellan LJ, Rybicki LA, et al. Survival of patients who have undergone allogeneic bone marrow transplantation: The relative importance of in-hospital lay care-partner support. J Psychosoc Oncol 2004; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/48\">",
"      Frick E, Motzke C, Fischer N, et al. Is perceived social support a predictor of survival for patients undergoing autologous peripheral blood stem cell transplantation? Psychooncology 2005; 14:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/49\">",
"      DuHamel KN, Mosher CE, Winkel G, et al. Randomized clinical trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic stem-cell transplantation. J Clin Oncol 2010; 28:3754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/50\">",
"      Lee SJ, Fairclough D, Parsons SK, et al. Recovery after stem-cell transplantation for hematologic diseases. J Clin Oncol 2001; 19:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/51\">",
"      Lee SJ, Fairclough D, Antin JH, Weeks JC. Discrepancies between patient and physician estimates for the success of stem cell transplantation. JAMA 2001; 285:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/52\">",
"      Ganti AK, Lee SJ, Vose JM, et al. Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning. J Clin Oncol 2007; 25:5643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/53\">",
"      Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/54\">",
"      Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/55\">",
"      Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/56\">",
"      Kataoka K, Nannya Y, Ueda K, et al. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study. Bone Marrow Transplant 2010; 45:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/57\">",
"      Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/58\">",
"      Horan JT, Logan BR, Agovi-Johnson MA, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol 2011; 29:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/59\">",
"      Passweg JR, Walker I, Sobocinski KA, et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004; 125:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/60\">",
"      Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115:4715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/61\">",
"      Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/62\">",
"      Smith AR, Majhail NS, MacMillan ML, et al. Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood 2011; 117:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/63\">",
"      Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/64\">",
"      Lim Z, Pagliuca A, Simpson S, et al. Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data. Br J Haematol 2007; 136:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/65\">",
"      Price KJ, Thall PF, Kish SK, et al. Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unit. Am J Respir Crit Care Med 1998; 158:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/66\">",
"      Soubani AO, Kseibi E, Bander JJ, et al. Outcome and prognostic factors of hematopoietic stem cell transplantation recipients admitted to a medical ICU. Chest 2004; 126:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/67\">",
"      P&egrave;ne F, Aubron C, Azoulay E, et al. Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports. J Clin Oncol 2006; 24:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/68\">",
"      Kew AK, Couban S, Patrick W, et al. Outcome of hematopoietic stem cell transplant recipients admitted to the intensive care unit. Biol Blood Marrow Transplant 2006; 12:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/69\">",
"      Rubenfeld GD, Crawford SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med 1996; 125:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/70\">",
"      Soci&eacute; G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101:3373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/71\">",
"      Lee SJ, Loberiza FR, Antin JH, et al. Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 35:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/72\">",
"      Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105:4215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/73\">",
"      Faraci M, Barra S, Cohen A, et al. Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. Int J Radiat Oncol Biol Phys 2005; 63:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/74\">",
"      Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110:3784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/75\">",
"      Abou-Mourad YR, Lau BC, Barnett MJ, et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant 2010; 45:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/76\">",
"      Norlin AC, Sairafi D, Mattsson J, et al. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant 2008; 41:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/77\">",
"      Ramaprasad C, Pouch S, Pitrak DL. Neutrophil function after bone marrow and hematopoietic stem cell transplant. Leuk Lymphoma 2010; 51:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/78\">",
"      Boer CC, Correa ME, Miranda EC, de Souza CA. Taste disorders and oral evaluation in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant 2010; 45:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/79\">",
"      Armenian SH, Sun CL, Francisco L, et al. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 2008; 26:5537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/80\">",
"      Majhail NS, Flowers ME, Ness KK, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2009; 43:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/81\">",
"      Hingorani S, Guthrie KA, Schoch G, et al. Chronic kidney disease in long-term survivors of hematopoietic cell transplant. Bone Marrow Transplant 2007; 39:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/82\">",
"      Gr&ouml;nroos MH, Bolme P, Winiarski J, Berg UB. Long-term renal function following bone marrow transplantation. Bone Marrow Transplant 2007; 39:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/83\">",
"      Inaba H, Yang J, Pan J, et al. Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Cancer 2010; 116:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/84\">",
"      Majhail NS, Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008; 41:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/85\">",
"      Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 2007; 109:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/86\">",
"      Tichelli A, Bucher C, Rov&oacute; A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007; 110:3463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/87\">",
"      Tichelli A, Bhatia S, Soci&eacute; G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol 2008; 142:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/88\">",
"      Griffith ML, Savani BN, Boord JB. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood 2010; 116:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/89\">",
"      Taskinen M, Saarinen-Pihkala UM, Hovi L, et al. Bone health in children and adolescents after allogeneic stem cell transplantation: high prevalence of vertebral compression fractures. Cancer 2007; 110:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/90\">",
"      Rov&oacute; A, Tichelli A, Passweg JR, et al. Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD. Blood 2006; 108:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/91\">",
"      Humphreys CT, Tallman B, Altmaier EM, Barnette V. Sexual functioning in patients undergoing bone marrow transplantation: a longitudinal study. Bone Marrow Transplant 2007; 39:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/92\">",
"      Hammond C, Abrams JR, Syrjala KL. Fertility and risk factors for elevated infertility concern in 10-year hematopoietic cell transplant survivors and case-matched controls. J Clin Oncol 2007; 25:3511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/93\">",
"      Syrjala KL, Kurland BF, Abrams JR, et al. Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. Blood 2008; 111:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/94\">",
"      Poppelreuter M, Weis J, Mumm A, et al. Rehabilitation of therapy-related cognitive deficits in patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/95\">",
"      Chang G, Meadows ME, Orav EJ, Antin JH. Mental status changes after hematopoietic stem cell transplantation. Cancer 2009; 115:4625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/96\">",
"      Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/39/29306/abstract/97\">",
"      Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28:1011.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15803 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-714CE7359B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29306=[""].join("\n");
var outline_f28_39_29306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H599816\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H875589\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1511687\">",
"      HEMATOPOIETIC SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H598154\">",
"      MUCOSITIS AND NUTRITIONAL SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H598162\">",
"      Overview and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H598169\">",
"      Total parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H598176\">",
"      - Glutamine supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H598183\">",
"      Growth factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H598191\">",
"      - Palifermin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H598198\">",
"      - Interleukin-11",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H598205\">",
"      Amifostine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H598212\">",
"      Nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90227195\">",
"      DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90227203\">",
"      Graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90227211\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90227219\">",
"      Cord colitis syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H598219\">",
"      HEPATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H598226\">",
"      Hepatic veno-occlusive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H598233\">",
"      Ursodeoxycholic acid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H598240\">",
"      PREVENTION OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H599675\">",
"      NEURO-PSYCHIATRIC MORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599683\">",
"      Psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599690\">",
"      Encephalopathy and delirium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599697\">",
"      Social and psychological support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H599704\">",
"      FUNCTIONAL RECOVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599711\">",
"      Patient expectations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599718\">",
"      End-of-life and advanced care planning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599725\">",
"      Estimating mortality risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599732\">",
"      Intensive care unit admission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H599739\">",
"      LONG-TERM COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H599816\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/15803\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/15803|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/7/4223\" title=\"figure 1\">",
"      Infections after autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/10/8362\" title=\"figure 2\">",
"      Infections after allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/15803|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/11/1214\" title=\"table 1\">",
"      Drugs that cause or prolong delirium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/31/36348\" title=\"table 2\">",
"      Risk score CML transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/48/7950\" title=\"table 3\">",
"      HCT-CI and CCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 4\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/60/26565?source=related_link\">",
"      Ethics in the intensive care unit: Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43719?source=related_link\">",
"      Functional problems in the patient with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=related_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17962?source=related_link\">",
"      Investigational therapies in the medical management of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=related_link\">",
"      Kidney disease following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14473?source=related_link\">",
"      Legal aspects of end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28280?source=related_link\">",
"      Malignancy after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=related_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=related_link\">",
"      Nutrition support in critically ill patients: Enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=related_link\">",
"      Nutrition support in critically ill patients: Parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=related_link\">",
"      Osteoporosis after solid organ or stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14745?source=related_link\">",
"      Pulmonary complications after autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=related_link\">",
"      Quality of life following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=related_link\">",
"      The approach to hematopoietic cell transplantation survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=related_link\">",
"      The role of parenteral and enteral/oral nutritional support in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7081?source=related_link\">",
"      Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=related_link\">",
"      Treatment of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43526?source=related_link\">",
"      Ursodeoxycholic acid in the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_39_29307="Sperm donor exclusion criteria";
var content_f28_39_29307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minimal sperm donor exclusion criteria based on sexual, social, and medical history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Sex with men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Injected drug (non medical) use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sex for drugs and/or money",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Sexual relations in the past 12 months with a person who meets any of the above criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Sexual relations within the past 12 months with an HIV or hepatitis infected person",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Exposure to HIV and/or hepatitis in the last 12 months (eg, open wound, mucous membranes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incarceration for more than 72 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment fof syphilis or gonorrhea in the past 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Acupuncture, body piercing, and/or tattooing in the last 12 months in which it is not certain that sterile technique was used",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recipients of human organ or tissue transplants or extracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of transmissible spongiform encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of transmissible Creutzfeldt-Jakob disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Changes in cognition, speech or gait",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29307=[""].join("\n");
var outline_f28_39_29307=null;
var title_f28_39_29308="Cytogenetics in AML";
var content_f28_39_29308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Phenotypes and frequencies of leukemias in the presence of various breakpoint sites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        FAB subtype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent all AML",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genes involved",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prognostic implication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MO - no maturation",
"       </td>",
"       <td>",
"        &plusmn;2",
"       </td>",
"       <td>",
"        hypodiploidy",
"       </td>",
"       <td>",
"        Not applicable",
"       </td>",
"       <td>",
"        Not available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M1 - minimal maturation",
"       </td>",
"       <td>",
"        &plusmn;20",
"       </td>",
"       <td>",
"        t(9;22)",
"       </td>",
"       <td>",
"        BCR-ABL",
"       </td>",
"       <td>",
"        Poor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M2 - limited maturation",
"       </td>",
"       <td>",
"        &plusmn;30",
"       </td>",
"       <td>",
"        t(8;21)",
"       </td>",
"       <td>",
"        ETO-AML1",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        With basophilia",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        t(6;9)",
"       </td>",
"       <td>",
"        DEK-CAN",
"       </td>",
"       <td>",
"        Poor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M3 - promyelocytic",
"       </td>",
"       <td>",
"        &plusmn;10",
"       </td>",
"       <td>",
"        t(15;17)",
"       </td>",
"       <td>",
"        PML-RARA",
"       </td>",
"       <td>",
"        Favorable, present in most patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M4 - myelomonocytic",
"       </td>",
"       <td>",
"        &plusmn;25",
"       </td>",
"       <td>",
"        t(...;11) or t(11;...)",
"       </td>",
"       <td>",
"        MLL-other",
"       </td>",
"       <td>",
"        Poor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M4E - myelomonocytic with eosinophilia",
"       </td>",
"       <td>",
"        &plusmn;10",
"       </td>",
"       <td>",
"        t(16;16) or (inv)16",
"       </td>",
"       <td>",
"        MYH11- CBFB",
"       </td>",
"       <td>",
"        Favorable, present in most patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M5 - monocytic",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        t(9;11) t(...;11) or t(11;...)",
"       </td>",
"       <td>",
"        AF9-MLL MLL-other",
"       </td>",
"       <td>",
"        Favorable Poor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M6 - erythroleukemia",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        t(3;5)",
"       </td>",
"       <td>",
"        Not available",
"       </td>",
"       <td>",
"        Poor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M7 - megakaryoblastic",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        t(1;22)",
"       </td>",
"       <td>",
"        Not available",
"       </td>",
"       <td>",
"        Very poor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FAB: French American British Classification.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29308=[""].join("\n");
var outline_f28_39_29308=null;
var title_f28_39_29309="Airway stent deployment";
var content_f28_39_29309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/60271/airstent_conv.mp4?title=Airway+stent+deployment\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Airway stent deployment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 231px; height: 205px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Video shows the bronchoscopic deployment of a studded silicone stent using rigid grasping forceps into a right main bronchus that has been narrowed by tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henri G Colt, MD and Praveen Mathur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29309=[""].join("\n");
var outline_f28_39_29309=null;
var title_f28_39_29310="Herpes esophagitis Ba swallow";
var content_f28_39_29310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 193px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium swallow in a patient with Herpes simplex esophagitis shows a single aphthous ulcer in the distal esophagus (arrow) on a background of normal esophageal mucosa. Other viruses, such as cytomegalovirus and HIV, and medications may also produce this appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29310=[""].join("\n");
var outline_f28_39_29310=null;
var title_f28_39_29311="Hepatorenal recess";
var content_f28_39_29311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatorenal recess on thoracic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hepatorenal recess is seen as a curvilinear structure between the liver and kidney. Although of similar shape, echogenicity and orientation as the diaphragm, the hepatorenal recess can be easily identified by identification of the adjacent organs. A similar structure may be seen on the left side and represents the splenorenal recess.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_39_29311=[""].join("\n");
var outline_f28_39_29311=null;
